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PREFACE 
During the last ten years, several investigators have reported that biological effects of 
endothelium-derived relaxing factor (EDRF; Furchgott and Zawadzki, 1980) are actually 
activities of a signal molecule, nitric oxide (NO; Moncada el al., 1988). This molecule is 
synthesised by endothelial vascular cells (Palmer el al., 1987, 1988; Ignarro, 1990). 
Endogenous NO is involved in many biological processes. The horseshoe crab (Lilllulus 
polypherus), that exists for 500 million years, synthesises NO from L-arginine to avoid 
aggregation of its circulating haemocytes (Radomski el al., 1991), wltile the blood sucking 
insect Rhodnius prolixus uses NO in its prey for vasodilatation and platelet anti-aggregation 
(Ribeiro el al., 1993). The goldfish Carassius auralus (Bruning el al., 1995) and the frog 
Xenopus laevis (Bruning and Mayer, 1996) use NO as a molecule for neuronal signalling. 
Evidence has accumulated that endogenous NO regulates not only mammalian blood 
vessels but many other systems (Moncada and Higgs, 1991). Almost every mammalian 
cell/system is under influence of NO, involving endotheliumMdependent relaxation (Furchgott 
and Zawadzki, 1980), neurotransmission (Garthwaite el al., 1988; Gillespie el al., 1989) and 
cell-mediated ilmllune response (Nathan and Hibbs, 1991). Appropriately, NO was 
proclaimed as a Molecule ojlhe Year for 1992 by the journal Science (Koshland, 1992). 
In addition, the beneficial effects of glyceryl trinitrate in coronary heart disease, known 
since 1867, have been recently explained through NO (Anggard, 1994). Alfred Nobel, who 
invented nitroglycerine. used the drug himself to relieve his coronary heart problems (Snyder 
and Bredt, 1992; HOlscher el al., 1995). 
Recently, it has been found that NO can exert not only cytoprotective but also cytotoxic 
effects in mammalian cells (Snyder and Bredt, 1992; Krencke el al., 1997). Moreover, it has 
been demonstrated that clarification of the dual effect of NO might have implications for 
clinical medicine with therapeutic opportunities (Snyder, 1993; Schmidt and \Valter, 1994; 
Vallance and Moncada, 1994). Thus, the main goal of this thesis is to highlight the 
importance of this molecule, particularly in the neuropharmacology. 
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PART I 
NITRIC OXIDE 
An Overview 

CHAPTERl 
NITRIC OXIDE: SYNTHESIS, MECHANISM OF ACTION AND 
DISTRIBUTION 
1.1 Nitric Oxide Synthase Isoenzymes 
The nitric oxide (NO) gas is a reactive and membrane permeable signal molecule, with an 
average life of about 15 s (Snyder and Bredt, 1992). The unconventional transmitter NO does 
not seem to be prestored or packed in vesicles, but is synthesised on demand with quick 
diffusion from its site of production in random direction (Lundberg, 1996). Therefore, much 
of the understanding of its functions is derived from the characterization of the synthesising 
enzyme nitric oxide synthase (NOS). 
So far three structurally distinct NOS isoenzymes have been purified and biochemically 
characterised. Distinction can be made on the basis of the sensitivity to Ca2t stimulation, the 
distinct genes that have been cloned/sequenced and on cell/organ localization (Bredt ef a/., 
199Ia,b; Nathan and Hibbs, 1991; Lowenstein ef a/., 1994). Neuronal NOS (n-NOS) or brain 
(b-NOS), denoted as NOS-I (Knowles ef a/., 1989; Bredt ef a/., 1990) and endothelial NOS 
(e-NOS), sometimes denoted as NOS-3 (Knowles and Moncada, 1992; Marsden ef a/., 1992) 
are constitutively expressed (constitutive NOS; c-NOS) and regulated by intracellular 
concentration of free Ca". The third isoenzyme is Ca"-independent and cytokine-inducible 
(inducible NOS; i-NOS; NOS-2; Hibbs ef a/., 1988; Moncada ef a/., 1988). However, recent 
results have found that both c-NOSs could also be upregulated (induced) during focal brain 
ischaemia; it is then followed by a delayed induction of i-NOS (Iadecola, 1997). The three 
distinct NOS isoenzymes (n-NOS, e-NOS, and i-NOS) are derived from three different genes, 
found on human chromosomes 12, 7 and 17, respectively (Wang and Marsed, 1995). A 
comparison of the NOSs shows great similarity in stmcture, with overall homology around 
50%, except the amino terminal, which is unique for each isoenzyme (Vallance and Moncada, 
1994). Unlike n-NOS and i-NOS, which are largely cytosolic, e-NOS is predominately 
(>90%) membrane bound (Snyder and Bredt, 1992). 
1.1.1 COllslitlllive Nitric Oxide SYllthases: II-NOS alld e-NOS 
e-NOS and n-NOS are regarded as c-NOSs because they are present as normal constituents of 
healthy cells and synthesise NO on demand in short time periods (second-minutes) after 
enzyme activation by calmodulin upon elevations of the intracellular Ca2t concentrations 
(Moncada ef a/., 1991). c-NOS makes relatively small amounts (picomols) of NO, which 
produces changes in the target cells by activating soluble guanylyl cyclase (Kiechle and 
Malinski, 1993; Presta ef ai., 1997). 
1.1.1.1 n-NOS. n-NOS has been found in various neuronal, epithelial and skeletal muscle 
cells (Bredt ef al., 1991c; Schmidt ef al., 1992; Nakane ef a/., 1993). Within the central 
nervous system (CNS), n-NOS is distributed in many brain areas (see details in Chapter 1.5, 
Bredt ef ai., 1991c) and spinal cord (Dawson ef aI., 1991). The highest expression is found in 
the cerebellum (Bredt ef a/., 1991). Distribution in the brain is not exclusively neuronal, 
because recently n-NOS has been found in astrocytes as well (Murphy ef al., 1995). During 
embryonic development, major presence of nwNOS occurs in a developing neuronal system, 
from sensory ganglia, olfactory neurons, to the thalamus and cerebral cortex (Bredt and 
Snyder, 1994). 
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Within the autonomic and peripheral nervous system (PNS), n-NOS is localized in 
non-adrenergic non-cholinergic (NANC, nitrergic) neurons (Rand el al., 1995), in the retina 
(Bredt el al., 1990), cardiovascular system (Forsterman el al., 1993), arteriovenous 
anastomoses (Funk el al., 1994), lung (Belvisi el al., 1992), gastrointestinal system (Mearin 
el al., 1993), genitourinary tract (Leone el al., 1994) and sensory system (Vincent and Hope, 
1992). Additionally, the cerebral vasculature is densely imlervated with NANC neurons 
found in the adventitial layers (Bredt el al., 1990; Faraci el al., 1994). In the peripheral 
vasculature, NANC innervation of the human corpus cavernosum has been demonstrated as 
an important factor in the mechanism of penile erection (Leone el al., 1994). 
Outside the nervous system, n-NOS is localized in the anterior pituitary, adrenal medulla, 
macula densa of the kidney (Snyder and Bredt, 1991), in the epithelium of the respiratory 
tract (Kobzik el al., 1993), fast-twitch fibres at the sarcolemma (Nakane el al.,; 1993, 
Kobzbik el al., 1994) and neuromuscular junction (Chao el al., 1997) of striated somatic and 
visceral muscle (Grozdanovic el al., 1995a), including myocardium (Silvagno el al., 1996). 
Expression of n-NOS in the sarcolemma region of visceral and somatic striated muscle has 
been species-independent (Grozdanovic el al., 1995 b). n-NOS in striated muscle, unlike 
other n-NOS, is slightly more massive and concentrated in the membrane (not in cytosol like 
other n-NOSs). This novel n-NOS isoenzyme, called II-NOS-fl, has a catalytic activity 
similar to n-NOS expressed in cerebellum, but with a function exclusively in skeletal muscle 
and heart (Silvagno el al., 1996). 
Stimulation of excitatory N-methyl-D-aspartate (NMDA) receptor by glutamate (GLU) 
leads to the opening of Ca2-t- ion channels, increasing intracellular Ca2+ concentration and 
activation ofn-NOS (Garthwaite el al., 1988). Recently, it has been found that the increase in 
NO production in focal brain ischaemia is accompanied by upregulation (induction) of both 
n-NOS activity and n-NOS gene expression. The increase in NOS activity corresponds to an 
increase of both n-NOS mRNA and a number of n-NOS-immunoreactive neurons (ladecola, 
1997). Additionally, after iI~ury in CNS or PNS, high levels of n-NOS are found in neurons 
that normally do not express n-NOS (Snyder, 1994). 
1.1.1.2 e-NOS. e-NOS is a constitutively expressed enzyme, found in the endothelium of 
human arteries (Yang el al., 1991), arterioles (Woolfson el al., 1990), veins (Vallance el al., 
1989; Janssens el al., 1992), platelets (Radomski el al., 1990), endocardium (Finkel el al., 
1992; Henderson el al., 1992). However, recent results have shown that e-NOS, in addition 
to the blood vessels, is also present in the various neuronal structures of the brain, including 
the hippocampus. This supports the idea that NO may have a role in memory processes 
(Snyder, 1994). 
The activators of e-NOS are substances released from nerves, such as acetylcholine 
(Ach), bradykinin, substance P and those released from platelets (e.g. thrombin and serotonin 
[5-HT]). They increase intracellular free Ca" and thereby cause activation of e-NOS. e-NOS 
can also be upregulated (induced). It has been shown that chronic exercise in dogs is a 
stimulus for endothelial cell e-NOS gene expression, which can explain the beneficial effects 
of physical exercise (Sessa el al., 1994). 
1.1.2 IlIdllcibie tvilric Oxide SYlllilase 
i-NOS is Ca"-independent as it contains tightly bound calmodulin (Cho el al., 1992). It is 
induced by products of infection, including bacterial endotoxins (Hibbs el al., 1988) and 
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exotoxins (Zembowicz el al., 1992), as well as inflammatory cytokines, such as tumour 
necrosis factor, interferon gamma and interleuklns 1 and 2 (Vallance and Moncada, 1993). 
i-NOS is not a normal constituent of cells but is induced in immune cells (maerophages, 
neutrophils, monocytes; Vallance and Moncada, 1993, 1994; Snyder, 1994) and in many 
other cells, such as those from the vascular endothelium, smooth muscle, myocardium, lung 
and liver cells. i-NOS can also be expressed in brain astrocytes as well as glial cells in the 
retina (Murphy el al., 1995). The high concentrations of NO produced by i-NOS have 
cytostatic effects on parasitic microorganisms and tumour cells. Once expressed, the enzyme 
continuously generates large amounts (nanomols) of NO, over periods of many hours or days. 
However, the released NO in higher quantities produced by i-NOS can have additional toxic 
effects. It interacts with iron-sulphur centred enzymes, impairs mitochondrial respiration 
(Hibbs el al., 1988; Stadler el al., 1991) and can damage DNA (Nguyen el al., 1992). 
Furthermore, continuous release of high amounts of NO acts with superoxide anion, also 
secreted from activated immune cells, causing oxidative injury and cell death. Reaction of 
NO with superoxide may lead to the formation of other more stable toxic reactive oxygen 
intermediates, including peroxynitrate and hydroxyl anion (Beckmen el al., 1990). 
Conceivably, constant ulII'egulated NO synthesis and cytotoxicity usually correlate with 
i-NOS activity and not with the regulated NO production by the two c-NOSs (with possible 
exceptions in brain injury; Kroneke el al., 1997). 
1.2 Biosynlhesis of Nil ric Oxide 
NOS catalyses oxidation of the semi-essential amino acid L-arginine (L-Arg) into equal 
amounts of NO and L-citrulline (Mayer el al., 1989; Palmer and Moncada, 1989; Moncada 
el al., 1991). Substrate oxidation occurs at a haem iron and requires nicotine amide 
dinucleotide phosphate (NADPH, Pollock el al., 1991). The byproduct L-citrulline is 
recycled back 10 L-Arg (Hecker el al., 1990); this process can be blocked by L-glutamine 
(Lee el al., 1996). This cycle has two functions: an excretory role to eliminate excess 
nitrogen created by the cell metabolism and a secretory role to regenerate L-Arg for NO 
synthesis (Angg"rd, 1994). 
1.2.1 Ca"alld BiosYlllhesis of Nilric Oxide 
In the brain, Ca" influx through GLU NMDA receptor cha.mels stimulates calmodulin 
thereby activating n-NOS. This mode of action explains the ability of GLU or neuronal 
depolarization to stimulate NO fonnation in a matter of seconds. In endothelial cells, 
biogenic substances such as Ach and bradykinin acting at the receptor sites mobilize 
intracellular Ca2+, which activates e-NOS. Thus, Ca 2f;.regulated c-NOSs releases NO, which 
mediates rapid events such as neurotransmission and blood vessel dilatation. The Ca2+ 
requirement for NOS activity reflects the affinity of Ca" for NOS cofactor calmodulin 
(Abu-Soud and Stuehr, 1993). L-Arg binding, however, is unaffected by Ca" or calmodulin 
(White and Marietta, 1992). In contrast, i-NOS generates NO at resting intracellular Ca" 
levels (Mayer, 1995). 
1.2.2 L-Argillille as Subslrate of Nitric Oxide SYllthase 
Generation of NO by Ca"/calmodulin-activated NOS is fi.lrther controlled by intracellular 
availability of substrate and cofactors. Normally, levels of L-Arg are sufficient for 
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continuous NO biosynthesis. The content of free L-Arg in total brain is about 10 l-lmol per 
100 g wet weight (Mayer, 1995), a concentration sufficient for saturation of NOSs. 
Nevertheless, several in vivo and in vitro studies have demonstrated biological effects of 
administration of L-Arg. L-Arg-stimulated NO formation indicates that NOS might not be 
substrate saturated in certain brain areas (Buclunann et al., 1996). Moreover, neurons can be 
dependent on transport of the NOS substrate from L-Arg pools. As observed with cultured 
endothelial cells, macrophages and neuronal cells (Schmidt ef al., 1993, 1994), a specific 
transport system is responsible for the uptake of L-Arg. TIns transport system is also 
important for several basic amino acids which may competitively reduce intracellular 
availability of L-Arg. It has been reported that L-Arg deficiency would not only decrease 
rates of NO formation but may induce generation of superoxide anions and hydrogen 
peroxide, which can participate in neurotoxicity. Thus, NO toxicity seems to be concurrent 
with the production of superoxide, precisely the NOS product under reduced L-Arg 
availability (Mayer, 1995). 
1.2.3 Cofactors of Nitric Oxide SYllthase 
All NOS isoenzymes are haemoproteins (White and Marietta, 1992) and require cofactors for 
their full activities: flavin mononucleotide (FMN), flavin adenine dinucleotide (FAD), 
NADPH and tetrahydrobiopterin (H4B, Moncada ef al., 1991; Klatt ef al., 1966). The 
intracellular concentration of NOS is regulated by the availability of H4B (Brand ef al., 
1994). 
1.3 Nitric Oxide Synthase Inhibitors 
NOS-blocking dmgs have been essential for evaluating the role of NO in physiological and 
pathophysiological processes. Therefore they can have particular importance in medicine 
with possible therapeutic implications. 
1.3.1 'Selective' II-NOS Illhibitors 
1.3.1.1 lndazole derivatives. Indazole derivatives are relatively selective n-NOS inhibitors. 
Recently, 7-lntro indazole (7-NI) has been reported as a NOS-blocking drug with ill vitro as 
well ill vivo selectivity for n-NOS (Babbedge ef al., 1993; Moore ef al., 1993a,b). TIns rather 
simple compound does not exhibit structural similarities with L-Arg 01' any of the known 
NOS cofactors (Fig. 1.1). Inhibition of n-NOS by 7-NI was shown to be reversible (Wolff 
and Gribin, 1994), competitive with L-Arg (Babbedge ef al., 1993) and also with H4B (Klatt 
ef al., 1994b). These data suggest that binding of the dmg occurs at a distinct site wInch 
interacts with the binding domains for both L-Arg and H4B. It has been proposed that the 
inhibitory effect of7-NI is a consequence of its binding to the haem group of NOS, resulting 
in decreased affinities of the enzyme for L-Arg and H4B, accounting for selectivity for 
n-NOS (Klatt ef al., 1994b). Additionally, it has been reported that 7-NI blocks formation of 
hydrogen peroxide, that is catalyzed by NOS in decreased L-Arg availability. Thus, 7-NI 
resembles imidazole, a known haem-site NOS inhibitor (Mayer ef al., 1994, 1995). 
Inhibition ofn-NOS by 7-NI (maximal effect: 0.5-1 h after Lp., injection) is relatively shmi-
lasting with complete recovery at either 4 h (oral administration) or 24 h (Lp. injection) in 
many brain regions (Babbedge ef al., 1993; MacKenzie ef al., 1994). 
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The availability of structurally 
distinct inhibitors selective for the n-NOS 
allows the possibility of dissociating 
effects of n-NOS from e-NOS and 
i-NOS. It has been reported that potent 
and selective inhibition of n-NOS 
compared to e-NOS and i-NOS may be 
usen,l to treat cerebral ischaemia (stroke) 
and other neurodegcnerative diseases 
(Furfine ef 01., 1994). 7-NI may be a 
valuable starting point for the 
development of selective, centrally acting 
n-NOS inhibitors devoid of 
cardiovascular side effects, serving as 
tools for studying the central 
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pharmacological effects of NO (Mayer, Figure 1.1 Structure oJil1dazole derivatives showing 
1995). poillls 0/ sllbSlillllioll. 
It has been recently shown that the 
other indazole derived substance, 3-bromo-7-nitro-indazole (3-Br-7-N!; Fig. 1.2) is 
approximately 4-fold more potent than 7-NI in inhibiting n-NOS (Bland-Ward and Moore, 
1995). However, unlike 7-NI, which does not affect blood pressure (Moore el 0/., 1993a,b), 
the cardiovascular effects of3-Br-7-NI are still unknown (Bland-Ward and Moore, 1995). 
1.3.1.2 Imidazole derivative. They also show some selectivity towards n-NOS. Like 7-NI, 
imidazole and its derivative 1-(2-trifluoromethylphenyl)imidazole (TRIM, Fig. 1.3) are 
haem-site NOS inhibitors (Mayer ef al., 1994; 1995). In addition to 7-NI and 3-Br-7-NI (Fig. 
1.1, 1.2; Bland-Ward and Moore, 1995), TRIM interferes with the binding of both L-Arg and 
H4B to NOS, which underlines the selectivity for n-NOS (Handy and Moore, 1997). Its 
effects are also competitively reversible by L-Arg (Handy el al., 1995; Handy and Moore, 
1997). Like 7-N!, which inhibits n-NOS 
in a selective with a little effect on 
e-NOS in vivo (Babbedge el al., 1993; 
Moore el 0/., 1993a), TRIM is also 
without cardiovascular effects in vivo 
(Handy el 0/., 1995). 
Concerning new and selective 
n-NOS inhibitors it has been reported that 
del ta-( S-methy Iisothi ourei do )-L-norval in 
exhibits a more than 40-fold weaker 
inhibitory effect on other NOS 
isoenzymes and reduces the size of focal 
cerebral ischaemia (Nagafuji el 0/., 
1995). 
Br 
Figure 1.2 Structural formula of 3-bromo 7-llitro 
indazole (3-Br-7-NI). Mw:242. 
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CF, 
1.3.2 'Seleclive' i-NOS Inftibilors 
It is of considerable interest to find 
inhibitors which would be more selective 
for i-NOS, because then a hyperactive 
NO system could be damped down 
without influencing any constitutive NO 
release. So far, there has been only a 
limited success. Unlike most L-Arg 
derived NOS inhibitors, some guanidino 
Figure 1.3 Structural formula of 1-(2-trifluoro and S-alkyl-isothioureas, particularly 
lIIethylphenyl)imidazole (TRIM). MIY:212. aminoethyl-isothiourea (Southan el al., 
1996) and S-ethyl-isothiourea, show 
selectivity towards i-NOS over n-NOS and e-NOS, with several potential therapeutic 
applications, such as treatment of sepsis and autoimmune diseases (Tracey et al., 1995). 
However, i-NOS inltibitors of even greater selectivity may need to be developed for 
therapeutic applications. Aminoguanidine is a also weak but selective inhibitor of i-NOS and 
is undergoing clinical exploration (Misko et al., 1993). 
1.3.3 Non-Specific NOS Inftibilors 
1.3.3.1 Citrulline Derivalives. It has been reported that S-methyl-L-thiocitrulline (S-Me-TC, 
Fig. 1.4) is the most potent n-NOS and i-NOS inhibitor described to date (Narayanan el al., 
1994), although this compound is about 15-fold more selective for n-NOS than for e-NOS 
NH.HCI 
II CO.H 
CH3S/"-..N~ 
H NH 
• 
(Furflne et al., 1994). Inhibition is 
reversible, stereoselective and 
competitive with L-Arg. In contrast to 
indazole and imidazole derivatives, 
S-Me-TC has a strong pressor activity 
that reverses hypotension in the septic 
shock (Narayanan et al., 1995; Joly 
et al., 1995). Compared to L-Arg-based 
NOS blocking drugs, S-Me-TC is not 
Figure 1.4 Structural formula of S-methyl- metabolised to citrulline, which can be 
L-Ihiocitrullille (S-Me-TC). MlI':266. converted back to L-Arg in vivo, thus 
sustaining overproduction of NO (Hattori 
el al., 1994). 
1.3.3.2 L-Arginine Derivatives. Analogues of L-Arg act by competing with L-Arg at the 
active site of the NOS and their action can be reversed by adding higher amounts of L-Arg 
(Mayer, 1995). Additionally, activation ofc-NOS or induction ofi-NOS increase the rate of 
L-Arg transport into endothelial and neuronal cells or macrophages, respectively. 
Competitive inhibition of this L-Arg transport mechanism by L-Arg analogues may result in 
apparent decreased NOS activity secondary to substrate reduction (Kiechle and Malinski, 
1993). Methylated L-Arg analogues such as L-NG-Illono-Illethyl-L-arginine (L-NMMA) and 
asynllllet,ic NG-dillleth),larginine (ADMA) have been found endogenously and observed to 
accumulate in renal failure. Perhaps endogenous methylarginines provide control over NO 
synthesis in vivo (Vallance et a/., I 992a,b). Because NO cannot be stored in vesicles like 
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other neurotransmitters, its release is regulated by NOS activity and modulated by NOS 
inhibitors. However, care must be taken in the experiments estimating biological roles of NO 
using L-Arg analogues as they can block not only NOS but they may interfere with other 
iron-dependent systems and inhibit mitochondrial electron transport (Peterson el al., 1992). 
Therefore, studies that use L-Arg analogues to modulate biologic effects of NO can not be 
conclusive since the obtained results are only due to the inhibition of NOS (Kiechle and 
Malinski, 1993). 
NOS isoenzymes vary in their susceptibility to inhibition by different L-Arg-analogues. 
For example, NG-nitro-L-arginine (L-NOARG) preferentially blocks n-NOS and e-NOS 
(Lambert el al., 1991), while L-NMMA selectively inhibits n-NOS and i-NOS (Feldman 
el al., 1993; Klatt el al., 1994 a). 
1.3.3.3 Olher NOS inhibitors. NOSs are inhibited by a wide variety of drugs which interfere 
with one of the multiple catalytic functions of the enzyme, such as: calmodulin antagonist, 
trifluoroperazine, preventing Ca"-calmodulin binding (Bredt and Snyder,1990), cyanide and 
carbon monoxide (CO) blocking function of the haem (MarIetta, 1993) or nitro blue 
tetrazolium inhibiting activity ofNADPH (Klatt el al., 1992). 
Recent results have brought into light new NOS blocking drugs such as 
selenium-containing antioxidant, ebselen, which inhibits both c-NOS and i-NOS (Anggard, 
1994). 
1.3.4 NO as NOS Illhibitor 
It has been shown that NOS can be inhibited by its reaction product NO (Rogers and Ignarro, 
1992; Assreuy el al., 1993; Buga el al., 1993; Griscavage el al., 1993; Rengasamy and Jolms, 
1993). Tllis feed-back blockade on NOS catalytic activity by NO (but not oxidation products 
such as nitrite, nitrate, peroxynitrate) modulates NO production in the cell of origin and in 
near neighbour cells. Conceivably, the possible therapeutic potential of exogenous NO 
administration (AllIer el al., 1991; Geggel el al., 1993; Rossaint, 1994; Rossaint el al., 1996) 
should consider the feed-back inhibition of NOS as clinically relevant. 
1.4 Mechanisms of NO Actions 
While the number of newly discovered potential targets of NO continually increase, under 
physiological conditions the major effects of NO still appear to be mediated primarily by the 
activation of the intracellular NO receptor soluble guanylyl cyclase, leading to the increase of 
cyclic guanosine 3',5'-monophosphate (cGMP, Garbers, 1992). Activation of soluble 
guanylyl cyclase is the main mechanism of action of NO in both the vascular and the nervous 
system (Arnold el al., 1977, Miki el al., 1977; Vincent and Hope, 1992). A growing family 
of guanylyl cyclase has been discovered but only the soluble form serves as the NO receptor 
(Ignarro, 1990; Mayer, 1994). The purified guanylyl cyclase contains haem, to which NO 
binds in a mrumer similar to its interactions with other haemoproteins, including 
haemoglobin. Precisely, NO binds with very high affinity to Fe" in the haem-active centre of 
the soluble guanylyl cyclase, causing the enzyme activation with resulting rises in cGMP 
levels (Snyder and Bredt, 1992). The cGMP formed may then regulate protein kinase, 
phosphodiesterases and ion channels. The intracellular effects of cGMP are acllieved by the 
regulation of cGMP-regulated cyclic nucleotide phosphodiesterases and each of these cGMP 
targets represents the regulatory proteins (Kiechel and Malinski, 1993; Schmidt el al., 1993). 
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Thus, the effects of NO on individual target cells may be determined by each cell's 
preprograuuned characteristic response to NO as a mediator molecule (Lancaster, 1997). 
However. under some pathophysiological conditions NO can act in a cGMP-independent 
way. For example, the target of NO as a toxic agent is different than as a messenger 
molecule. NO binds avidly to Fe2+ -sulphur centres of enzymes, including those involved in 
the mitochondrial electron transport chain and the DNA synthesis (Hibbs ef al., 1988). The 
cytotoxic effect of macrophages-derived NO on parasites or tumour cells is the result of NO 
reaction with Fe2+-containing enzymes, leading to massive oxidative- and DNA injury 
(Lundberg, 1996). The reaction of NO with superoxide anions, another product of activated 
immune cells, leads to the fomlation of a cytotoxic oxidant, peroxynitrate, which can induce 
tissue damage and other pathophysiological processes, including inflammation and 
ischaemia-reperfusion injury (Anggard, 1994; Iadecola, 1997). A similar mechanism is 
probably active in brain ischaemia-reperfusion damage accompanied with overstimulation of 
OLU NMDA receptors. Accordingly, recent findings have implicated that NOS inhibitors, 
particularly selective ones, may have a therapeutic benefit in endotoxic shock (Narayanan 
ef al., 1995), stroke and neurological damage associated with excess OLU release (Snyder 
and Bredt, 1992; Iadecola, 1997). 
While small amounts of NO from c-NOS bind to haem-containing enzymes such as 
soluble guanylyl cyclase, excess NO from i-NOS may bind to thiols. It has been suggested 
that NO circulates in mammalian plasma bound to thiol-group of albumin, serving as a store 
which prolongs the actions of released NO (Anggard, 1994). 
Interestingly, CO, as a normal body compound, also appears to be able to activate soluble 
guanylyl cyclase via a similar mechanism as NO, exhibiting many of the physiological effects 
ascribed to NO. However, these activities are distinguishable by NOS inhibitors (Snyder and 
Bredt, 1992)_ 
NO diffuses within quite large spatial limits of about 0.3-004 mm which makes actions of 
NO significantly long range compared to other neurotransmitters (Lancaster, 1997). 
Nevertheless, NO can be rapidly inactivated by superoxide. Fe2f, Fe3+ and O2 • scavenged by 
haemoglobin or quickly converted by oxygen and water into nitrates and nitrites. All those 
substances are found in great abundance in biological systems, making NO a short lived 
molecule (Snyder and Bredt, 1992; Kiechle and Malinski, 1993; Anggard, 1994). 
1.5 Distribution of NOS in the Nervous System 
There is a rather detailed understanding of the distribution of the neurons producing NO 
throughout the nervous system (Vincent, 1994). This is due to the identification of NOS as 
the enzyme responsible for the neuronal NADPH diaphorase (NADPH-d) histochemical 
reaction (Hope ef al., 1991), together with the development of antibodies to the purified NOS 
(Bredt ef al., 1990). There is an association between neurons expressing NOS mRNA or 
NOS immunoreactivity and those expressing NADPH-d (Dawson ef al., 1991; Bredt ef al., 
199Ic). Recently, it has been demonstrated that mice lacking a n-NOS gene, show a loss of 
NADPH-d staining in the nervous system (Huang ef al., 1993). Therefore, neurons that 
express NOS can be identified either by NADPH-d histochemistry or by NOS 
immunocytochemistry. In the nervous tissue, histochemical NADPH·d reaction is considered 
a suitable marker for NOS activity (Hope ef al., 1991; Dawson ef al., 1991; Orozdanovic 
ef al., 1995a). Accordingly, these results made possible the anatomicallocaHzation of the 
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sites of synthesis of the short-lived molecule NO (Snyder and Bredt, 1992). The expression 
of NOS in multiple regions of the nervous system supports a role of NO as a signalling 
molecule in these areas (Endoh et al., 1994). 
It has been found that the pyramidal cells of the cerebral cortex do not contain NOS 
(Vincent and Kimura, 1992), but can be stained with antibodies to soluble guanylyl cyclase 
(Ariano et al., 1982; Nakane et al., 1983). NOS is found in cortical cerebral neurons 
scattered inlayers II-VI and in the subcortical white matter (Leigh et 0/., 1990; Vincent and 
Kimura, 1992). Similar cell staining has been reported in human cortex (Springall et 0/., 
1992). In humans only a few neurons in the subcortical white matter contain NADPH-d 
(Meyer et al., 1992). Since these cells are the oldest neurons in the cerebral c0l1ex it may 
suggest a possible role for NO in cortical development (Vincent and Hope, 1992). 
Additionally, the striatum contains the highest activities of soluble guanylyl cyclase and 
cGMP phosphodiesterase in the brain (Greenberg et al., 1978). The results implicate that in 
the striatum NOS expressed neurons may regulate the response of the output cells to cortical, 
nigral and local inputs (Vincent and Hope, 1992). NOS is present in various populations of 
hypothalamic neurons and NO appears to playa major role in regulation of hypothalamic 
functions. NADPH-d has also been described in supraoptic and paraventricular nuclei in 
humans (Leigh et al., 1990; Sangruchi and Kowall, 1991; Vincent and Kimura, 1992). In 
addition to being present in hypothalamic neurosecretory neurons, there is recent evidence for 
NOS ilmnunoreactivity and NOS mRNA expression in the anterior pituitary (Ceccatelli et al., 
1993). NADPH-d histochemistry indicates that the NO system is present throughout the 
visual pathway (Vincent and Hope, 1992). In the human eye, cone photoreceptors appear to 
display NADPH-d activity (Provis and Mittrofanis, 1990). Neurons in midbrain, pons, 
medulla and ascending reticular system in the human brain also appear to express NOS 
(Kowall and Mueller, 1988; Nakamura et al., 1988; Vincent and I'Iope, 1992). NADPH-d 
positive neurons have been described in the nuclei of the solitary tract, vagus and 
hypoglossus (Kowal and Muller, 1988). NOS activity (FortsterlUann et al., 1990) and cGMP 
(Greenberg et al., 1978) have been found in the cerebellum at the highest levels within the 
brain (Springall et 0/., 1992). In the cerebellar cortex NADPH-d histochemistry and 
inununohistochemistry for NOS indicate that the NOS is present in basket and granule cells, 
but not in Purkinje cells, which showed inununohistochemical stained for soluble guanylyl 
cyclase (Vincent and Hope, 1992). NOS inuuunoreactivity has been seen.in human spinal 
cord, particularly in dorsal root ganglia neurons (Springal et al., 1992; Terenghi et al., 1993), 
although some ventral horn motoneurons also appear to contain NOS (Springall et al., 1992; 
Terenghi et al., 1993). Since some of the ependymal cells are NADPH-d positive, it is 
suggested that they may be involved in the modulation of NO levels in the cerebrospinal fluid 
(CSF, Tang et al., 1995). Histological studies have shown that NANC neurons in the 
cardiovascular, respiratory, gastrointestinal and urogenital system are stained by NADPH-d 
(Vincent and Hope, 1992). Concerning cerebral vasculature NANC nerves are shown by 
NADPH-d histochemistry and inuuunocytochemistry, indicating a crucial role of NO and 
soluble guanylyl cyclase in the cerebral circulation and permeability of the blood-brain 
barrier (loo et al., 1983; Vincent and Hope, 1992). 
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CHAPTER 2 
PHYSIOLOGICAL AND PATHOPHYSIOLOGICAL ROLES OF 
NITRIC OXIDE 
NO is an ubiquitous cellular messenger that plays a role in a variety of biological processes. 
Several functions for this new regulatory molecule have been identified in the nervous 
system, in the endothelium-dependent vasodilatation and in the host-defence mechanisms 
(Snyder and Bredt, 1992). NO can be synthesised by a variety of tissues throughout the body, 
but the brain is the richest source of NOS under physiological conditions. Because both NOS 
and soluble guanylyl cyclase are widely distributed in the nervous system, it is likely that NO 
is associated with other mediator systems, not only in the eNS but also in the sensory and 
motor areas of the PNS, where NO is produced in wide variety of neurons (Moncada el al., 
1991). NO formation is linked to NMDA receptor activity in the brain and to neuronal 
nicotinic receptor activity in myenteric neurons (Bredt, 1996). NO signalling is not restricted 
to defined synapses and the actions of NO are not limited to anatomical stmctures or cerebral 
circulation, but provide transient functional localization based on transcellular diffusion 
(Bredt el al., 1991). While NO has a short half-life (-7 sec), tltis diffusible intra- and 
intercellular messenger molecule possesses tremendous potential to modulate 
neurotransmission (Gaily el al., 1990). 
NO is rapidly emerging as one of the main signal molecules in the eNS and PNS (Snyder 
and Bredt, 1992). NO is now recognized as a major, atypical, neuronal messenger (Bredt, 
1996), acting both as a neurotransmitter and as a second messenger in diverse biological 
functions (Snyder and Bredt, 1991,1992; Moncada and Higgs, 1993; Bredt, 1996). In some 
parts of eNS and in PNS, NO might be formed presynaptically and thus act as a 
neurotransmitter. Within eNS, NO also acts as a retrograde messenger, being released 
postsynaptically to act on presynaptic nerve endings and astrocytes (Garthwaite, 1991). 
2.1 Central Nervous System 
Histochemical studies suggest a widespread role for the NO/cGMP system in the eNS (Bredt 
el al., 1990; Springall el al., 1992). Only 2% of brain neurons contain NOS, but these 
neurons ramify sufficiently to contact almost all brain cells (Bredt et al., 1990; Dawson el al., 
1992). This latter point highlights the potential importance of NO in eNS. The overall NOS 
activity varies by about 8-fold over all of the brain regions (Forsterman el al., 1990; East and 
Garthwaite, 1991). All regions of the brain have the potential to produce surprisingly ltigh 
concentrations of NO, though these concentrations are far lower than what has been used 
in vitro to show toxicity (Varner and Beckman, 1995). 
\Vithin the brain NO can originate from four different sources: neurons, endothelium of 
cerebral vasculature, NANC nerves and inununostimulated microglia and astrocytes 
(Bruhwyler el al., 1993). NOS is found in excitatory GLU or inhibitory gama-aminobutyric 
acid (GABA) neurons. Indeed, NO would appear to rank with these latter two as one of the 
most common of all neuronal messenger molecules. The differential staining of nen'e cell 
bodies, dendrites and axon terminals in various brain regions may weB indicate different 
modes of NO transmission. In some situations, NO would be expected to be released from 
the cell bodies and dendrites in response to Ca2-l- influx following synaptic activation. In other 
areas, where NOS is concentrated in nerve terminals, one might predict NO synthesis to be 
triggered by ea2-!- influx following action potential invasion of the nen'e ending. Given that 
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the NO receptor appears to be soluble guanylyl cyclase, the varied actions of NO in these 
different situations may well be mediated by multiple actions of cGMP and its targets in the 
neurons responding to NO (Vincent, 1995). 
Physiological functions of NO in the CNS are implicated by the discrete and highly 
conserved distribution of NOS in subpopulaHon of central neurons of all mammalian brains 
so far examined (Hope el al., 1991; Bredt el al., 1991). Accordingly, some NO actions 
include: 
Modulation of neurotransmitter release (Schuman and Madison, 1994; Guevara-Guzman 
elal., 1994; Montague el al., 1994), 
Memory and learning (Bohme el al., 1991, 1993; Snyder and Bredt, 1992; Schuman and 
Medison, 1991, 1994; Shibuki and Okada, 1991), 
Vigilance (Dzoljic and De Vries, 1994; Bagetta el al., 1994; Nistico el al., 1994; Dzoljic 
el al., 1996) and resetting o/Ihe circadian rhylhm (Amir el al., 1995), 
Nociceplion (Meller el al., 1990, 1993), 
Conlrol 0/ sensDlY jimcliolls (Breer and Shepherd, 1993; Koch el al., 1994), 
IlIlake o/waler and/ood (Bruhwyler el al., 1993; AImr, 1995), 
Modulalion o/behaviour (Chapman el al., 1992; Nelson el al., 1995), 
Regulalion o/lleuronal excilability, including seizures (Kirkby el al., 1996; Facciolo el 
al., 1996; Proctor el al., 1996) and an<iety (Facciolo el al., 1996), 
Imolvemeni ill Irophic jimclions (Williams el al., 1994; Bredt and Snyder, 1994; 
Northington el al., 1997), 
Control afcerebrovascular system (Bruhwyler et al., 1993; Faraci and Brian, 1994; Van 
Gelderen and Saxena, 1994; Van Gelderen el al., 1995), 
Regulation of inflammation (Salvemini et al., 1995; Schneider-Schaulies et al., 1993; 
Bohne el al., 1994; Koprowski el al., 1993), 
Involvement in trauma (Mesenge et al., 1996), 
Neurotoxicity (Dawson et al., 1991; Snyder and Bredt, 1992; Dawson and Dawson, 
1996; Iadecola, 1997). 
2.1.1 Neurotrallsmitter Release 
Experimental findings support a role for NO in the modulation of neurotransmitter release, 
affecting the presynaptic membrane as a retrograde messenger. The mechanism by which it 
acts might involve cGMP as a second messenger (O'Sullivan and Burgoyne, 1990). NO 
donors (Le. sodium nitropnlsside, nitrosothiols, etc) have been shown to stimulate the release 
of GLU (Prast and Phillipu, 1992) as well as aspartate (ASP). Furthermore, NO inhibits the 
uptake of GLU (Lonart and Jollllson, 1994; 1995), while NOS inhibitors decreased the release 
of GLU (Montague el al., 1994). Stimulation of excitatory neurotransmitters release might 
be of importance in neuropsychiatric diseases. The disturbance of the GLU activity underlies 
schizophrenia (Schmidt, 1990, 1991; Bmhwyle el al., 1993). Sodium nitropmsside induces 
increase of the endogenous striatal dopamine (DA) release, attenuated by L-NMMA (Prast 
and Philippu, 1992; Zim and Luo, 1992). Thesc data implicate the possibility of 
manipulations of the eNS functions, through modulation of NO system and consequently 
DA, to correct DA deficiency in Parkinson's disease (Brohwyler et al., 1993; Connop et al., 
1996). Moreover, NO might be able to evoke the catecholamine release at sites located at 
some distance from the sites of NO formation (Youdim and Lavie, 1994). NO donors 
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stimulate release of acetylcholine (Ach) from basal forebrain (BF, Prast and Phillipu, 1992), 
while NOS inhibitors decreased the release of Ach (Prast and Philippu, 1992; Lonar! el al., 
1992). The brain regions containing cholinergic systems are involved in cognitive function. 
It has been rep0l1ed that NO is implicated in a number of acute and chronic 
neurodegenerative conditions associated with impaired memory, such as Alzheimer's disease 
(Meldnnll and Garthwaite, 1990). 
2.1.2 Memory allff Leaming 
As a retrograde messenger NO affects a long term potentiation (LTP, O'Dell el al., 1991) and 
long term depression (LTD, Shibuki and Okada, 1991), the fundamental mechanisms of 
learning and memOlY formation by which a particular neuron 'remembers' the signals 
previously received (Snyder and Bredt, 1992; Schmidt and Waiter, 1994; Vallance and 
Moncada, 1994). Memory involves a long-term increase or decrease in transmission across 
certain synapses after the repetitive stimulation of neurons. In memory models, particular 
neurons have been repetitively stimulated and then a persistent increase or decrease in 
synaptic transmission has been detected (Snyder and Bredt, 1992). NO released from the 
postsynaptic neuron acts as retrograde messenger on the presynaptic terminal to increase 
neurotransmitter release, enhance the postsynaptic response and increase firing of the target 
neuron. Thus, NO affects LTP and LTD (O'Dell el al., 1991; Chapman el al., 1992; Schuman 
and Medison, 1991, 1994). This activity-dependent synaptic efficiency seems to be the 
mechanism by which mammals learn and remember (Chapman el al., 1992). Additionally, 
NO would have many actions which can act to alter both shorl-term and long-term synaptic 
events that change cellular function. Short-term plasticity can last for several hundred 
milliseconds, while synaptic strength can also be persistently enhanced or depressed for 
periods of hours to days during long-term plasticity (Bliss and Collingride, 1993; Linden, 
1994). Because NO is freely diffusible it may affect the plasticity across many synapses in 
local domain (Schuman and Madison, 1994). In vivo, processes of spatial learning and 
memOlY were intemlpted by NOS inhibitors, interferiilg with the acquisition and retention of 
learned behaviour tasks on spatial learning (Bohme el al., 1991, 1993). LTD has been 
reported to be prevented by an NOS inhibitor and methylene blue, an inhibitor of guanylyl 
cyclase (Schuman and Medison, 1994). 
2.1.3 Vigilal/ce 
NO mediates a short term electrocortical activation, an alerting response important in control 
of the arousal slale (Bagetta el al., 1993). Cholinergic neurons arising from the mesopontine 
tegmental nuclei contain NOS (Vincent and Hope, 1992). Released NO is involved in 
mechanisms supporting neuroactivity that is conducible to wakefulness (Pape and Mager, 
1994). Accordingly, a significant decrease of brain NO levels has been found during slow 
wave sleep (Burlet el al., 1995) compared to wakefulness or rapid eye movement (Williams 
el al., 1997), known as vigilance stages with increased neuronal activity. It was found that 
NOS activity in the rat brain is higher during the dark phase (active period), compared to the 
light phase (sleeping period, Kopas el al., 1995). Results are consistcnt with findings that 
NOS inhibitors decrease wakefulness (Dzoljic and de Vries, 1994; Dzoljic el al., 1996). 
Furthermore, blockade of NMDA receptors, NO synthesis, or cGMP production in the 
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suprachiasmatic nucleus inhibited the stimulating effect of light on heart rate. This extends a 
role of NO in the brain circadiall rhylhm (Spessert el al., 1995; Amir and Edelstein, 1997). 
2.1.4 Paill Perceptioll 
The NO system is involved is lIociceplioll (Schmidt and Walter, 1994). It has been shown 
that NO is involved in both spinal and supraspinal processing of pain (Moore el al., 1991; 
Babbedge ef al., 1993a,b; Meller and Gebhart, 1993). In differentpaill models, NO induces 
spinal hyperalgesia, resulting in facilitation of peripheral inputs and central sensitization 
(Meller and Gebhart, 1993; Stanfa el al., 1996). Along with the importance of activation of 
the NMDA receptor in the lumbar dorsal hom for the maintenance of thermal hyperalgesia 
and chronic pain (Woolf el al., 1991; Meller et Gebhart, 1993), it has been demonstrated that 
the NO system in the spinal cord is required for the acute nociceptive effects of NMDA. 
Moreover, immunocytochemistry has demonstrated that the dorsal horn of the spinal cord is 
also a site of action of NO. This is consistent with data showing the ability of intrathecally 
administered NOS inhibitors to block hyperalgesia. Likewise, L-NAME produced a potent 
and stereoselective antinociceptive effect in the formalin-induced paw-licking test, the acetic 
acid-induced abdominal constriction test and the hot-plate test (Moore el al., 1991). 
Furthermore, L-NAME retains a considerable antinociceptive effect following 
intracerebroventricular (i.e.v.) administration. This supports the hypothesis of central 
mechanisms of nociceptive NO action (Babbedge el al., 1993a,b; Moore el al., I 993a,b). 
Thus, NOS inhibition or inactivation of guanylyl cyclase might serve as useful analgesics 
(Meller et Gebhart, 1993; Moore el al., 1993a,b; Gaffen ef al., 1994). 
In addition, NO is involved in peripheral analgesia. The peripheral analgesic effeci of 
Ach has also been proposed to be mediated via NO (Duarte el al., 1990). Ach, L-Arg and 
sodium nitropmsside induced analgesia in an animal model, and L-NMMA prevented the 
analgesia induced by both Ach and L-Arg. Whether this is the result of NO generation in the 
nociceptors or in cells closely associated with them and whether the NO pathway controls the 
input of nociceptive information into the nervous system requires further investigation 
(Moncada el al., 1991). After damage of the peripheral axons of sensory neurons, a marked 
up-regUlation of the NOS expression in primary sensory neurons occurs in spinal ganglia 
(Hokfelt el al., 1994). 
2.1.5 Sellsory Fllllctioll 
NO may be involved in the sensory junctions, including adaptive regulation of visual and 
olfactory signalling. It has been shown that by enhancing or attenuating the receptor 
responses of one neuron in an NO-dependent mechanism with strong stimulation (high 
odorant concentration, strong light), may either lead to the recmitment of adjacent neurons to 
augment signal intensity or may allow for adaptation (to odour, light intensity) or 
cross-adaptation (different odours; Breer and Sheperd, 1993; Koch el al., 1994). 
2.1.6 Food alld Water Intake 
NOS inhibitors reduce food intake in food-deprived or benzodiazepine- chlordiazepoxide-
treated mice. L-Arg reverses these effects of NOS inhibitors (Morley and Flood, 1991; 
Czech, 1996). Therefore, it has been suggested that, along with noradrenaline (NA) or 
adrenaline, NO could be an intercellular mediator for the physiologic modulation of food 
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illiake, while NOS inhibitors might be suitable agents for the treatment of obesity (Bruhwyler 
el al., 1993). This is in accordance with the finding that endogenous NO-stimulated release 
of NA (Guevara-Guzman el al., 1994; Montague el al., 1994) inhibits the uptake of NA 
(Lonart and Johnson, 1994; 1995), while NOS inhibitors decrease the release of NA and 
adrenaline (Montague el al., 1994) and enhance NA uptake (Kiss el al., 1996). While waler 
intake may be influenced by different mechanisms (direct action of thirst neurons. release of 
substances that affect these neurons or altered water or electrolyte balance in the body), 
L-Arg is able to inhibit drinking in water-deprived rats, when injected into the preoptic area 
(Calapai el al., 1992). It has been shown that NOS levels within the hypothalamo-
neurohypophyseal system are increased (upregulated) during neurohormone demand, such as 
that following osmotic stimulation (Luckman el al., 1997). In addition, concerning other 
autonomic regulation, it has been found recently that the human ventrolateral medulla, the 
region which is critically involved in cardiovascular, respiratory and autonomic functions, 
contains abundant NADPHMd reactive neurons, in close vicinity to catecholamine neurons 
(Benarroch and Smithson, 1997). 
2.1.7 Behaviour 
NO has also been implicated in different forms of behavioural cOlllrol (Bomne el al., 1991, 
1993; Chapman el al., 1992; HOlscher and Rose, 1992). For example, studies with NOS 
knockout mice have shown an increase in aggressive behaviour and excessive inappropriate 
sexual behavioul" in these animals (Nelson el al., 1995). The importance of compensatory 
mechanisms in mice without NOS for contribution of NOS in cell physiology and behaviour 
is still unknown (Good, 1996). Moreover, NOS inhibitors decreased 10coII/0101" aClivity 
(Pudiak el al., 1993; Sandi el al., 1995; Star and Star, 1995) and the righting reflex (Dzoljic 
el al., 1996). 
2.1.8 Neurol/al E,·cilability 
NOS inllibitors have shown contradictory results in affecting neuronal excitability, exerting 
anticonvulsant (Osonoe el al., 1994; Van Leeuwen el al., 1995) or proconvulsant (Starr and 
Starr, 1993; Rundfelt el al., 1995) effects. However, it has been demonstrated that pro- or 
anti-convulsant activity of NOS inllibitors vary depending on numerous factors, including the 
model of seizure, dose, route and time of administration of NOS inllibitors (Kirkby e/ a/., 
1996). These behavioural variations could very likely be a consequence of NO interacting in 
a regional-specific manner with the different neurotransmitter propagating system (Facciolo 
el al., 1996). On the basis of the effects exerted by L-NAME, the influences of this NOS 
inllibitor on convulsive behaviours were linked to the variations of benzodiazepine binding 
activities in the limbic areas. These areas are, apart from their involvement in memory and 
spatial tasks, strongly linked with the control of sociosexual behaviours, especially of the 
aggressive-defensive type (Unmeto el al., 1975). It has been shown that GABA-ergic 
terminals contain NOS (Valtschanoff el ai., 1993) and GABAA receptor activity is modulated 
by NO (Zarri el al., 1994). On the basis of recent results it has been suggested that the 
interaction between the NOS inhibition and GABAA complex may exert an important 
neuroprotective role in the control of convulsive and Gllxio/ylic behaviours (Facciolo e/ al., 
1996). In accordance with that hypothesis are results that NOS inhibitors, microinjected into 
dorsal central grey, exert anxiolytic effect (Guimaraes el al., 1994). Additionally, NOS 
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inhibitors block seizures induced by OABAA antagonist, bicuculline (proctor el al., 1996). In 
that epileptic model the removal ofloeal GABA~ergic inhibition allows seizures to occur as a 
result of unopposed glutaminergic excitation within limbic region. Whereas activation of 
NMDA OLU receptor triggers synthesis of NO (Snyder, 1991), NO may in turn act to 
potentiate the excitatory influence of OLU, acting as a retrograde messenger to stimulate 
depolarization-dependent release ofOLU (O'Dell el 01.,1991; Schuman and Medison, 1994). 
cOMP has also been suggested to playa role in seizures, as perfusion of cOMP analogues 
into the hippocampal grafts triggers epileptiform activity (Freedman el 01., 1979) and cOMP 
levels increase in several brain region prior to the onset of seizure (Ferrendelli el 01., 1980). 
It has been reported that NO participates in both functional and dysfunctional consequences 
of excitatory neurotransmission (e,g. neuronal excitotoxicity and epilepsy) via cGMP 
(Dawson el al., 1991). Based on this, NO may contribute to the epileptogenesis in response 
to excessive OLU-mediated excitation (Proctor el 01., 1996). In addition, EAA mediated 
convulsant activity may occur through the subsequent activation of NOS, as i.e.v. injections 
of exogenous L-Arg induce behavioural and electroencephalographic (EEO) activation 
(Mollace el 01., 1991). L-Arg also displays proconvulsant effects in rats treated with 
subconvulsive doses of NMDA and these effects are prevented by L-NAME. Solutions of 
NO instilled i.c.v. produce brief but violent convulsive episodes in rats (Smith el al., 1991). 
Furthermore, results from animal models of epilepsy have shown that NO mediates the 
increase in cerebral blood flow (CBF) following application pentylenetetrazol (Faraci el 01., 
1993) and bicuculline (pereira de Vasconceros el 01., 1995). Recent data implicate a neuronal 
source of NO playing a role in the increase in CBF evoked by kainate-induced seizures 
(Montecot el 01., 1997) or cerebral vasodilatation in response to NMDA (Faraci and Brian, 
1995). Accordingly, the role of NO in seizure phenomena is complex and still unclear. 
2.1.9 Trophic FUllctiolls 
With regard to potential cellular sites of action, these include a number of enzymes involved 
in cellular metabolism and DNA synthesis. These actions of NO clearly playa role in the 
modulation of cellular activity and cellular proliferation. Thus, it has been reported that in 
the nervous system, NO may serve a trophic funcHon, acting as a retrograde messenger to 
ingrown axons, thereby establishing other synaptic connections (Williams el al., 1994; Bredt 
and Snyder, 1994; Northington el 01.,1997). Additionally, the transient expression ofn-NOS 
in the nervous system may reflect a role in developmental processes (Bredt and Snyder, 1994; 
Mendez-Medina el 01., 1994). Likewise, it has been demonstrated that the activity of NOS 
showed a developmental pattern associated with the maturative processes of the brain 
(Lizasoain el al., 1996) and retina (Ientile el al., 1996). It is proposed that high levels of NO 
production occurs immediately before sYllaplogellesis (Ientile el al., 1996). 
2.1.10 Cerebral Circulalioll 
A unique feature of cerebral circulatory control is the weak functioning of adrenergic 
vasoconstrictor nerve and the dominant functioning of NANC vasodilator nerves (Kelly e/ aI" 
1995). The results strongly support the hypothesis that NO acts as a neurotransmitter in the 
vasodilator nerves in the cerebral arteries (Toda el 01., 1990a,b; Toda and Okamura, 1991). 
NANC axons are abundant in the proximal anterior and middle cerebral arteries, but are less 
numerous in small pial alieries (Adachi el 01., 1992; Northington el 01., 1992; Toda, 1993; 
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Faraci and Brian, 1994; Van Gelderen and Saxena, 1994; Van Gelderen el al. 1995). The role 
of NO in the regulation of basal CDF and activity-dependent cerebrovascular dilatation in 
experimental models is supported by a significant alllount of data (Faraci et al., 1993; Dirnagl 
el 01., 1994; Faraci and Brian, 1994; Zhang el 01.,1994). NANC derived NO acts 10 maintain 
cerebrovascular tone and necessary CBF in the brain even in a circulatory emergency. It has 
been shown that characteristics in the production and action of NO are similar in cerebral 
NANC nerves and endothelial cells (Toda and Okamura, 1991). In some primate arleries, the 
vasodilator nerve function develops with age, although it has not been determined whether 
this is due to age-dependent maturation of the perivascular nerves or to the increased 
sensitivity with age of the smooth muscle to nitro-vasodilators. NOS inhibitors can impair 
the response to nerve stimulation but do not affect Ihe relaxation caused by NO (Toda el al., 
1990a,b; Toda and Okamura, 1991). These data are sufficient to support the concepl of 
neurohumoral transmission with NO from vasodilator nerves to cerebroarterial smooth 
muscle. NO released from endothelium also mediates the cerebroalierial dilatation in 
response to chemical (vasodilator substances) or physical (blood flow change) stimuli. 
Neurogenic responses via NO are similarly observed in primate and subprimate mammals, 
while the response mediated via endothelial-synthesised NO following activation of dmg 
receptors frequently vary between animal species. Recent studies on cultured smooth muscle 
cells indicale that the NO production is also due to expression of i-NOS following cytokine or 
lipopolysaharide (LPS) stimulation (Buse el al., 1992). Nevertheless, NO derived from both 
nerve and endothelium undoubtedly plays an important role in the regulation of cerebral 
vascular tone in vitro and in vivo. Changes in vascular functions caused by NOS inhibitors 
ill vivo reflect the physiological role of NO released from nerve and/or endothelium under 
resting conditions (Toda, 1993). 
In addition, anatomical and neurochemical evidence suggests a role of (',holinergic BF 
neurons in the regulalion 0/ corlical CBF via the NOlcGMP pathway (Bruhwyler el al., 
1993). Excitotoxic destmction of BF neurons resulted in reduced cholinergic innervation of 
the cerebral cortex and a corresponding decrement in CBF when loss of cholinergic 
innervation exceeds 40% (Arneric, 1989). The most plausible mechanism suggested is that 
freely diffusible NO, as a second messenger transmitter, was released from BF neurons, 
activating guanylyl cyclase in adjacent cells (Dimagl el al., 1994; Ishizaki el al., 1991; Toda 
and Okamura, 1991). Increasing substrate availability to NOS with intravenous L-Arg 
administration modestly enhanced the BF-elicited response, while a NOS inhibitor blocked 
the BF-elicited cortical CBF response (Raszkiewicz el al., 1992). 
Similarly, it has been shown that NO pa11icipates in the regulation of CBF and 
cerebro-vascular resistance (CVR) under normoxic condition (Kozniewska et al., 1992; \Vang 
el al., 1995). Lately il has been suggested that NO plays an even more important role in 
regulating cerebral vascular tone and enhances CBF during hypoxemia than normoxemia 
(Crabb and Harding, 1996). Thus, in conditions of cerebral ischaemia n-NOS and its mRNA 
have been shown to increase (upregulated) in NANC neurons (Zhang et al., 1994). However, 
one of the most imp0l1ant aspects of the cerebral circulation is the coupling of the cerebral 
metabolic activity and the CBF. NO appears as a key coupling molecule that links changes in 
CBF and metabolism. It has been shown that NOS inhibitors reduce neuronally induced 
regional CBF responses (Goadsby el al., 1992; Northington el al., 1992; Lindauer el al., 
1996). 
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Concerning migraine, pain is probably due to depolarization of perivascular NANC 
nerve terminals (Moskowitz and Macfarlane, 1993). Large cerebral blood vessels contain far 
more n-NOS than small ones. The connection between cerebral blood vessel diameter and 
n-NOS levels fits with physiologic studies showing a prominent NANC relaxation 
mechanism in large cerebral vessels, which can play a role in the pathophysiology of 
migraine (Toda, 1981; Snyder and Bredt, 1991). 
Moreover, the findings using NOS inhibitors suggest that production of NO contributes 
to dismption of the blood-brain barrier during various inflammatory conditions (Hurst and 
Clark, 1997), multiple sclerosis (Johnson et al., 1995; Thompson el al., 1992), bacterial 
meningitis (Boje et al., 1996), cerebral ischaemia (Chi et al., 1994) and acute hypertension 
(Mayhan, 1995). In acute hypertension NOS inhibitors prevent NO-mediated disruption of 
the blood-brain barrier (Mayhan, 1995). 
In addition to the endothelial-derived NO within the nervous system, it has been shown 
that NO is produced in other extraneuronal tissues. Glial cells (mainly microglia) also 
synthesize NO via i-NOS. Astrocytes express i-NOS and n-NOS, although at lower levels 
than neurons (Murphy el al., 1995). 
2.1.11 lIifTommolioll 
During systemic ilif/ammalioll induced by intraperitoneal injection of LPS, cerebral levels of 
i-NOS mRNA are affected, with increased expression in the anterior pituitary, chorioid 
plexus and meninges and, latcr on, in the paraventricular nucleus and arcuate nucleus. This is 
accompanied with production of NO in the brain parenchyma and in the CSF (Mitrovic el al., 
1994, 1995). Since cytokines and LPS are not present in the normal brain in the quantities 
that cause induction of the enzyme in vitro, results have shown that i-NOS expression will 
occur in vivo only under pathological condition, such as inflammation/injection or injury, 
while NOS inhibitors can have antiintlanunatory effects (Salvemini et al., 1995). Evidence 
for induction of i-NOS in CNS in vivo has only recently been found and are provided by 
models of acute eNS infections, autoimmune reactions, ischaemia, seizure, migraine, spinal 
hyperalgesia, opioid tolerance and traumatic injury. In a number of these studies, especially 
those using NOS inhibitors, it is not clear whether the NOS induced is i-NOS or c-NOSs 
(n-NOS or e-NOS). Therefore, selective NOS blocking drugs are essential for evaluating the 
role of NO in physiological and pathophysiological processes with particular clinical and 
therapeutic implications (Mesenge et al., 1996). 
During acute or chronic viral injection in the eNS a variety of cytokines are produced in 
increased amounts, including interferon ganuna and interleukin-l (Frei et aI" 1988; 
Beveniste, 1992; Sclmeider-Schaulies et al., 1993). Studies demonstrate that i-NOS is 
expressed in vivo in the brain during acute viral infection (Adams et al., 1990), Recently, 
such induction of i-NOS has been reported ;n vivo in other eNS infections, such as acute 
cerebral loxoplasmosis (Gazzinelli el al., 1993) and reduced replication of Toxoplasma 
gOlldii with NO produced either by i-NOS or released from sodium nitroprusside (Bohne 
el al., 1994). Additionally, a possible cytotoxic role for NO under such conditions has been 
suggested by the fact that macrophages expressing i-NOS and producing NO have been 
shown to be cytotoxic for cells infected with intracellular pathogens (Adams et al., J 990) and 
tumour cells (Stuehr and Nathan, 1989). This toxicity could result in the promotion of the 
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clearance of vims from infected cells and/or contribute to tissue damage through cytotoxic 
effects on uninfected neighbour cells. 
Furthermore, expression of i-NOS has been reported during experimental allergic 
encephalitis (EAE), an autoinUllune demyelinating process considered as a model for human 
multiple sc/erosis (MS; Koprowski el al., 1993). When stimulated by interferon-a and 
interleukin-fi ill vitro human astrocytes produce NO, whereas microglial cells generate 
oxygen radicals. i-NOS is present in MS lesions (Okuda el al., 1995) and its inhibition 
attenuates the development of EAE in rodents (Zhao el al., 1996). Brains of animals with 
EAE have been shown to express increased levels of cytokines (Benveniste, 1992). 
Additionally, cytokine-activated microglial cytotoxicity for oligodendrocytes in vitro has 
recently been shown to be mediated by NO (Merrill el al. ,I., 1993). Therefore, a glial source 
and possible cytotoxic role for NO produced by i-NOS during eNS demyelination in vil'o is 
suggested. In the experimentally produced autoimmune disease EAE, microglia destroy 
oligodendrocytes in a NO-dependent fashion (Merrill el al., 1993). i-NOS-positive 
infiltrating macrophages have been found in necrotic areas, thus, the damage of myelin and 
oligodendrocytes in MS results in a cytokine-mediated increase in NO production by 
macrophages/microglia (Okuda et al., 1995), Increased i-NOS expression has been found in 
rats developing EAE and this preceded detectable clinical signs and symptoms (Koprowski 
et al., 1993), However, administration of L-Arg derived NOS inhibitors in experimental 
autoimmune neuritis and experimental autoitmnune encephalomyelitis had only little or no 
effect (Zielasek el al., 1995). 
2.1.12 Trauma 
Similar to inflammatory processes in the eNS, traumatic ily'wy of the brain results in an 
increased expression of cytokines such as interleukin-l by resident cells and infiltrating 
macrophages, creating an environment conductive for induction of i-NOS in vivo, In two 
models of traumatic injury, cerebral stab wound and ventral spinal root avulsion, expression 
of i-NOS in vivo has been reported (Moncada el al., 1991; Vallance and Moncada, 1994; 
Anggard, 1994; Dawson and Dawson, 1996). Additionally, NOS inhibitors reduced 
neurological deficit following traumatic brain ir~ury (Mesenge el al., 1996). 
2.1.13 Neuroloxicity 
NO may be involved in pathologic changes occurring with ischaemia and seizures (Dawson 
el al., 1991). It is suggested that NO plays a role in NMDA receptor-mediated excitotoxicity 
(Dawson el al., 1991) while n-NOS inhibitors may be useful in the treatment of neurologic 
diseases in which excitotoxic mechanisms playa role (Buisson et al., 1992; Dawson and 
Snyder, 1994; Schulz el al., 1995). Thus, neuronal NO production appears to exacerbate 
acute ischaemic injury, whereas vascular NO protects after middle cerebral artery occlusion. 
The data emphasize the importance of developing selective inhibitors of the n-NOS (Huang 
et al., 1994). Moreover, NOS has also been shown to release reactive oxygen intermediates 
in the presence of low concentrations of L-Arg or tetrahydrobiopterin (Heinzl et al., 1992; 
Pou et al., 1992). Furthermore, NO reacts with reactive oxygen intermediates such as 
superoxide and peroxide, forming even more toxic peroxynitrate anions, which have been 
implicated in the development of many diseases such as ischaemia reperfusion injury and 
inflammation (Beckman el al., 1990; Radi el al., 1991; Noronha-Dutra el al., 1993; Kooy and 
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Royall, 1994). Therefore, it is possible that not only NO but also reactive oxygen radicals are 
involved in tissue injury, while NOS inhibitors could be protective (Ishii et al., 1997). 
Inhibition of NOS has yielded conflicting effects upon the outcome of cerebral and 
spinal cord insults. In contrast to results obtained with non~selective NOS inhibitors, studies 
using n-NOS and i-NOS inhibitors have uniformly showed reduction in infarct size. These 
findings suggest that both n-NOS and i-NOS activity are detrimental to the ischaemic brain, 
while e-NOS activity might be protective, at least in the early stages (Margaill el al., 1997). 
Accordingly, immediately after ischaemia, intravascular administration of L-Arg or of NO 
donors as sodium nitropmsside and 3-morpholino sydnonimine reduces infarct size, 
improving blood flow in the penumbra, that surrounded ischaemic tissue. However, L-Arg is 
not effective when it is administered more than 30 min after induction of ischaemia, while 
NO generating drugs lose their efficacy more than 2 h post ischaemia. Evidently, beneficial 
effect of NO production at the vascular level is protective only during the very early stages of 
cerebral ischaemia (IadecoJa, 1997). Consistent with increased glutaminergic transmission, 
NMDA excitability and consequent n-NOS activity in the brain ischaemia-reperfusion is 
resistance to GLU of the n-NOS knockout neuronal cultures and mice (ladecola, 1997). 
Recent data support a neuroprotective role of NOS inhibitors in transient global ischaemia in 
the gerbil (Kohno el al., 1997). A better understanding of the balance between the 
physiological functions of NO and the mechanisms of toxicity will determine the therapeutic 
potential of modulating NO production (Varner and Beckman, 1995). 
The important role of GLU and Ca2+ in mechanisms of cell ily'wy induced by severe 
cerebral hypoxia or ischaemia has been emphasized (Chleide e/ al., 1991; Dawson et al., 
1991). Convincing evidence related to the involvement of NO in neurotoxic processes has 
been obtained in experiments showing that production of NO following NMDA receptor 
activation induced extended damage in primary rat cortical cultures (Dawson e/ al., 1991), 
and in rat hippocampal slices (Izumi el al., 1992). Similarly, cortical cultures exposed to NO 
donors, sodium nitroprusside and S-nitroso-N-acetylpenicillamine exhibited a delayed 
neurotoxicity, which follows the same time course as NMDA neurotoxicity (Dawson and 
Dawson, 1996). Elimination ofn-NOS through transgenic technology results in a culture that 
is resistant to NMDA neurotoxicity indicating that n-NOS neurons are the source of 
neurotoxic NO (Dawson and Dawson, 1996). Most neural destruction in stroke seems to 
result from massive release of GLU, which, activating NMDA receptors, with consecutive 
stimulation of NOS and increasing activity of the NO/cGMP system, causes excess excitation 
leading to neuronal death (Snyder and Bredt, 1992; Choi, \993). Tins model is supported by 
the ability of NOS inhibitors to block the nellroloxic effecls of GLU and NMDA in brain 
cultures (Dawson e/ al., 1991). The results from culture have been translated into clinically 
relevant models, as in several species low doses of NOS inhibitors, administered after ligation 
of the middle cerebral artery, provide marked protection against stroke injury (Nowicki et al., 
1991). Thus, NO, whether endogenously synthesized or directly produced from an NO 
donor, seems to be a primary signal in the sequence of events leading to neuronal death 
(Loiacono el al., 1992). 
Nellrotoxic des/ruction by NMDA of neurons in culture, a model for stroke, can kill 90% 
of neurons, whereas NADPH-d neurons are completely preserved (Snyder and Bredt, 1992). 
Furthermore, striatal neurons expressing NADPH-d are spared in Huntington's chorea 
(Ferrante el al., 1985; Kowall el al., 1987; Morton el al., 1993), although a significant 
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decrease in the striatal neuropil NADPH-d staining occurs in this disease (Morton et 01., 
(993). Moreover, NADPH-d positive neurons survive in greater numbers than neighbouring 
NADPH-d negative neurons in Alzheimer's dementia (Hyman et al., 1992), ischaemia 
(Uemura el al., 1990), some forms of excitoloxicily (Koh el al., 1988) and in amyolrophic 
laleral sclerosis (ALS; Welts and Vaughn, 1994). Something about NOS makes neurons 
resist neurotoxic damage. A paradox has arisen because the NOS product NO is also a result 
of OLU activity, while OLU itself is responsible for nellrotoxicity. A possible explanation 
could be that NO is toxic for adjacent neurons (Snyder and Bredt, 1992, Rogers and Ignarro, 
1992; Rengsamy and Johnson, 1993). However, expression of NOS does not necessarily 
make a neuron resistant to excitotoxicity (Endoh el al., 1994). Highlighting that paradox 
could provide therapeutic opportunities for major neurologic pathological states, including 
Huntington's chorea, Alzheimer's dementia and stroke (Snyder and Bredt, 1992). 
2.2 Non-Adrenergic Non-Cholinergic (NANC) Nerves 
Nerves whose transmitter is neither Ach nor NA (NANC system; nitrergic ncurons) are found 
in the cardiovascular, respiratory, gastrointestinal and genitourinary systems. In each of these 
systems, immunohistochemical studies have established that nMNOS is present in the NANC 
neurons (Bredt el al., 1990), being concentrated in neuronal axons (Llewellyn-Smith el al., 
1992; Berezin el al., 1994), and upregulated (increased in expression) after nerve injury (Wu 
el al., 1994; Vizzard el al., 1995). Smooth muscle cells contain the receptor for NO, soluble 
guanylyl cyclase. Thus, in specific pathways of the PNS, NO fimctions as a NANC 
neurotransmitter throughout the body, producing relaxation of smooth muscle in cerebral 
vasculature, respiratory, urogenital and gastrointestinal systems, where it is involved in 
vasolbronchodilatation, gut peristalsis and penile erection (Burnstock, 1981; Bredt, 1996). 
The peripheral NANC neurons usually use NO as one of many neuromediators to 
decrease smooth, cardiac and possibly skeletal muscle tone contractility and intracellular 
Ca2+. Cardiac JllANC neurons illl1crvate the pacemakers and myocardium to mediate negative 
inotropic autonomic influences (Balligand et al., 1993). 
In human bronchi in vitro, bronchodilatation mediated by the NANC neurons is blocked 
by NOS inhibitors (Belvisi el al., 1992) and results of NO inhalation by healthy hl!mans 
(Gustafsson el al., 1991) suggest the physiological role for NO in the mechanisms matching 
ventilation and perfusion (Wiklund el al., 1990). 
Within the genitollrinmy system NO relaxes smooth muscle of the upper and lower 
urinary tract (Persson et al., 1993), utems (Kurtzman et al., 1993) and corpus cavernosum 
(Hibbs el al., 1988). Recently NOS activity has been found in rat and human uterus 
(Kurtzman el al., 1993), while administration of NOS inhibitors blocks labour in sheep 
(Heymann el al., 1993). These results implicate that basal production of NO maintains the 
uterus in a quiescent state during pregnancy (Natuzzi et al., 1993). NANC ncrves have been 
immunohistochemically identified in human corpus cavernosum (Leone et al., 1994), while 
NOS inhibitors block neurogenic relaxation of corpus cavernosum (Raifer el al., 1992; 
Burnett at el., 1992). Thus, corpus cavernosum relaxes in response to stimulation ofNANC 
nerves to cause penile erection. L-NMMA blocks erection in experimental animals (Burnett 
el al., 1992), while NO donors promote erection in patients (Meyhoff el al., 1992). It was 
previously thought that vasoactive substances, such as vasoactive intestinal peptide (VIP) and 
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substance p) were mediators of penile erection. Nevertheless, it has been demonstrated that 
NO is the major physiological mediator of penile erection. 
In the gastrointestinal system, production of NO in response to nerve stimulation 
mediates adaptive relaxation of the stomach (the mechanism by which the gut accommodates 
food, Desai el al., 1991), relaxation of sphincters (including sphincter Oddi; Kaufman el al., 
1993) and the relaxant part in the peristaltic cycle (Burleigh, 1992). In human gut, NANC 
l.leurons have been demonstrated in the myenteric plexus (Mearin el al., 1993), sphincter Oddi 
(Kaufman el al., 1993) and duodenal sphincter (Yanderwinden el al., 1992). 
In striated muscle of the oesophagus, NOS immunoreactivity is confined to NANC nerve 
fibres terminating on motor endplates (Wor! el al., 1997). In addition, besides the NANC 
system, in the skeletal muscle, NO is confined to the sarcolemma of fast-twitch myofibres, 
where it attenuates force development (Nakane el al., 1993; Kobzbik el al., 1994). Induction 
of NOS in adult spinal mo!oneurOl1S has been associated with motoneuronal death and it has 
been suggested that NO is involved in cell death induced by deprivation of trophic factors 
(Kanda, 1996). 
2.3 Cardiovascular System 
Biological roles of NO were first recognized in the cardiovascular system. Furchgott and 
Zawadzki (1980) found that blood vessel relaxation in response to Ach requires the 
endothelium, which releases a labile substance that diffuses to the adjacent smooth muscle. 
This endogenous relaxing factor appeared to be NO, the active metabolite of nitroglycerin 
and other organic nitrates, as they all dilate blood vessels by stimulating cGMP formation 
through activation of guanylyl cyclase (Arnoldt el al., 1977). Under physiological 
conditions, the major source of NO in the cardiovascular system is e-NOS and in some 
vessels n-NOS from NANC neurons. Only under pathological conditions, i-NOS is 
expressed in other cells including vascular smooth muscle, producing higher amounts of NO. 
Major roles of NO in cardiovascular system are control of vascular tone and platelet and 
leucocyte functions (Vallance and Moncada, 1994). 
It is likely that NO-dependent vasodilator tone is entirely locally regulated and, as such, 
is probably one of the simplest and yet most fundamental adaptive mechanisms in the 
cardiovascular system. The available evidence, therefore, indicates that the cardiovascular 
system is in a state of constant active vasodilatation dependent on the generation of NO. 
Indeed, NO can now be considered the endogenous vasodilator (Moncada el al., 1988). 
2.3.1 Elldolhelial cells 
Endothelial cells were found to generate sufficient NO from L-Arg to fully account for 
endothelial-derived relaxing activity (palmer el ai., 1987). NO is crucial in the regulation of 
blood flow and blood pressure (Moncada el al., 1991) and also inhibits platelet aggregation 
and adhesion (Radomski e/ al., 1987); these actions are mediated via the stimulation of 
soluble guanylyl cyclase. Endothelium-dependent, L-NMMA-inhibitable relaxation has been 
demonstrated in isolated arteries, veins and microvasculature. Systemic infusion of NOS 
inhibitors increase blood pressure by inhibiting e-NOS (Calver el al., 1993). Local 
administration of L-NMMA into the brachial artery of man reduces forearm blood flow by 
40%. Thus, the resistance vessels are in a continuous state of NO~mediated vasodilatation. 
However, basal release of NO does not control the resting tone of peripheral veins, although 
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it may have an effect on central veins (Anggiird, 1994). Endothelium-derived NO inhibits 
platelet adhesion and addition of L-NMMA to a perfused vascular bed ill vilro increases the 
adhesion of platelets and leucocytes (Vallance el al., 1989; Radomski el al., 1987; Kubes 
el al., 1991). However, short term administration of a NOS inhibitor to healthy animals 
(Remuzzi el al., 1990) or humans (Vallance ef al., 1992) does not cause generalised platelet 
aggregation. These results implicate that endothelium-derived NO, together with 
prostacyclin, make a defence layer against the aggregation of activated platelets. Therefore, 
the physiological role of endothelium derived NO is to provide vasodilatation and prevent 
platelets and leucocytes adhesion (Anggard, 1994). Additionally, the NO system is present in 
human plalelels and NO synthesised by that c-NOS may act as a negative feed-back system 
to limit the extent of activation of c-NOS (Radomski el al., 1990). 
Accordingly, endothelium maintains blood pressure and flow, while endothelium 
damage leads to cardiovascular disease (Calver el al., 1993; Vene el al., 1990). Genetic 
abnormality in familial hyperholesterolemia (Flavahan, 1992) and type I insulin-dependent 
diabetes mellitus (Calver el al., 1992) cause an abnormal endothelium-dependent vascular 
response. Acquired endothelial dysfunction is associated with smoking and dietary 
hyperlipidaemia (Henderson, 1991). The net effect of impaired release of endothelial 
mediators sllch as NO and prostacyclin is loss of vasodilator tone and exaggerated and 
paradoxical vasoconstrictor response to mental and physical stress (Anggarcl, 1994). 
In contrast, overproduction of NO by i-NOS induced in vascular smooth muscle, 
endothelial cells, leucocytes, endocardium and myocardium by endotoxins in sepsis and 
endotoxic shock causes generalised vasodilatation, hypotension and decreased myocardial 
contractility. This is blocked by NOS inhibitors, restoring blood pressure and vascular 
responsiveness to pressor agents in animal models and humans (Calver el al., 1993; Laszlo 
et al., 1995). Even in irreversible haemorrhagic shock, L-NAME overcomes vascular 
paralysis (Thiemermann ef al., 1993). 
2.3.2. MyocardlulII 
Cardiac function is regulated by both sympathetic noradrenergic and vagal cholinergic 
nerves, but there is also an extensive NANC innervation (Pabla and Curtis, 1996). Recently, 
induced NOS Was detected in fibres innervating conducting and contractile cardiocytes, 
cardiac ganglion cells and coronary arteries and both c-NOS and i-NOS activities are present 
in the human myocardium (De Belder el al., 1993). c-NOS is present in myocardium and 
endocardium (Henderson el al., 1992; Finkel ef al., 1992), while the cardiomyopathic 
ventricle expresses i-NOS (De Belder ef al., 1993, 1995). However, NOS inhibitors usually 
cause a fall rather than a rise in cardiac output, probably due to reflex changes in peripheral 
resistance and increased blood pressure (Klabunde el al., 1991; Petros el al., 1994). Fm1her, 
NO deficiency induced myocardial infarction in hypercholesterolemic stroke-prone 
spontaneously hypertensive rats (Ikeda el al., 1997), while acute inhibition of NO 
biosynthesis by L-NAME causes myocardial necrosis (Moreno el al., 1997). However, in the 
genetically hypertensive rat strain cardiovascular stl11cture has been more sensitive to NOS 
inhibition than either normal or spontaneously hypertensive rat strain (Ledinghham and 
Lave11y, 1997). Recent results implicate that L-NOARG does not completely inhibit 
endothelial cell NO synthesis in human isolated small coronary 3l1eries and that 
nOII-NO-dependent relaxation to bradykinin appears to be mediated by a K+ -sensitive 
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vasodilator mechanism, possibly endothelium-derived hyperpolaryzing factor (Kemp and 
Cocks, 1997). 
Moreover, NO production is influenced by cyclical hormonal changes in women, with a 
significant increase at mid cycle, protecting against cardiovascular diseases in the 
premenopausal period (Kharitonov el al., 1994). 
2.4 Other Systems 
2.4.1 1mmlllle Syslem 
It has been suggested that NO production originated as an ancient first-line defence against 
intracellular parasites. While most messenger activities of NO are based on cell-specific 
expression and regulation of Ca"-dependent c-NOSs (n-NOS and e-NOS), almost every cell 
is able to express Ca2+ -independent i-NOS during cell-mediated immune response (Nathan 
and Hibbs, 1991; Nathan and Xie, 1994). Thus, the cells produce NO as a biological weapon 
(Snyder and Bredt, 1992; Hmsher el al., 1995). 
Activation of the immune defence results in the induction of macrophage i-NOS, which 
generates large amounts of NO. \Vhen a macrophage encounters a pathogen, it engulfs the 
organism and kills it with NO, causing massive oxidative damage. NO is effective against 
various microbes (viruses, bacteria, parasites and helminths), as well as tumour cells and 
alloantigens (Knox el al., 1994). A reaction between oxygen and NO leads to the formation 
of strong oxidants (nitrogen dioxide and peroxynitrates) that are even more toxic than NO 
itself. In some cases, the inununologic defence increases become toxic to the host, with 
severe oxidative damage, hypotension and shock. Thus, NO is a toxic mediator utilised for 
host defence, contributing to the local and systemic inflammatory response and potentially 
damaging the host cells (Anggard, 1994). 
However, the induction of i-NOS and ceH-mediated immune responses by cytokines or 
microbial products can involve specific reactions such as T-cell recognition of specific 
antigen, while the NO cell-mediated immune response is always nonspecific. NO produced 
by macrophages suppress lymphocyte function and may have a particular role in inhibiting 
certain subtypes of T lymphocytes (Liew el al., 1991). Thus, NO may also have role as a 
immune modulator, regulating lymphocyte function. Other cells of the inunune system, 
including neutrophils (Kirk el al., 1990) and lymphocytes (Salvemini el al., 1989), may also 
release NO acting as immune modulator. 
2.4.2. Respiralory System 
NOS is present in lung epithelium and other pulmonary cells and NO may be a physiological 
mediator in the respiratory system (Jorens et al., 1993), causing NANC nerve-dependent 
bronchodilatation (Barnes, 1993). Reduced NO production may be involved in pulmonary 
vasoconstriction conditions (Sprague et al., 1992). Accordingly, NOS inhibitors increase 
pulmonary vascular resistance. Contrary, inhalation of NO abolishes pulmonary 
vasoconstriction in humans. In alveolar macrophages, NO constitutes an important first line 
of host defence against infection in the lung and NO is an essential component of the 
microbicidal activity of cytokine-activated macrophages (Persson et al., 1994; Kharitonov 
elal., 1994). 
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2.4.3. Gastrointestillal System 
In the gastrointestinal system NO transmission is present in the myenteric plexus of the 
stomach and intestine, responsible for gastric dilatation and peristalsis (Desai et al., 1991). 
NO-transmission has been identified in the lower oesophageal, iIIeocolonic and internal and 
anal sphincters. In gut smooth muscle, the essential role of NO is particularly evidenced by 
development of a grossly enlarged stomach and spasm of sphincter and the circular muscle 
layer in mice lacking II-NOS (Huang et al., 1993). Further data provides evidences that NO 
is released in the stomach and colonic wall during vagal nerve activity, at concentrations able 
to cause inhibition of smooth muscle contractions in vivo (Iversen e/ al., 1997). Evidently, 
NO has important roles in the gastrointestinal tract maintaining adaptive dilatation, 
peristalsis, compartmentalisation and control of special internal sphincters (Deasi e/ al., 1991; 
Niioka el al., 1997). 
2.4.4 Gellitourillary System 
In the genitourinary system, NANC produced NO causes relaxation of corpus cavernosum 
and consecutive penile erection (Leone e/ al., 1994), while during pregnancy it causes 
maintenance of uterine contractile quiescence (Yallampalli e/ al., 1993). In the kidney, NO 
may have a local signalling role (Thomp el al., 1996). It has been demonstrated that the 
macula densa synthesises NO in response to sodium reabsorption and this dilates the afferent 
arteriole to increase glomerular filtration (\Vilcox e/ al., 1992). 
2.4.5 Elldocrine Syslem 
Results within the endocrine system show that NO stimulates release of insulin from 
pancreatic beta cells (Scluniqt el al., 1992), regulatcs release of renin from kidney (Reid and 
Chiu, 1995) and is involved in the regulation of thyroid hormone production (Millatt el al., 
1993). Additionally, there is morphological evidence ofNANC itmervation in the pancreas 
and adrenal gland (Bredt el al., 1990). Along with the role of cGMP in hormone secretion, 
effects of NO in modulating levels of cGMP in the endocrine system are implicated. 
Accordingly, L-Arg has been used for many years for testing pituitary function and it 
stimulates the release of a variety of hormones such as growth hormone, prolactin, glucagon, 
somatostatin, catecholamines, insulin and pancreatic polypeptide (Barbul e/ al., 1986). 
However, recently it has been suggested that NO may playa role in the destmction of 
pancreatic beta cells during the development of autoinunune type I diabetes mellitus (Corbett 
el al., 1993). Treatment with NOS inhibitors reduced macrophage infiltration into pancreas 
and prevents hyperglycaemia. Selective i-NOS inhibitors would be of potential value 
preventing immunogenic destruction and progression of autoimmune type I diabetes mellitus 
(Anggilrd,1994). 
Involvement of NO in peptide hormone release extends from the hypothaiamo-pituitary 
site affecting the corticotrophin releasing hormone/corticotrophin system, to the adrenal 
cortex where adrenocorticoid synthesis is inhibited. This anti-adrenocorticoid effect of NO 
and the immunosuppressive effects of glucocorticoids upon cytokine-induced i-NOS 
expression can provide maintainance of the equilibrium of both processes that control the 
strength of systemic endocrine as well as immune responses. 
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2.4.6 Reproduction 
NO can promote reproduction on several levels, beginning with enhanced luteinizing 
hormone-releasing factor secretion, which induces mating behaviour. In males, additionally 
to relaxation of corpus cavernosum, NO may modulate motility of spermicytcs (Shmidt and 
Walter, 1994). In pregnant females, NOS is expressed in the placental villi, regulating 
placental blood flow and is further induced with plasma progesterone levels. Afterwards 
NOS expression decreases to allow the delivery (Yallampalli e1 al., 1993). 
Evidently, NO systems have important roles in both, physiological and 
pathophysiological processes. This implicates the importance of NO systems in clinical 
medicine with promising therapeutic possibilities. 
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CHAPTER 3 
NITRIC OXIDE AND CLINICAL MEDICINE: 
THERAPEUTIC ASPECTS 
Based on numerous biological roles of NO, its impact on clinical medicine is developing. 
However, the ubiquity of NO and its involvement in a wide variety of physiological and 
pathophysiological mechanisms implicate that drugs designed to modifY NO biological 
activity may have distinct effects. The list of pathological conditions in which NO is an 
important mediator is increasing (Moncada and Higgs, 1993) and the changes of the 
L-Arg/NO/cGMP system could be implicated in a wide variety of diseases. Thus, further 
clinical applications of NO, its aIlalogues or of newly developed NOS inhibitors are 
forthcoming. The therapeutic challenge would consist in manipulating the NO pathways 
selectively (Moncada el al., 1991). 
3.1 Diseases with Hypofunction of Nitric Oxide System 
3.1.1. Cartliovascular Diseases 
The most common conditions with hypofunction of the NO system are hypertension Gnd 
vasospastic diseases. Decreased synthesis or action of NO has been implicated in virtually 
every pathophysiologic state associated with increased vascular tone, vasospasm or enhanced 
adhesion of platelets and leucocytes to the vessel wall (Anggard, 1994). Likewise, the NO 
system is impaired in patients with essential hypertension (Calver e/ al., 1993). Diminished 
basal NO~mediated vasodilatation has been demonstrated in patients not only with 
hypertension (Calver el al., 1992a; Panza el al., 1993), but also with hypercholesterolemia 
(Creager el al., 1992), atheroma (Ludmer el al., 1986) and angiopathy in diabetes mellitus 
(Calver el al., 1992b; Johnstone el al., 1993). In addition, endothelial functions, including 
NO release and actions, are clearly impaired in important vascular diseases, such as 
atherosclerosis, reperfusion injury and vasculopathy associated with angioplasty, bypass 
surgery and transplantation (Nathan, 1992; Bucala e/ al., 1991; Hogan e/ al., 1992; Busse and 
Fleming, 1993). However, treatment of hypertension may restore NO~mediated vasodilatation 
towards normal (Calver el al., 1991 a). Flow-dependent coronary dilatation by NO has been 
demonstrated in humans (Drexler el al., 1989), while decreased endothelium-dependent 
relaxation has been reported in arteriosclerotic coronary arteries (Moncada, 1992). 
Concerning therapy, llitl'ovasodilalors have been in clinical practice for about 100 years 
and are still widely used in conditions such as coronary heart disease, congestive heart failure, 
hypertensive emergences, pulmonary hypertension, fibrinolysis, percutaneous coronary 
angioplasty and complications after cardiac catheterization (Moncada e/ al., 1991). 
NO-containing vasodilatator drugs, including glyceryl trinitrate, other nitrate esters, sodium 
nitroprusside and a new one, molsidomine, have been used clinically to decrease systemic 
vascular resistance and blood pressure. However, only recently their mechanism of action via 
the liberation of NO, followed by increased cGMP, vascular smooth muscle relaxation and 
inhibition of platelet aggregation (Murad el al., 1979; Ignarro, 1989) has come to light. In 
addition, it has been shown that NO donors, glyceryl trinitrate or sodium nitroprusside, also 
decrease myocardial contractility (Grocott-Mason e/ al., 1993). However, nitrovasodilators 
preferentially dilate veins (MacAllister el al., 1995a) and this is the basis for at least part of 
the efficacy of glyceryl trinitrate in the treatment of heart failure and coronary heart disease, 
explaining also unwanted postural hypotension as a side effect. The venoseiectivity is most 
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easily explained by the observations that veins have low basal output of NO (Vallance el £II., 
1989) and consequently the guanylyl cyclase in venous smooth muscle is upregulated. 
Likewise, results from animal studies implicate that nitrovasodilators have an exaggerated 
effect in vessels with damaged endothelium or impaired NO production (Moncada ef al., 
1991). This effect also occurs in human coronary vessels ill vivo and contributes to the 
anti-anginal effect of Ilitrovasodilators. The anti-platelet effect of conventional 
nitrovasodilators is smaller than dilatation, but the new drug S-nitroso-glutathione 
metabolises NO within platelets, inhibiting platelet aggregation at doses that cause only 
minimal vasodilatation (Radomski e/ al., 1992), Recent results implicate a possible 
protective role for nitrovasodilators in stroke, but it is not yet clear whether tlus is a vascular, 
platelet or neuronal effect of the drugs (Vallance and Moncada, 1994). 
New therapeutic approaches may be aimed specifically at preserving endothelial integrity 
and boosting a failing NO system by administration of L-Arg or preventing its destnlCtion by 
using antioxidants. In advanced states of endothelial dysfunction it would not be possible to 
enhance endogenous NO synthesis. Therefore, substitution with exogenous NO generators 
would be beneficial. Traditional NO donors, such as nitroglycerine, will be replaced by new 
NO generators having both vasodilating and anti-adhesive effects without development of 
tolerance (Anggard, 1994). 
Further enhancement of the NO system has been obtained by agonist-stimulated NO 
synthesis (Vallance and Moncada, 1994). c-NOS activators, such as Ach, bradykinin, 
substance P and 5-HT, activate e-NOS and stimulate endothelial cells to release NO. It has 
been suggested to develop such agonists to cause long-term stimulation of the NO system. 
For example, inhibition of angiotensin-converting enzyme (ACE) by captopril or enalapril 
increases bradykinin levels with subsequent stimulation of endothelium-dependent NO 
release. This is an additional mechanism of action of these drugs (Vanhoutte et al., 1989). 
Moreover, it has been reported that new ACE inhibitors show potentiation of memory 
retention via endothelial-derived bradykinin, activated e-NOS and the subsequent formation 
of NO (Hock and Weimer, 1992). 
Accordingly, new technology explores the possibility of enhancing endogenous NO 
production and activity, using it in treatment of common vascular degenerative diseases such 
as atherosclerosis, vascular thrombosis and I'estenosis. Moreover, the enhancement of the 
NO system could be achieved by increasing concentrations of L-Al'g, incorporated into a 
physiologically acceptable vehicle for oral use or it may he administered intravascularly 
(Calver el £II., 1991). Infusion of L-Arg decreases blood pressure in healthy volunteers and 
patients with hypertension (Hishikawa et al' J 1992) and corrects endothelial dysfunction in 
patients with hyperholesterolemia (Creager el £II., 1992; Drexler el al., 1991). Beneficial 
effects of dietary L-Arg supplementation in cardiovascular disease is under current 
investigation (Vallance and Moncada, 1994). A new form of NO donors, called 
S-nitrosothiols, because NO is attached to a thiol, release free NO into the blood. This shows 
that NO attached to thiol can provide a regulatory function in a new blood substitute 
(Stampler el al., 1996). Since superoxide rapidly inactivates NO and it has been suggested 
that giving superoxide dismutase and blocking the endogenous production of superoxide 
might protect NO activity (Gryglewski el al., 1986). Components of the NO metabolic 
pathway may be also manipulated by enhancing the amount of present NOS, either 
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specifically in the vascular lesion site or systemically in the vascular network (Vallance and 
Moncada, 1994). 
Furthermore, development of an NO sensor on the tip of a catheter used for angioplasty 
would allow detection of local NO production after Ach or bradykinin treatment (Bassenge, 
1992). This clinical test for detemlination of the functional state of the endothelial lining 
could be monitored in regions of arteriosclerosis before and after angioplasty. It could be 
used to determine the functionality of endothelial cells covering denuded vascular surfaces. 
The effect of nitrovasodilators could also be monitored with this ultramicrosensor for NO 
(Creager ef al., 1992; Drexler ef al., 1991). Once developed, the clinical assessment of NO 
production and effects in specific sites of the coronary vasculature would become a useful 
clinical tool (Kiechle and Malinski, 1993; Vallance ef al., 1995). 
3.1.2. RespiralOlY Diseases 
NADPH-d and inununostaining have shown expression of c-NOS in human nerve elements 
and large vessel endothelium and i-NOS in alveolar macrophages in human lung (Kobzbik 
ef al., 1993). NOS is found in respiratory epithelial cells (Robbins el al., 1993). In the 
respiratory system decrease of NO production by c-NOS provides a link between pulmonary 
hypertension and chronic lung disease, while abnonnalities ofNANC neurons supplying the 
airways could increase bronchial constriction (Dinh-Xuan e/ al., 1993). Accordingly, NO 
was detected in exhaled air of humans (Gustafsson ef al., 1991). In addition, inhalation of 
NO gas by humans has resulted in the reversal of pulmonary vasoconstriction caused by 
hypoxia (Blomqvist ef al., 1993) or pulmonary hypertension (Kinsella ef al., 1992; Rossaint 
ef al.,1993). Adult patients with severe respiratory distress syndrome treated with NO 
inhalation show reduced pulmonary artery pressure and increased arterial oxygenation 
(Rossaint ef al., 1993). Bilateral pulmonary infiltrates secondary to pneumococcal 
pneumonia were reversed by NO inhalation (Blomqvist ef al.,1993). Recent results implicate 
that inhaled NO is beneficial in the treatment of pulmonary hypertension, common in 
neonatal and adult respiratory distress syndrome and after cardiopulmonary bypass surgery 
(Frostell ef al., 1991, 1993; Pepke-Zabe ef al., 1991; Rossiant ef al., 1993; Winberg ef al., 
1994). 
It has been found that inhaled NO in low concentrations 50-80 ppm (2-3.2 ~molll) causes 
selective pulmonary vasodilatation, bronchodilatation, improving arterial oxygenation, 
without causing systemic vasodilatation. Inhalation of very low concentrations of NO gas (in 
order of 100 parts per billion) appears to cause selective vasodilatation of vessels supplying 
ventilated alveoli and this therapeutic strategy might be useful in certain patients with acute 
lung injury (Benzing ef al., 1995; Samama ef al., 1995) or other causes of pulmonary 
hypertension (pepke-Zaba ef al., 1991; Gerlach ef al., 1993). Inhaled NO at low 
concentrations «80 ppm) is rapidly taken up by the capillary blood of the lung, causing an 
increase in excretion of nitrates. Since the airways follow the pulmonary arteries into the 
lung as far as the precapillary level, it is easy to understand how some inhaled NO can diffuse 
over to resistance pulrilOnary arterioles. By acting on the abluminal side of the arteriolar 
vascular smooth muscle, NO causes specific vasodiJatation in the well-ventilated segments of 
the lung. Following diffusion into the blood, it is rapidly inactivated by binding to 
haemoglobin and thus will not have any generalised vascular effect. Tllis selective 
vasodilatation is observed by NO in pulmonary vasoconstriction and pulmonary 
66 Chapter 3: Nitric oxide and clinical medicine: therapeutic aspects 
hypertension. There remain substantial issues to be addressed about long-term consequences 
ofinhaled NO, but it is clear that breathing 20-40 ppm (about 0.6-1.6 IlmoVI) for several days 
does not cause obvious toxicity in humans (Schmidt and Walter, 1994). Although inhaled 
NO has been successfully used in treatment of acule pulmonmy hyperlension (Higenbottam, 
1993) it is still an experimental therapy. Some chronic and severe pulmonmy hypertension 
appears to be associated with structural changes, rendering these conditions resistant to NO 
inhalation (Roger el al., 1996). Inhalation of NO may be associated with risks. Although it 
is generally well tolerated, NO can cause tissue damage by free radical formation and 
intlanunation due to increased capillary penneability. Precise control of NO concentration in 
the inspired gas of continuous flow respiratory devices provides the possibility of using 
inhaled NO with appropriate safety precautions (Hudome el al., 1996). Inhalation of NO will 
develope in the future, because efficacy and safety evaluation will help to determine its 
position in treating acute pulmonary hypertension and bronchial aSlhma (Anggard, 1994; 
Dhillon el al., 1996). 
NO reacts with other free radicals and with some metals, but is remarkably unreactive 
with most biological molecules. While NO is a free radical, it is not necessarily highly 
reactive or destmctive. NO has the highest diffusional coefficient of any biological molecule, 
being lA-fold higher than oxygen or CO at 37'C degree. Inhalation of NO from ambient air 
and nasopharynx epithelium, acts in concert with local synthesis in epithelial, endothelial and 
neuronal cells to optimize ventilation and regulate bronchial epithelial ciliary motility, mucus 
secretion and airway tone (Schmidt el al., 1992 a). Contrary, concerning morbidity of the 
upper aerodigestive tracts, reduced salivary NO levels in smokers may potentiate roles in the 
pathogenesis of smoking related diseases (Bodis and Haregewoin, 1994). 
3.1.3 Gaslrointestinal Diseases 
No is also formed in the stomach from both exogenous and endogenous (epithelium, 
endothelium) sources, through the conversion of nutritional nitrate to nitrite by facultative 
anaerobic bacteria (Sclunidt el al., 1992a). Inhibition of NOS blocks mucosal hyperaemia 
and aggravates experimental gaslric IIlceralion, suggesting a physiological cytoprotective 
effect of NO on mucosa that may provide resistance to Heliobacler pylori (Kim and Kim, 
1996). However, gastric NO formation could have a mutagenic risk by its potential for 
nitrosamine formation from nutritional amine precursors. 
The discovery of a deficient NOS in the pylorus in infanlile hypertrophic pylorospasm 
may be the first example of absent NO production in gastrointestinal smooth muscle, while in 
achalasia, Hirschsp1'lmg's disease, NANC nerves are missing or lack nRNOS (Vanderwinden 
el al., 1992; Mearin el al., 1993; Sclunidt and Walter, 1994). The absence of dilatatory 
activity of NO released locally in the pylorip muscle could explain the pylorospasm in 
children with this condition. This is consistent with dil11inished NO synthesis in 
opiate-induced constipation (Calignano el al., 1992). Additional data suggest a novel clinical 
approach using local NO donors to control gastrointestinal motility and regulate sphincteric 
function (Slivka el al., 1994). An ointment containing 0.5% nitroglycerine is recently 
introduced in' the therapy of haemorrhoids and fissures, because nitroglycerine ointment 
releases NO, which opens the anal sphincter, allowing blood to flow from the area and relieve 
haemorrhoids and fissures (Gorfine, 1995). 
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3.1.4 Diseases of Gellitourillary Tract 
Based on the findings thal' NOS is expressed in man's pelvic NANC neurons, innervating 
corpora cavernosa and in neuronal plexuses of the adventitial layer of the penile cavernosus 
arteries, NO is identified as a neuronal mediator of penile erection in men (Burnett et al., 
1993). NOS inhibitors abolish electrophysiologically produced penile erections in men 
(Raifer et al., 1992). Accordingly, deficient NO-mediated relaxation of the corpus 
cavernosum may be associated with impotence (Saenz et al., 1989). Application of NO 
donors causes relaxation of human corpus cavemosum and penile erection (Meyhoff et al., 
1992). Therefore, local application of NO donors have a beneficial effect in impotence 
among adult men, especially in those with diabetes mellitus. It has been suggested that 
erectile impotence in chronic diabetic males is a part of the peripheral neurological 
degeneration involving the NO pathway (Ignarro et al., 1990; Anggard, 1994). Moreover, 
peripheral cGMP mechanisms have been found in testicular tissue and vas deferens derived 
NO may upregulate motility of sperrniocytes via Ca" influx (Schmidt and Walter, 1994). NO 
pathway may have a role in the control of human prostatic smooth muscle activity and/or in 
secretory neurotransmission (Hedlund el al., 1997). 
Concenting women, immunoreactive NOS nerve fibres have been found in the adventitia 
of the human uterine artery, where NO mediates vasodilatation (Toda el al., 1994). In 
pregnant females NO regulates placental blood flow, nutrition and growth in uterus during 
preterm, contributing to the maintenance of uterine quiescence and maternal vasodilatation. 
NO is involved in the pathogenesis and clinical features of hypertensive disorders during 
pregnancy (Nobunaga el al., 1996). Contrary, during parturition with uterine contraction, NO 
activity decreases to allow delivery (Yallampalli el al., 1993; Morris el al., 1995). Based on 
these results, nitroglyceryl patches have been applied successfully in blocking paitiful ulerine 
conlractions and prelel'lll labour (Lee el al., 1994). 
Hypertension and immune dysfunction in patients with chronic or end-stage renal failure 
may be secondary to NOS blockade by an increased concentration of two endogenous L-Arg 
derived NOS inhibitors: L-NMMA and ADMA (Vallance el al., I 992a). Patients with 
chronic renal failure have decreased plasma L-Arg concentrations and elevated plasma 
ADMA levels. NO deficiency leads to hypertension and renal damage (Baylis and Vallance, 
1996). ADMA, as potent competitive inhibitor of NOS, might induce vasoconstriction, that 
can further cause some complications of rellal failure (MacAllister el al., I 996a,b). 
Moreover, inhibition of the activity of dimethylarginine dimethylaminohydrolase (DDAH), 
an enzyme that metabolizes L-NMMA and ADMA, provides an alternative mechanism for 
modulating NO system (MacAllister el al., I 996a,b). 
Involvement of NO in regulation of bladder function increases new therapeutic 
possibilities for treatment of incontinence, because in the urinary system, NANC nerves 
control bladder outflow (Person el al., 1993). 
3.1.5 Ollcology 
It has been shown that certain types of immunotherapy can induce NOS, such as injection of 
interleukin-2 in treatment of renal lumours. Elevated NO production could participate in the 
anli-Iumour effecls of this immunotherapy (Habeas el al., 1992). 
Regarding the major goal in the anlicancer Iherapy to enhance the effectiveness of 
clinically used chemotherapeutic agents, NO delivery systems increase cisplatin cytotoxicity, 
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providing insight into strategies for participation of NO donors with cisplatin therapy (Wink 
el al., 1997). Further therapy is planned by devising a successful method of attaching NO 
donors into synthetic biomaterial substrates, implants which could become IIbiologically 
alive", Such implants could be used to sensitize tumour cells to be morc vulnerable to 
radiation, modulate inflammatory reactions, facilitate wound healing, boost the immune 
system (Chu, 1995). In addition, NOS inhibitors caused changes in tumour pathology, 
indicating promise for potential applications in therapy (Adams and Stratford, 1994). 
3.2 Diseases with Hypel'function of Nitric Oxide System 
In contrast to previous pathological conditions, other diseases could involve hyperfunction of 
NO system. Examples of these are septic shock, chronic inflammation, autoimmune disease, 
and stroke, accompanied with abounding release of NO from i-NOS. However, usually NO 
produced by i-NOS is involved in host-defence mechanisms, killing of pathogens including 
leislunania, mycobacterium tuberculosis, malaria parasites and certain fungi, mediates 
non~specific immunity and is toxic to tumour cells (Moncada et al., 1991; Habeas et al., 
1991). Nitrate and nitrite (stable breakdown products of NO) are produced by human 
macrophages, their amounts are variable and increased in injlammatOJY conditions (Habeas 
el al., 1992). Food intake could not account for the increase of nitrate levels (Snyder and 
Bredt, 1992; H6Ischer el al., 1995). 
3.2.1 SepsIs 
Patients, adults and newborns, with sepsis have high levels of nitrogen oxides, nitrite and 
nitrate, in semm and urine (Marzinzig et al., 1997), which may be useful in forecasting the 
severity of illness and occurrence of septic shock (Ochoa el al., 1991; Shi el al., 1993). It has 
been suggested that NO produced by i-NOS and pro-inflammatory cytokines contribute to 
reversible myocardial depression in patients with sepsis and congestive heart failure (Oddis 
el al., 1997). In studies on the ability of NOS inhibitors to reverse the haemodynamic effects 
of septic shock, some of them have recently been studied in critically ill humans with some 
success (Schilling el al., 1993). Preliminary studies in humans suggest that NOS inhibitors 
improve blood pressure and stabilize haemodynamics (Vallance and Moncada, 1993; Wolfe 
and Dasta, 1995). Likewise, L-NMMA restores hypotension in patients with septic shock 
(Petros el al., 1994). Selective i-NOS blocking drugs prevent cytotoxic effects of endotoxin 
and some cytokines in vitro and would be useful dmgs to prevent NO overproduction 
accompanied with toxicity and to reverse septic hypolension (Radomski el al., 1993). 
Accordingly, selective i-NOS inhibitors, like amino guanidine, that can block pathologic NO 
production without affecting physiological endothelial, neuronal or platelet function, are in 
current development (Misko el al., 1993; Vallance and Moncada, 1994). 
3.2.2 Inflammalion 
NO synthesis is increased in general inflammatory conditions (erythema, vascular leakiness). 
Similarly, an increased concentration of NO in the exhaled air of patient with seasonal 
rhinitis (Martin el al., 1996) and aSlhma (Person el al., 1994; Kharitonov ef al., 1994), may 
reflect inflammation of the airways, and exhaled NO may be a useful means for monitoring 
aslhma severity and treatment efficacy (Kharitonov el al., 1994). It is likely that excretion of 
NO from the lung represents an overflow from NO produced locally rather than NO extracted 
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from the blood. The measurement of NO in exhaled breath could, therefore become a useful 
indicator of pulmonary NO production in various lung diseases (AnggArd, 1994). 
Induction of i-NOS by endotoxin or cytokines appears to be part of the chronic 
inflammatOlY response and could contribute to vasodilatation, vascular leakage and tissue 
damage in a number of inflammatory conditions. NOS inhibitors decreased such NO release. 
Increased concentrations of nitrite in synovial fluid and serum in patients with osteoarthritis 
and rheumatoid arthritis, have suggested increased NOS activity in chronic rheumatic 
diseases (Farrell el 01., 1992; Ueki el 01., 1996). NOS inhibitors suppressed adjuvant-induced 
at1hritis (Connor el al., 1995). There are data showing induction of i-NOS during chronic 
inflammatory diseases, in the gut of patients with chronic ulcerative colitis and Crohn's 
disease (Middleton el 01., 1993; Boughton-Smith el 01., 1993). 
In the heart, increased production of NO following expression of the i-NOS could 
contribute to the pathogenesis of myocarditis, dilaled cardiomyopalhy and poslparlum 
cardiomyopalhy (De Belder el 01., 1993; 1995). The further cytotoxicity in the heart is 
caused by reaction of NO with superoxide forming peroxynitrate and contributing to tissue 
damage in inflarurnation and ischaemia-reperfusion (Downey el 01., 1990). 
3.2.3 Emloloxemla 
Increased activity of the NO system may be involved in maintaining vasodilatation and 
systemic circulatory disturbances in patients with severe cirrhosis and liver failure, usually 
accompanied with endotoxemia (Sogni el 01., 1995; Matsumoto el 01., 1995). Likewise, 
over-production of NO in platelets has been suggested as a cause of the bleeding tendency of 
uraemia (Remuzzi el 01., 1990; Zoja el 01., 1991). 
3,2,4 Autoimmullity 
It has been reported that the feed-back blockade on NOS catalytic activity by NO (but not 
oxidation products, such as nitrite, nitrate, peroxynitrate) serves not only to modulate NO 
production in the cell of origin but also in the neighbouring cells (Griscavage el 01., 1993; 
Rengasamy and Johns, 1993). This could be an important amplification mechanism in the 
response to invading pathogens. Alternatively, it may represent an uncontrolled process with 
disastrous consequences for host integrity. Unregulated NO production becomes self-
destructive, like in autoimmune diseases, immune rejection of allograft and graft verSllS host 
disease (Schoedon el 01., 1993). Concerning autoirrnnunity, NOS inhibitors prevent 
anti-DNA immune complex glomerulonephritis and reduce the intensity of inflammatory 
arlhritis (Weinberg et 01., 1994). Additionally, pancreatic beta cells have limited capacity for 
free radical scavenging and are thus highly sensitive to NO cytotoxicity. In 
pharmacologically induced models of insulin-dependent diabetes mellitus, progressive 
autoiinmune insulitis, dysfunction and eventual killing of pancreatic beta cells correlate with 
the induction of i-NOS and has been decreased by NOS inhibitors. Therefore, NO has been 
added to the Jist of mediators involved in processes of local and systemic inflammation in 
humans (Green el 01.,1994). 
Anti-itif!ammalory glucocorticoids inhibit induction of i-NOS but are ineffective once the 
enzyme is expressed (Radomski el 01., 1990). Tills can explain why glucocorticoids facilitate 
the spread of injections, malignancy and prevent the consequences of delayed hypersensitivity 
in conditions such as transplantl'ejection and vasculitis (Moncada et al., 1991). Similarly, 
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the anti-fungal imidazole compound, econazole, inhibits i-NOS (Bogle and Vallance, 1996), 
while the anti-inflammatory and cytotoxic drug methotrexate blocks synthesis of NOS 
cofactor H4B (Gross et al., 1992). These effects could participate in the therapeutic efficacy 
of drugs. Development of more specific anti-injlammalOJy and immunosuppressive agents 
that simultaneously block i-NOS accompanied with new therapeutic approaches would be 
beneficial for clinical practice (Salvemini et al., 1995; Pfeilschifter et al., 1996). 
3.3 Disturbed Nitric Oxide System and Neuropsychiatric Diseases 
Conditions which are not only associated with hypo- or hyper-function of NO system, but 
also with combined hypo/hyper-function of NO mechanisms, have been described. 
3.3.1 Bmilt Ischaemia 
In brain ischaemia-reperfusion damage the situation is more complex than in the other part of 
the body. NO formation initially is protective and increased, inducing collateral perfusion, 
but after time NO formation from c-NOSs ceases. Upon reoxygenation, NO production from 
i-NOS occurs, but is accompanied with the presence of peroxynitrate formation, leading to 
tissue damage. Precisely, the reaction of NO with superoxide forms peroxynitrate that causes 
cytotoxic oxidation (Beckman et al., 1990), contributing to tissue injury in brain 
ischaemia-reperfusion (Lipton et al., 1993). Evidence suggests that NO production is 
enhanced at all stages of cerebral ischaemia. At the onset of ischaemia, microvascular and 
parenchymal NO overproduction are driven by upregulation of e-NOS and n-NOS. At later 
times, i-NOS is responsible for the synthesis of NO. Thus, vascular-derived NO protects 
against brain injury, while neuronal-derived NO leads to neurotoxicity. In the presence of 
high levels of GLU following ischaemia-reperfusion, NOS containing cells would act like 
activated macrophages continuously releasing large amounts of NO killing neighbouring 
cells. While neurons are extremely sensitive toward NO, other cells are much less sensitive 
(Kr6ncke et al., 1997). Consequently, n-NOS inhibitors, such as indazole derivatives, 
ameliorate the damage by impairing OLU-induced NO synthesis without interfering with the 
beneficial vascular effects of endothelial NO. At later times (>6 hours), i-NOS inhibitors, 
such as amino guanidine, improve ischaemic-reperfusion tissue injury (Iadecola, 1997). 
Accordingly, comparing usefulness of different NOS inhibitors, it has been described that 
nitro-L-Arg and L-NAME worsen/oeal isehaemie brain damage due to particular blockade 
of e-NOS, while relatively selective n-NOS inhibitors, 7-NI (Dalkara et al., 1994), 
ARL17477 or S-methyl-isothiureido-L-norvaline as well as Illore specific i-NOS inhibitor 
aminoguanidine reduce infarct size (ladecola, 1997). 
Evidently, manipulation of the NO system might be used to devise new strategies for 
stroke treatment. Results suggest that the effect of NO in ischaemic brain damage depends 
on the stage of evolution of the ischaemic process and on the cell type producing NO. In 
patients who reached medical attention within the first few hours of onset of ischaemia. NO 
donors might be useful, particularly when interventional approaches to restore blood flow are 
not feasible. Regarding the hypotension that they cause, the safest and most effective 
administration of these agents would be in an intensive-care unit. Later on, ll-NOS inhibitors 
would be beneficial. perhaps in conjunction with OLU-receptors antagonists to increase 
neuroprotection. At later stages after onset of ischaemia (> 12 hours), i-NOS inhibitors could 
be administered to block the deleterious effect of NO produced by i-NOS. Generally, most 
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patients with ischaemic stroke arrive at the emergency room many hours after the onset of 
symptoms and, therefore, i-NOS inhibitors would be particularly valuable. Although 
lubeluzole, a compound with some NOS inhibitory properties, is currently clinically tested in 
stroke patients, selective inhibitors of n-NOS and i-NOS for human use are not yet available 
(ladecola, 1997). Additionally, a few basic conditions have to be fulfilled before NOS 
inhibitors can be used in clinical medicine. Because of the stage-dependent double-edged 
role of NO in ischaemic damage, evaluation of the time of onset of ischaemia and of the stage 
of evolution of ischaemic injury are necessary for successful treatment with NOS inhibitors. 
Magnetic resonance imaging could be useful in that estimation. Further research, such as 
establishment of clinical trials are needed to define the safety and therapeutic potentials of 
selective NOS inhibitors (Meldrum, 1995; ladecola, 1997). 
3.3.2 Migraille alld Subarachlloid Haemorrhage 
Disorders of endothelium or neurally derived NO have been involved in the pathogenesis of 
migraine (Appenzeller, 1991) and vasospasm after subarachnoid haemorrhage (Edwards 
ef al., 1992). Wlule in peripheral blood vessels, NO is produced bye-NOS, in cerebral 
vasculature additional NO is synthesised by n-NOS in NANC neurons, highly concentrated in 
adventitial layers. These nerve plexuses also include 5-HT neurons which constrict the 
arteries via 5-HTm receptors that are responsible for clinically efficient anti-migraine drugs 
such as sumatriptan (Saxena, 1995). Therefore, selective vasodilatation of such cerebral 
vessels by NO may playa role in the pathophysiology of migraille (Snyder and Bredt, 1991). 
NO may play a key role in migraine and other vascular headaches since both, glyceryl 
trinitrate, as a NO donor, and histamine, increasing endothelium-derived NO, cause a 
pulsating dose-dependent headache like migraine. At relatively high doses of glyceryl 
trinitrate migraine sufferers develop a stronger and more migraine-like headache 
accompanied with more pronounced cerebral arterial dilatation than controls. After 
glyceryl-trinitrate infusion, non-migraineurs remain headache free while migraineurs develop 
a migraine-like attack. Accordingly, it has been suggested that migraine may be caused by 
increased amounts and/or affinity of an enzyme in the NO-triggered cascade of reactions. NO 
may also be involved in the pathogenesis of other vascular headaches, e.g. cluster and 
symptomatic vascular headaches (Olesen ef 01., 1994). Recent results suggest that combined 
measurements of systemic levels of NO and endothelin-l together with transcranial Doppler 
velocity data would provide useful information on the haemodynamic changes of cerebral 
blood flow regulation in migraineurs, thereby adding new insights into the mechanism of the 
migraine attack (Nattero ef 01., 1996). In addition, while diminished NO or interference with 
its action is involved in vasospasm following subarachnoid haemorrhage (\Vatkins, 1995), it 
has been proposed that facilitating the release (Tanazawa ef 01., 1996) and enhancing the 
effect of NO by using drugs that increase intracellular Ca" (cyclopyazonic acid) and free 
radicals scavengers (superoxide dismutase) may therapeutically prevent the effect of cerebral 
vasospasm in subarachnoid haemorrhage (Hans, 1996). 
3.3.3 Seiwres 
Additionally to functions matching neuronal activity with nutritive blood flow and protection 
of neurons from degeneration, NO could be involved in neurotoxicity underlying ischaemia 
and seizures (Varner and Beckman, 1995). Firstly, NOS can be inhibited by its reaction 
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product NO (Rogers and IgnaITo, 1992; Assreuy ef al., 1993; Buga ef al., 1993). 
Alternatively, it may represent an uncontrolled process with disastrous consequences for eNS 
integrity (Schoedon ef al., 1993). Secondly, results implicate that NO may protect neurons 
against overstimulation by GLU due to feed-back blockade of NMDA receptors, while 
neurotoxic effects may be mediated by peroxynitrate rather than NO itself (Lipton ef al., 
1993). It has been reported that GLU,an excitatory neurotransmitter which initiates the 
synthesis of NO in eNS, accounts for synaptic transmission at more sites in the brain than 
any other neurotransmitter (Snyder and Bredt, 1992). However, cytotoxicity in experimental 
models of cerebral stroke/seizure postulates a release of GLU causing an overstimulation of 
NMDA receptors, leading to prolonged release of NO. It is likely that excessive NMDA 
receptor activation, with the consequent increase in intraneuronal Ca2+, contributes to GLU 
neurotoxicity by enhanced production of NO (Dawson ef al., 1991; Moncada ef al., 1991). It 
has been suggested that NO contributes to the epileplogenesis in response to excessive 
OLU-mediated excitation (proctor ef al., 1996). cOMP has been suggested to have a role in 
seizures, because the levels of this nucleotide increase in several brain regions prior to the 
onset of drug-induced convulsions (peITendeHi ef al., 1980). Infhsion of cOMP analogues 
onto grafts of hippocampus triggers prolonged epileptiform activity in the pyramidal neurons 
(Freedman ef al., 1979). Accordingly, NO participates in both functional and dysfunctional 
mechanisms of excitatory heurotransmission (neuronal excitotoxicity and epilepsy) via cOMP 
(Dawson ef al., 1991). It is therefore important to note that antagonists ofEAA receptors or 
inhibitors of OLU release or NOS inhibitors have both antiepileptic actions and also protect 
against ischaemic damage which is thought to be mediated by excessive release of OLU 
(Snyder and Bredt, 1992; Meldnun, 1995). Recent results indicate that selective n-NOS 
inhibitors may have therapeutic benefit in stroke and neurologic damage associated with 
excessive OLU release (Snyder and Bredt, 1992). 
An understanding of the role of NO in seizures is still in its infancy. Nevertheless, such 
improved understanding might contribute to innovations in the treatment of seizure disorders. 
Based on present results the precise mechanism of NO in the expression of seizures is still 
unclear and controversial (De Sarro et al., 1991; Rundfelt et al., 1995; Van Leeuwen et al., 
1995; Kirkby ef al., 1996). Furthermore, kindling phenomena and dysregulated mechanisms 
of ceHular Ca" ion homeostasis have been hypothesised to be involved in pathophysiology of 
seizures and bipolar disorders (Dubovski ef al., 1992). It is likely that excessive NMDA 
receptor activation, with the consequent increase in intraneuronal Ca2+, contributes to OLU 
neurotoxicity by enhanced production of NO, playing a role in neuroexcitation during seizure 
or bipolar disorders (Moncada ef al., 1991; Karatinos ef al., 1995). In accordance with that 
are results that carabamazepine, an potent anti epileptic drug, inhibits influx of Ca2+ ions and 
has beneficial therapeutic effects in patients with resistant epilepsy or manic-depressive 
disorders (Narasapur, 1983). 
3.3.4 Schizophrellia 
Development of interventions for schizophrenia on the basis of the NO pathway has been 
suggested (Karson ef al., 1994). A study of the distribution ofNADPH-d stained neurons in 
postmortem brains of five chronic schizophrenic patients, compared with brains of five age-
and gender-matched controls, showed a decrease of these stained neurons in the superficial 
layers but an increase in the deep layers of the white matter of the dorsolateral prepirifonn 
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cortex (Akbarian el al., 1993a). Further data demonstrated lower numbers of NADPH-d 
stained neurons in the hippocampal formation but greater numbers in the parahippocampal 
and lateral lobe white matter in brains of seven chronic schizophrenic patients (Akbarian 
el al., 1993 b). Related to previous studies (prast and Philippu, 1992; Zhu and Luo, 1992) 
and these results (Lorrain and Hull, 1993), it has been suggested that NO plays a role in DA 
release in certain brain areas, Accordingly, as excess dopaminergic activity in mesolimbic 
structures has been implicated in the pathophysiology of psychosis, the NO pathway supports 
the possible link between abnormalities of central dopaminergic regulation and the 
pathogenesis of psychosis (Karatinos el al., 1995). 
3.3.5 OpioM Depelldellce alld Opiale Withdrawal 
NO is also implicated in the function of opioids in the brain, in both their addictive and 
analgesic properties. Consequently, manipulations of the NO pathway can lead to new 
treatments of opioid dependence and opiate withdrawal (Karatinos el al., 1995). Additional 
data supported the neuroexcitatory role of NO showing that NO donor isosorbide dinitrate 
aggravated the opioid withdrawal syndrome (Adams el al., 1993), wltile NOS inhibitors 
attenuated naloxone induced withdrawal syndrome (Adams el al., 1993; Cappendijk el al., 
1993, 1995; Dzoljic el al., 1994). Thus, results implicate the idea that NOS inltibitors may be 
potentially useful in the treatment of opioid withdrawal syndrome (Bhargava and Sanjay, 
1996). 
3.3.6 Paill 
The central transmission of noxious input evoked by thermal, chemical and mechanical 
stimuli is blocked by the L-NAME (Radhakrishnan and Henry, 1993), implicating NO as a 
general mediator in central pain processing (Holthusen and Ding, 1997). Therefore, it has 
been suggested that NOS inltibitors could be potentially 1I0vei analgesics (Hao and Xu, 
1996). 
3.3.7 eNS TUlllours 
A mutagenicity of NO towards human cells has been shown (Nguyen el ai., 1992), 
accompanied with findings of high levels of c-NOSs (n-NOS and e-NOS; Cobbs el al., 1995). 
Thus, selective NOS inhibitors could be useful in blocking pathophysiological processes 
important to these tumours (Cobbs el al., 1995). 
3.3.8 Mulliple Sclerosis 
The involvement of i-NOS and NO in MS has been demonstrated (Koprowski el al., 1993; 
10lmson el al., 1995). Induction of human i-NOS occurs in the demyelinated regions of MS 
brains (Bo el al., 1994). NO may be directly toxic to the myelin-producing oligodendrocytes 
(Merrill el al., 1993). Useful for cliltical practice are also data obtained from analysis of 
peripheral blood from patients with MS, supporting a role of monocytic i-NOS in MS 
(L6pez-Moratalla el al., 1997). 
Accordingly, production of NO by i-NOS is implicated in the pathogenesis of several 
types of brain diseases and injury, including focal cerebral ischaemia (Iadecola el al., 1997), 
demyelinating diseases (Koprowski el al., 1993; Iadecola el al., 1995) and sepsis (Wong 
el al., 1996). In some cases, use of seleclive i-NOS inhibitors has directly demonstrated that 
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i-NOS-derived NO contributes to the development of the pathological symptoms (ladecola 
el al., 1995). To prevent potentially deteriorated i-NOS activity, efforts are in progress to 
develop highly specific i-NOS-inhibitors. However, use of such agents has been limited due 
to the cross-inhibition of n-NOS and e-NOS. As an alternative to the use of enzyme 
inhibitors to prevent glial i-NOS expression, the means of regulation the transcription of the 
i-NOS gene have been examined (Murphy el al., 1993; Nathan, 1992). 
3.3.9 Ollter Neuropsychialric Diseases 
Modulation of NO system may he useful for various neuropsychiatric conditions such as 
depression, stress (IIlowsky and Kirch, 1988; Patel, 1994), anorexia and bulimia neul'osa 
(Squadrito el al., 1993, 1994), sexl/al (Kirkeby el al., 1993; McCann el al., 1994) and sleep 
disorders (Karatinos el al., 1995; Williams el al., 1997). 
According to coupling local levels of neuronal activity in the brain to local blood flow 
and important influence on synaptic transmission (Snyder, 1992; Snyder and Bredt, 1992; 
Zorumski el al., 1993), NO has been implicated in several other clinical conditions. Deficit 
in memory can be seen in a variety of neuropsychiatric diseases, including different types of 
dementia and amnestic disorders. The role that NO might have in the memory functions 
provides a possible physiological way for pharmacological intervention. Although evidence 
exists that NO can have memory~enhancing functions, the precise role in memory still is not 
fully clarified. However, recent data implicated the NO system in Alzheimer's disease, a 
cognitive disorder with prominent memory impairment. NADPH~d staining in the neuropil 
of the hippocampus is decreased in patients with Alzheimer's disease (Rebeck ef al., 1993). 
Since NO is the retrograde messenger responsible for increasing the synaptic efficiency of 
presynaptic glutaminergic neurons in the induction of LTP (Snyder and Bredt, 1992), the 
latter data could explain the impaired ability of patients with Alzheimer's disease to learn new 
information. \Vhether medications designed to modulate the NO system, such as NO donors, 
would improve memory performance in humans, would be an exciting topic for further study. 
The investigators have shown an involvement of NO in the induction ofLTP rather than in its 
maintenance (Schuman and Medison, 1994). Therefore, the manipulations of the NO 
pathway should be primary designed to improve memory performance influencing memory 
acquisition (Karatinos et al., 1995). Evidence for the involvement of the NO system in 
human neuropathology is steadily increasing. Striatal neurons stained by NADPH~d are 
spared in Huntingtoll's chorea (Ferrante el al., 1985; Kowall ef al., 1987; Morton et al., 
1993), although a dramatic decrease (- 95%) in the striatal neurons that expressed NADPH-d 
occurs in this disease (Morton el al., 1993). It has been proposed that over-production of NO 
could contribute to cell death in the nervous system, while inhibition of NOS by NO 
(Griscavage el al., 1994) could be protective against that neuroloxicity. Regarding that the 
primary stimulus for NO synthesis in eNS is activation of glutaminergic NMDA receptor 
(Garthwaite, 1991), an involvement of NMDA receptors overactivity in numerous 
neurodegenerative conditions has been shown, including Huntington's chorea, Alzheimer's 
dementia, stroke and ALS (Bredt, 1996). However, NOS~containing neurons may possess a 
safety system against NO~mediated toxicity that allow them to survive in an environment rich 
in NO (Dawson el al., 1991; Snyder and Bredt, 1992). NO-induced NMDA receptor 
blockade via negative feed back could be a protective mechanism against an excess of 
NMDA receptor stimulation (Manzoni el al., 1992). Accordingly, NADPH-d positive 
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neurons survive in a greater numbers than neighbouring NADPH-d negative neurons not only 
in Huntington's chorea (Morton et al., 1993) but also in Alzheimer's dementia (I-lyman et al., 
1992), ischaemia (Uemura et al., 1990), some forms of excitotoxicity (Koh et al., 1988) and 
in amyotrophic lateral sclerosis (ALS), in which somatic motor neurons degenerate but 
au(onomic motor neurons are relatively spared (Welts and Vauglm, 1994). Both, NOS 
inhibitors and superoxide dismutase were neuroprotective, pointing out the importance of 
superoxide anion in subsequent neuronal damage. Therefore, increasing the amount of 
superoxide dismutase available for scavenging superoxide and reducing the amount of NO by 
administration of NOS inhibitors could reduce neurotoxicity caused by superoxide and NO, 
due to NMDA overstimulafion (Dawson ef al., 1996). 
Recent evidence suggests that nellrotoxic mechanisms may play role in etiology of 
Parkinson's disease. Likewise, selective n-NOS inhibitors exert protection, implicating their 
use in novel therapeutic strategies for Parkinson's disease (Connop ef aI., 1994, 1996; Schulz 
e/ al., 1995). For example, in an animal model of Parkinson's disease, NOS inhibitors 
provide protection against l-methyl-4-phenyl-1 ,2,3,6-tetrahydrophyridine (MPTP)-induced 
striatal DA depletion (Santiago et al., 1994; Prezedborski et al., 1996). Confirming the role 
of NO in MPTP induced neurotoxicity, n-NOS null transgenic mice are resistant to MPTP 
induced striatal dopamine depletion (Prezedborski et al., 1996). Additionally, in an animal 
model of Huntington's disease, NOS inhibitors are protective against 3-nitropropionic 
acid-induced or malonate-induced lesions (Schultz et al., 1995). 
The role of NO in cerebral damage in AIDS dementia has been reported (Snyder, 1993). 
AIDS dementia may be derived from neurotoxic effects of the coat protein of the HlV virus 
which kills neurons when acting in conjunction with OLU at NMDA receptors. NOS 
inhibitors block this form of neurotoxicity and thus may have a role in the therapy of AIDS 
dementia (Dawson ef al., 1993). 
More recent studies have found that in normal human biopsies n-NOS and dystrophin are 
colocalized beneath the sarcolenlllla of muscle fibres (Kobzbik et al., 1994) .. Results have 
shown that NO promotes relaxation through the cGMP pathway, while NOS inhibitors 
augmented contractile function of skeletal muscle (Kobzbik et al., 1994). In biopsies from 
patients with Duchenne muscular dystrophy, the disruption of dystrophin is accompanied 
with dramatically reduced n-NOS levels, providing evidence for the importance of both NO 
and dystrophin for signalling in striated muscle. The selective enrichment of n-NOS in 
fast-twitch muscle fibres (Kobzbik et al., 1994) could help to explain the preferential 
degeneration of this fibre type seen in Duchelme muscular dystrophy (Webster et al., 1988). 
Translocation of n-NOS from sarcolemma to myocyte cytosol in dystrophic muscle may also 
have implications for the pathogenesis of NO in muscular dystrophy. Regarding the already 
reported role of endogenous NO in cytotoxicity (Nathan and Xue, 1994; Lipton and 
Rosenberg, 1994; Huang et al., 1994), it is suggested that inappropriate cytosolic n-NOS 
activity in dystrophic muscle is toxic to myocytes. Free radical oxygen intermediates, which 
occur at high levels in skeletal muscle (Reid et al., 1992a,b), are known to contribute to 
cytotoxic damage in various muscle diseases including Duchellue muscular dystrophy 
(Davison et al., 1988). Abnormal n-NOS in dystrophic muscle may increase the toxic 
interaction of NO and superoxide and contribute to myofibre necrosis. During the states of 
great hyperactivity of muscle, hydroxyl free radicals formed from NO and superoxide could 
lead to muscle damage. In such circumstances, NOS inhibitors might display a therapeutic 
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benefit (Snyder, 1994). Selective loss of sarcolemmal n-NOS in patients with Duchene 
(Brerunan ef al., 1995) and Becker /IIl/scl/lar dyslrophy implicates new possibilities for design 
of dystrophin-gene therapy (Chao el al., 1996). Moreover, it has been shown that the 
relationship of dystrophin and sarcolennnal n-NOS in DI/chenne /III/scl/lar dyslrophy is 
analogous to relationship of huntington-associated protein and brain ll-NOS in Hunting/f)n 
disease (Li el al., 1996). 
Conceivably, NO can be a double-edged sword (Schmidt and Walter, 1994). On the 
one side, in the low, constitutive mode, it has beneficial effects, mediating and protecting 
neuronal activity. On the other side, in the high, unregulated mode, it is an indiscriminately 
damaging molecule (Anggard, 1994). The possibility that NO can exist in distinct 
oxidation-reduction states, with different biological actions, provides further elucidation of 
mechanisms for the neuroprotective and neurotoxic effects of NO (Lipton el al., 1993). The 
designation 'nitric oxide' should be used for the reduced, negatively charged form of the 
molecule, while the oxidized, positively charged form, the nitrosonium ion. Accordingly, 
oxidized NO, in the form of the nitrosonium ion, reacts with NMDA receptor to block 
neurotransmission. Precisely, an oxidized, positively charged form can bind to NMDA-
receptor complex (Lipton el al., 1993, 1994), resulting in changes in sensitivity of the 
NMDA-receptor complex to the actions of OLU. Thus, NO exerts negative feed-back to the 
NMDA receptor, reducing intracellular Ca2+ with a consecutive decrease of NOS activity. On 
the contrary, the neurotoxic actions of NO are ascribed to the reduced, negatively charged 
form of the molecule. This reduced form of NO reacts with the superoxide anion to form 
peroxynitrate, the final neurotoxic agent. Reduced form ofNO~induced toxicity is a complex 
process involving multiple pathways generally leading to cell death (Burney el al., 1997). In 
cerebral cortical cultures. conditions favouring the reduced form of the molecule give rise to 
neurotoxicity, while neuroprotective actions occur in the presence of positively charged 
nitrosonium ions. Nitrosonium ions also block NMDA receptor~mediated current (Lipton 
el al., 19943). These evidences implicate specific therapeutic methods. Therefore, further 
elucidation of neuroprotective versus neurotoxic effects of NO could fmd new treatment 
opportunities (Anggard, 1994). Since NOS inhibitors showed up to 70% protection from 
neural slroke injury, the pharmaceutical industry should make an effort to develop NOS 
inhibitors as antistroke drugs. The ideal therapeutic agent should be one that prevents the 
formation of the reduced form of NO while enhancing the formation of the oxidized form of 
the molecule. Useful would be drugs which could be converted to nitric oxide, but only to 
the oxidized nitrosonium ion. Similar consideration would apply to drugs aimed at AIDS 
dementia and neuJ'odegenerative conditions, including Hungtinlon's and Parkinson's 
diseases, which may also involve overstimulation ofNMDA receptors (Snyder, 1992; Snyder 
and Bredt, 1992). Therefore, it is suggested that modulations of the NO pathway may 
become useful and important for new therapeutic strategies for various diseases in clinical 
medicine. especially in neuropsychiatry. 
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Neuropharmacological experiments 

CHAPTER 4 
NITRIC OXIDE AND SEIZURES 
Anticonvulsant Activity of New amI Potent Inhibitors of 
Nitric Oxide Synthase 
4.1 Abstract 
The effects ofllcw and potent NOS inhibitors, S~methyl-L-thiocitrulline (S-Me-TC), 3-bromo 7-nitro 
indazole (3-Br-7-NI) and 1-(2-trifluoromethylphenyl) imidazole (TRIM), were examined on the 
pilocarpine-induced seizures in mice. 3-Br-7-NI and TRIM decreased the frequency of status 
epilepticus and mortality, while TruM, in addition, significantly reduced the incidence of seizures. 
The latencies to onsets of seizures, status epilepticus and mortality were significantly prolonged by 
all three NOS inhibitors, while duration of seizures was reduced by 3-Br-7-NI and TRIM. These data 
suggest an excitatory effect of NO in the neuronal structures involved in the pilocarpine-induced 
seizures. 
4.2 Introduction 
In the eNS NO is considered as a retrograde messenger being involved in the modulation of 
neuronal excitability. Accordingly, it has been shown that L-Arg-derived NOS inhibitors, 
NG-nitro-L-arginine methyl ester (L-NAME), NG-nitro-L-arginine (L-NOARG) and NG_ 
monomethyl-L-arginine (L-NMMA) affect seizure threshold. However, both proconvulsant 
and anticonvulsant effects have been reported. 
L-NAME worsened seizures induced by kainate (Kirkby ef al., 1996a; Rigaud-Monnet 
ef al., 1994), N·methyl·D-aspartate (NMDA; Buisson ef al., 1993) and pilocarpine (StalT and 
Starr, 1993) in rats and mice. Similarly, L-NMMA reduced the convulsive threshold in the 
kainate-induced convulsions in mice (Przegalinski ef al., 1994). Potent NOS inhibitor 
L-NOARG increased the severity of kainate-induced seizures in mice and rats (Penix ef af., 
1994) and potentiated epileptic activity in rats induced by various convulsant compounds, 
such as quinolinate (Haberny ef al., 1992), bicuculline (Wang ef al., 1994) and pilocarpine 
(Maggio ef al., 1995). 
In contrast. L-NAME antagonized pentylenetetrazol-induced kindling (Becker ef al., 
1995) and seizures induced by various excitatory drugs: kainic acid (De Sarro ef al., 1991), 
quinolinic acid (Nakamura ef al., 1995), NMDA (De Sarro ef al., 1991), pentylenetetrazol 
(Osonoe ef al .• 1994), cocaine (Przewlocka ef al., 1994) and picrotoxin (Kirkby ef al., 1996b). 
Similarly, L-NOARG protected rats against oxygen- (Zhang ef al., 1993) and 
pentylenetetrazol-induced convulsions (Osonoe ef al., 1994). 
Recently, NOS inhibitors which are not L-Arg derivatives became available. Some of 
them are relatively selective inhibitors of NOS, affecting predominantly n-NOS, without 
increasing blood pressure. 7-NI is a relatively selective inhibitor of n-NOS, which does not 
affect blood pressure (Moore ef al.,1993) but influences local cerebral blood flow (Kovach 
ef al., 1994). This drug attenuates kainate-elicited convulsions in rats (MOlsch ef al., 1994) or 
pilocarpine- (Van Leeuwen ef al., 1995) and picrotoxin- (Kirkby ef al., 1996b) induced 
seizures in mice. However, this subject remains still controversial, since 7-NI does not affect 
bicuculline- and pentylenetetrazol-induced seizures (Penix ef af., 1994) or even worsened 
kainate-induced convulsions in mice (Kirkby ef al., 1996b). 
In order to elucidate fm1her the role of NO in epilepsy we have examined the effect of 
three new, potent and relatively selective n-NOS inhibitors, which are not derivatives of 
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L-Arg, 3-Br-7-NI, TRIM and S-Me-TC on pilocarpine-induced seizures in mice (Turski 
et 01.,1984). 3-Br-7-NI exhibits greater potency than 7-NI as an inhibitor ofn-NOS in vih'o 
(Bland-Ward and Moore, 1995). TRIM has shown selectivity for inhibition of n-NOS 
compared with e-NOS ;n vitro and lack of vasopressor activity in the anaesthetized mouse 
(Handy et 01., 1995). S-Me-TC is more selective for rat n-NOS compared to rat e-NOS 
(Furfine et 01., 1994). In addition, S-Me-TC is the most potent NOS inhibitor described to 
date with strong pressor activity (Narayanan et 01.,1994). 
It seems that animal model of epilepsy is important factor determining proconvulsant or 
anticonvulsant effects of NOS inhibitors (Kirkby et 01., 1996 b). We selected the pilocarpine 
model of seizures, because biochemical analysis of brains from animals subjected to 
pilocarpine-induced seizures provided evidence for an involvement of EAA in the initiation 
of epileptogenesis. This lead to the suggestion that blocking excitatory amino acid receptors, 
or their associated second messenger systems could be the feasible way of arresting seizure 
activity in human status epilepticus (Walton et 01., 1990). Furthermore, it has been shown 
that cholinomimetics-induced seizures are accompanied by a widespread damage of brain 
structures (forebrain, neocortex, olfactory cortex, thalamus, amygdaloid complex, substantia 
nigra and particularly hippocampal formation), resembling that frequently observed in 
autopsied brains of human epileptics (Turski et al., 1984). Therefore, we found that 
pilocarpine-induced epilepsy is an appropriate animal model to examine the role of NO in 
seizures. 
4.3 Methods 
4.3.1 Animals 
Experiments were performed on adult, male Swiss mice (28-35 g). A week prior to the 
experiments, animals were housed in groups of 5-10 in a room with controlled temperature 
(21'C), humidity (55%), on a standard light-dark cycle (light: 07.00-19.00 h) and with free 
access to food and water. 
4.3.2 Drug Administration Selledllie 
Mice (n~ 100) were divided in 5 equal groups. All drugs, except scopolamine, were 
administered intraperitoneally. Two groups of animals received vehicle (saline 0.1 ml or 
dimethyl sulfoxide, DMSO, 0.025 ml). Each of the other three groups was treated with one 
of the NOS inhibitors. In all 100 animals seizures were induced by pilocarpine (300 mglkg) 
following the method of Turski et 01. (1984). Pilocarpine was administered 30 min after 
injection of vehicle or NOS inhibitor. The dose of all three NOS inhibitors, used in this 
study, was 120 mglkg. The selected dose for NOS inhibitors, which had a similar molecular 
weight (S-Me-TC, 266; 3-Br-7-NI, 242; TRlM, 212), was based on our preliminary 
experiments and biologically active concentrations of these dmgs used by other authors 
(Bland-Ward and Moore, 1995; Furfine et 01., 1994). In order to minimize peripheral 
cholinergic effects, scopolamine (l mglkg) was injected subcutaneously (s.c.) 30 min prior to 
administration of pilocarpine (Turski et 01.,1984). 
4.3.3 Behavioural Assessments 
Behavioural assessments took place between 09.00-18.00 It and were carried out in 
transparent, plexiglas compartments (40x25x 15 cm). Prior to administration of the drug each 
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animal was habituated to the environment for 30 min. After habituation the mice were 
removed, injected with the corresponding dmg and rapidly returned to the experimental cage. 
Convulsions were evaluated by observation of the frequencies and latencies to 
occurrence of seizures, status epilepticus and mortality. Latency was defined as the time 
measured from injection of pilocarpine until the onset of the corresponding seizure parameter. 
Continuous seizures of 3 min and more in duration were defined as a status epilepticus. The 
animals were observed for a period of 3 II following pilocarpine injection. Tllis relative long 
period of observation was selected, because a few published experiments in vivo were not 
sufficiently informative in respect to the duration of activity of these new NOS inhibitors. 
4.3.4 Ethical Approval 
The experiments and protocol of this study were approved by the Faculty Commission for 
experiments, handling and care of animals. 
4.3.5 Chemical Agellts 
1-(2-trifluoromethylphenyl)imidazole (TRIM, RBI) and 3-bromo 7-nitro indazole (3-Br-7-NI, 
Affinili, UK) were dissolved in dimethyl sulfoxide (DMSO, Merck). S-methyl-L-thiocitrulline 
(S-Me-TC; Alexis, Switzerland), pilocarpine hydrochloride (Sigma) and scopolamine 
methylnitrate (Sigma) were dissolved in saline (0.9% NaCI). Drug solutions were prepared 
before each experiments. 
4.3.6 Statistics 
Frequencies of seizure, status epilepticus and mortality were compared by Fisher's exact 
probability test or Chi-squared test. The latencies of these parameters were compared by 
two-tailed Student's I-lest and for 3-Br-7-NI and TRIM data were analysed by ANOVA 
followed by multiple comparisons, Dunnett test. Statistical significance was accepted at a 
probability (P) value of 0.05. 
4.4 Results 
4.4.1 COlltl'ol Allimals 
Two groups of .. limals (n~20 each) injected with vehicle in identical volume used to dissolve 
the drugs (saline 0.1 ml or DMSO 0.025 ml), did not show any behavioural changes. 
Administration of pilocarpine (300 mg/kg), 30 min following vehicle (saline or DMSO), 
produced in both control groups a sequence of behavioural alterations consisting of an initial 
akinesia, tremor of the whole body, ataxic lurching, with progression into motor seizures with 
clonus of the upper extremities, rearing and falling. This was usually accompanied by 
stereotyped behaviours like repeated head twitches, grooming and occasionally jumping fits. 
Seizures occurred in almost all control animals (l00% in saline and 95% in DMSO group, 
Fig. 4.1). Mean latency of the seizures was 9-10 min (10.2±0.4 min in saline and 9.1±0.S 
min in DMSO group; Table 4.1). The paroxysmal activity,_ in the form of motor seizures, 
lasted about II min (IO.S±1.2 min in saline and 11.3±1.3 min in DMSO group; Table 4.2). 
In the majority of animals, convulsions developed into a status epilepticus (80% for saline 
and 75% for DMSO group; Fig. 4.1) with a mean latency of about 17 min (16.9±1.2 min in 
saline and 16.S±1.3 min in DMSO group; Table 4.1) and of about 4 min in duration 
(4.1±0.S min in saline and 3.9±1.2 min in DMSO group, Table 4.2). Status epilepticus was 
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generally lethal to mice (80% for saline and 75% for DMSO group; Fig. 4.1). Mean latency 
to mortality in both groups was about 19 min (l9.3±0.9 min in saline and 18.8±I.2 min in 
DMSO group; Table 4.1). 
~ 100 
lS 
r:: 80 
" 
" Oi 60 
0.. 
40 
20 
o 
_SalIne I::::::::IS-Me-TC 
DOMSO ~3-Br-7-NI mTRIM 
Seizures Status Mortality 
eplleptlous 
Figure 4.1 Frequency a/pilocarpine (300 mglkgJ-il1duced seizIn-est status epilepliclis and mortality 
ill mice (11=100, divided ill 5 equal groups) pretreated (30 mill prior to pilocarpine) with vehicle 
(saline, 0.1 1111 OJ' DMSO, 0.025 1111) or NOS inhibitors (120 mg/kg), S-methyl-L-thiocih'ulline 
(S-Me-Te), 3-brolll0 7-IIi/ro illdazole (3-Br-7-NI) alld i-(2-trijlllorolllethyl-phellyljilllidazole (TRIM). 
All drugs were administered intraperitoneal/y. 111e dala are expressed as percentages of the effect of 
pilocarpine in vehicle-treated animals. Significance 01 p<O.05 le)'el (binomial lest: Fisher's and 
Chi-squared lest) to vehicle-treated group. 
Table 4.1 Latencies (m;n) to pilocarpine (300 mglkg}-induced seizures, status epileplicus 
and mortality in mice, pretreated (30 min prior topilocarpine) wilh vehicle (saline, 0.1 1111 
or DMSO, 0.0251111) or NOS illl.ibitors (120 lIIg1kg), S-methyl-L-thiocilrltlline (S-Me-TC), 
3-bl'olllo 7-nilro indazole (3-Br-7-NI) and 1 '(2-lrif/uol'O-methyl-phenyl)imidazole· (TRIM). 
AI/ d/'Ugs were administered intraperitoneal/y. 
Vehicle NOS Inhibitor 
Saline DMS{) S-Me-TC 3~Br-7-NI TRIM 
SeiZllre 10.2±0.4 9.1±0.S 31.8±L2* 21.1±2.3* 22.2±1.8* 
Status epilepticus 16.9±1.2 16.8±1.3 33.7±1.5* 32.5±2.6* 33.5±2.4* 
Mortality 19.3±0.9 . 18.8±1.2 50.2±5.6* 37.2±2.S> 37.4±2.J* 
Values are mealls ± S.E.M,5 groups, 1I~20 in each group. 
• p<0,05 significant differences fronl cOlltrol (I-test; ANOVA, Dunnell test). 
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T~ble 4;2 DIIIYIIiOIl (1IIIIIrO! Rill!carplll~ OOOm$/kf;J-Illdllfed $~Izures ands/a/us 
epi/eptiC/ls In mice, prelrealed (30 min prior 10 pl/ocG/plne) wilh vehicle (saline; OJ IlIl or 
DMSO,. 0.02SIII1) 01' NOS}lIhlbilol's (120m$/kf;J,S,m~/hyl-L-lhiocill'/I/1ine (S-Me-TC), 
3-bl'omo 7"l1ifl'o Indazole (3-BI',7-NI) .. and.l,(2-II'if!uol'omelhylphenyi)imidazole (TRIM). 
All dl'u$$ wel'e adtililiiSlel'edilllrapet'i!ol/eally. . 
Vehicle NOS Inhibitor 
Saline DMSO S-Me-TC 3-Br-7-NI TRIM ~--~~~~~~~~~~~~~ 
Seizure 
Status epilepticus 
10.8±L2 
4.1±0.& 
11.3±L3 
3.9±L2 
9.I±L1 
4.9±2.4 
Values are means ±S.E;M,5gro~ps,n=20 in each group . 
5.1±0.8* 
3.7±1.9 
• p<0.05 significantdifferenc"'!./l:om control (Mest,ANOVA , Dunnell test). 
4.4.2 Allimals Trealed lVilIt NOS Inltlbilors 
4.7±1.6* 
3.7±1.9 
Pretreatment of animals (3 groups, n~20 each group) with NOS inhibitors, S-Me-Te, 
3-Br-7-NJ and TRIM (120 mg/kg, each), 30 min prior to pilocarpine (300 mg/kg) decreased 
the mortality in mice (to 35-60%), reduced the occurrence of status epilepticus (to 40-65%) 
and seizures (to 70-90%; Fig. 4.1). Latencies of seizures, status epilepticus and mortality 
were significantly prolonged (2-3 times) following administration of NOS inhibitors 
(Table 4.1). Duration of paroxysmal motor seizures, but not the duration of status 
epilepticus, was significantly reduced by 3-Br-7-NI (5.1±0.8 min) and TRIM (4.7±1.6 min.), 
compared to the control (DMSO 11.3±1.3, Table 4.2). 
4.5 Discussion 
The present data show that new and potent non-L-Arg derived NOS inhibitors, 3-Br-7-NI, 
TRIM and S-Me-TC, attenuate pilocarpine-induced seizures in mice. It has been shown that 
pilocarpine-induced seizures involve predominantly limbic system (Turski el al., 1984). This 
provides evidence for the involvement of NO in motor limbic epilepsy. The results of tIus 
study are consistent with the finding that L-Arg-derived NOS inhibitor L-NAME reduces the 
severity of seizures induced by acetylcholinesterase inhibitor, tacrine (Bagetta et al., 1992). 
The idea of involvement of NO in the cholinergic model of seizure is supported by the 
evidence of the excessive release of EAA in pilocarpine-induced epilepsy (Walton et al., 
1990) and by the fact that L-Arg, the precursor of NO, potentiates epileptogenic properties of 
NMDA (De SaiTO el al., 1993; Mollace el al., 1991). In addition, recent studies indicate that 
NO affects the transporters of various neurotransmitters, including those which exert an 
excitatory function in the eNS. Accordingly, NO can inhibit GLU (Lonart et Johnson, 1994; 
1995) and NA (Lonart and Johnson, 1995; Miller and Hoffinan, 1994) uptake, while 7-NI 
enhances the function ofNA uptake carrier (Kiss el al., 1996). Our data are in line with these 
studies, since decrease of NO synthesis by NOS inhibitors may facilitate the uptake of 
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excitatory neurotransmitters, leading to their inactivation and decreased concentration in the 
synaptic space. This may explain (at least partially) the decrease of neuronal excitability 
following administration of NOS inhibitors. 
Although S-Me-TC is the most potent NOS inhibitor described to date (Narayanan 
ef al.,1995), 3-Br-7-NI and TRIM are more efficient in reducing the duration of seizures and 
the frequency of seizures, status epilepticus and mortality. The reason is not known but 
several possibilities could be considered. One of the explanations might be that S-Me-TC, as 
the most potent NOS inhibitor, blocks more completely the negative feedback mechanism 
exerted by NO on the NMDA receptor (Hoyt ef al., 1992; Izumi ef al., 1992; Kirkby ef al., 
1996a; Rundfelt ef al., 1995). Activation of NMDA receptors and corresponding 
glutaminergic transmission may lead to an increase of neuronal excitation. In addition, 
S-Me-TC acting as an inhibitor of e-NOS (Joly ef al., 1995; Narayanan e/ al., 1994), induces 
vasoconstriction and reduces tissue perfusion and oxygenation. The resulting impainnent of 
cerebrovascular autoregulation may cause a disbalance between increased metabolic demand 
and reduced blood flow during seizure with further spread of epilepsy (Kirkby ef al., 1996b; 
Narayanan et al., 1994). Furthermore, an increase of systemic blood pressure may affect the 
neuronal excitability in the CNS. It has been reported that rise in blood pressure produced 
mechanically (by occlusion of thoracic aorta or by balloon inflation into descending aorta) or 
by hypertensive agents can stimulate wakefulness and cortical arousal (Baust e/ al., 1967; 
Ebenezer, 1994; Furfine ef al., 1994). Pressure-induced arousal is mediated by afferent 
impulses from peripheral pressoreceptors (Bowes e/ al., 1981). Therefore, it could be 
expected that potent pressor effect of S-Me-TC may attenuate its own anticonvulsant 
properties. This may contribute to the less prominent anticonvulsant effect of S-Me-Te, 
compared to other two NOS inhibitors examined in this study. Tllis implicates that 
insufficient anti epileptic action of S-Me-TC could be due to both, increased activity of 
NMDA receptors (due to weaker negative feedback by NO) and significant cerebral and 
peripheral vasoconstriction (due to inhibition of e-NOS). Nevertheless, S-Me-TC is more 
potent than the other two NOS inhibitors in delaying the occurrence of convulsions, status 
epilepticus and mortality. This suggests that the main action of S-Me-TC, and probably of 
the other two NOS inhibitors, is on the mechanism of onset and genesis of epilepsy, rather 
than on the mechanism of maintenance of seizures. Based on experiments in which L-Arg 
potentiated EAA-induced seizures, De Sarro ef al. (l993) suggested also that NO might 
contribute mainly to the genesis of seizure activity. Concerning the role of cyclic nucleotide 
levels in the brain, it has been suggested that cGMP levels increased by pentylenetetrazol 
may have a role in seizure onset and/or propagation, whereas cAMP may be involved in 
processes that aUenuate or terminate seizures (Ferrendelli e/ al., 1980). The fact that NO 
increases cGMP levels (BageUa ef al., 1993; Garthwaite, 1991) could explain why the most 
potent NOS inhibitor used in tlus study affects mainly genesis and propagation of seizure. 
Although the effects of NOS inhibitor on seizures is predominantly of central origin 
(neuronal and/or vascular), the peripheral component should also be considered. Recent 
results have shown that n-NOS is expressed at higher levels in the skeletal muscle (Nakane 
ef al., 1993) and it is localized in fast-twitch muscle fibres at the sarcolenm,. (Kobzik ef al., 
1994). An inverse correlation has been shown between n-NOS activity and skeletal muscle 
force. Contractile function is augmented by blockers of NOS and it has been suggested that 
NO produced near sarcolennna opposes contractile force of skeletal muscle (Kobzik e/ al., 
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1994). Evidently, there remains a possibility that motor expression of seizures following 
administration of NOS inhibitors could be modified by both, central aud peripheral 
(sarcolemmal) n-NOS. However, the participation of the inhibition of sarcolemmaln-NOS in 
motor seizure phe.nomena has not been studied yet, but evidently this aspect deserves serious 
consideration. 
In conclllsion, pilocarpine-induced seizures in mice can be attenuated by NOS-inhibitors, 
3-Br-7-NI, TRIM and in a lesser extent with SoMe-Teo We suggest that NO acts as a central 
endogenously active substance with proconvulsant properties in the motor limbic structures in 
mice. However, at this time the involvement of peripheral NO in the modulation of motor 
seizure phenomena cannot be excluded. The new, potent and relative selective NOS 
inhibitors used in this study, could be useful tools to examine further the role of central and 
peripheral NO in epilepsy. 
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CHAPTERS 
NITRIC OXIDE AND LOCOMOTION 
New and Potent Inhibitors of Nitric Oxide Synthase Reduce 
Motor Activity in Mice 
5.1 Abstract 
Potent inhibitors of NOS, 3~bromo· 7-nitro indazole (3-Br-7-NI), 1-(2-trifluoromethylphellyl) 
imidazole (TRIM), S-methyl-L-thiocitrulline (S-Me-TC) and 7-nitro indazole (7-N!), reduced 
locomotion in mice. These results indicate that activity of NOS and corresponding NO release are of 
importance for spontaneous locomotion. 
5.2 Introduction 
Recent evidence suggests that NO plays an important role in motor activity. NOS inhibitor, 
NG-nitro-L-arginine-methyl-ester (L-NAME) reduced spontaneous locomotor activity (Sandi 
ef al., 1995) and hyperlocomotion induced by cocaine (Pudiak and Bozarth, 1993), morphine 
(Calignano e/ al., 1993), substance P (Mancliso et al., 1994) or methamphetamine in mice 
(Ohno and Watanabe, 1995) and rats (Abekawa ef al., 1994). The other L-Arg-derived NOS 
inhibitor, NG-nitro-L-arginine (L-NOARG) suppressed increased locomotion induced by Dl 
and D2 receptors agonists (Starr and Starr, 1995). 
The relatively selective n-NOS inhibitor, 7-NI, reduced locomotion in rats (COIllOp 
ef al., 1994) and mice (Starr and Starr, 1995. Recently we have shown that central depression 
induced by 7-NI is associated with a loss of the righting reflex (Dzoljic ef al., 1996). The role 
of endogenous NO in expression of locomotion became of particular interest after 
identification of n-NOS at the sarcolemma of skeletal muscles (Nakane ef al., 1993) and the 
evidence that NOS inhibitors affected skeletal muscle contraction (Kobzik ef al., 1994). 
In order to elucidate further the role of NO in motor activity, we examined the effects of 
new and potent non-L-Arg derived n-NOS inhibitors, 3-Br-7-NI, TRIM and S-Me-TC, on 
locomotion in mice. These substances are relatively selective inhibitors of n-NOS 
(Bland-Ward and Moore, 1995; Furfine ef al., 1994; Handy ef al., 1995). Similar to 7-NI 
(Moore ef al., 1993), TRIM lacks vasopressor activity in the anaesthetized mouse (Handy 
ef al., 1995), while S-Me-TC is the most potent NOS inhibitor described to date with a strong 
pressor activity (Narayanan ef al., 1995). Although the effect of 7-NI on locomotion has 
already been examined (COIllOp ef al., 1994; Starr and Starr, 1995; Dzoljic ef al., 1996), for 
comparison we included this dmg in the study. 
5.3 Methods 
5.3.1 AI/imals 
Adult, male Swiss mice (28-35 g) were housed in a room with controlled temperature (21°C), 
humidity (55%), standard light-dark cycle (light: 07.00-19.00 h) and free access to food and 
water. 
5.3.2 Procedllres 
The animals (n~80) were divided into six groups (n~13-14 each). Each group was treated 
intraperitoneally (Lp.) with one of the vehicles (saline or dimethyl sulfoxide, DMSO) or one 
of the NOS inhibitors (7-NI, molecular weight: 160; 3-Br-7-NI, 242; TRIM, 212, and 
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S-Me-TC, 266). The selected dose for the NOS inhibitors (120 mglkg) was based on the 
effects observed in our preliminary experiments and biologically active concentrations of 
these drugs used by other authors (Bland-Ward and Moore, 1995; Furfine el al., 1994; 
COllllOP el al., 1994; Handy el al., 1995; Narayanan el al., 1995). 
5.3.3 Behaviollral Assesslllelli 
Behavoural assesment was carried out in animals placed in plexiglas compartments 
(40x25x25 em) and cumulative locomotor activity of mice was measured by a Varimex 
apparatus (Columbus Instruments, Ohio, USA). After I h of habituation the mice were 
removed, injected with the corresponding dmg and rapidly returned to the experimental 
chamber. The motility of the mice was recorded during l~h before dmg treatment and 3 h 
following vehicle/dmg administration. Only horizontal displacements of the animal across 
the cage were recorded. 
5.3.4 Elhical Approval 
The experiments and protocol of this study were approved by the Faculty Commission for 
experiments, handling and care animals. 
5.3.5 Drugs 
S-Me-TC (Alexis) was dissolved in saline (0.9% NaCl). 7-NI (Lancasler), 3-Br-7-NI 
(AjJinili) and TRIM (RBI) were dissolved in DMSO (Merck). 
5.3.6 Sialislics 
The results were expressed as meanS±S.E.M. At each time point (l sl h, 2nd hand yd h after 
vehicle/drug administration). the significance ofthe difference between cumulative locomotor 
scores of the drug-treated groups versus the relevant control group was determined by 
Student's t-test (when two experimental groups were involved: saline v. S-Me-TC) or by 
one-way analysis of variance (ANOVA, when four experimental groups were involved: 
DMSO v. 3-Br-7-N1, TRIM and 7-NI). ANOVA was followed by multiple comparisons 
using Dunnett test, when F ratios reached significance (P<O. 05). 
5.4 Results 
5.4.1 COlllrol Allilllais 
Control animals injected with vehicle in an identical volume used to dissolve the drugs 
(saline 0.1 ml or DMSO 0.025 m!) did not show any behavioural changes. However, ill the 
I" h before injection they were more active (meallS±S.E.M, saline: 581±65, DMSO: 
687± I 06) than ill the following 3 h after vehicle administration. Additionally, a gradual 
increase in locomotion was observed in this 3 h period (saline: I" h: 181±27, 2'd h: 264±32, 
3,d h: 340±44 and DMSO: 197±21, 294±37, 365±42, respectively; Fig. 5.1). The higher 
locomotor scores in the 1st h prior to vehicles administration might be due to the increase in 
the exploratory behaviour caused by enviromnental novelty. The decrease in locomotion in 
the next 3 h after vehicle administration is probably a reflection of anxiety induced by 
handling and i.p. injection. However, a gradual increase of locomotor activity in the 
following 3 h after vehicle administration might be due to corresponding decrease of anxiety. 
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Figure 5.1 Cumulative locomotor activity/collnts of mice treated with vehicles (used as cOllfrol, 
DMSO, 0.025 ml, n=14 or saline, 0.1 ml, n=13) or lIitric oxide synthase (NOS) inhibitors (120 
mglkg), 7-lIitro indazote (7-N/, 11=14), 3-bromo-7-nitro indazote (3-Br-7-N!, 11=14), S-methyt-
L-thiocitrulline (S-llIe-Te, 11=13), Gild 1-(2-triJIlloro-methytphellyl)imidazole (TRIM, 11=14), 1 II 
before Gnd 3 h after intraperitoneal administration of the vehicle/drug. S-Me-TC was dissoh'ed ill 
saline while 7-N!, 3-Br-7-NI and TRIM were dissolved ill DMSo. The vertical lines represent 
meal1s±S.E.M alld asterisks denote significance at a level of P<0.05 (Student's t-test or ANOVA 
followed by Dunllell test). Note the prominent decrease ill locomotion following administmtion of 
NOS inhibitors compared to the cO/llral. 
5.4.2 AI/illlais Treated witll NOS II/ilibitors 
These animals looked alert but less active, spending more time on sitting still in the cages, 
than normal mice treated with vehicle. However, no signs of abnormal posture were 
observed, except ataxic behaviour caused by TRIM in the 1 sl h after injection. The 
impression of quiescence and bradykinesia, following NOS inhibitors, con'esponded with 
reduced motility (Fig. 5.1). The decrease of loco Illation caused by S-Me-TC (l" h: 94±7, 2'd 
h: 121±8, 3,d h: 149±13), 3-Br-7-NI (91±13, I 49±22, 188±30) and TRIM (76±12, 99±13, 
119±13) lasted for 3 h, while a similar effect of7-NI (138±13) lasted I h (saline v. S-Me-TC, 
Student's t-test: P<0.05; DMSO v. 3-Br-7-NI, TRIM and 7-NI, ANOVA followed by DUllllett 
test when F ratio reached significance: I" h- F~12.4, 2"" h- F~12.4, 3,d h- F~14.3, P<0.05; 
Fig. 5.1). 
5.5 Discussion 
Reduced locomotion in mice following administration of NOS inhibitors observed in this 
study is in accordance with the decrease in the EEG rhythmic slow "activity (RSA=theta 
rhythm, 6-9 Hz) in rats by 7-NI, 3-Br-7-NJ and S-Me-TC (Dzoljic el al., 1996). The RSA in 
the rat is associated with locomotion and other voluntary movements (Depoortere, 1987). 
The prominent decrease in power ofRSA, following administration of NOS inhibitors, might 
reflect a depression of central neuronal structures involved in the locomotion. 
104 Chapter 5: Nitric oxide and locomotion 
The mode of action of NOS inhibitors in locomotion is not known, but the effect of NO 
on central neurotransmitters, particularly on DA in basal ganglia could he of importance. It 
has been shown that NO induces DA release from striatal (Zhu and Luo, 1992) and 
hippocampal slices (Lonart el al., 1992). Striatal dopamincrgic transmission is involved in 
the control of locomotion (Angulio and McEwen, 1994) and NOS is widely distributed in 
striatal neurons (Snyder and Bredt, 1991). The idea that NOS inhibitors decrease locomotor 
activity by reducing dopaminergic transmission is consistent with the fact that these dmgs 
reduce hypennotility induced by dopamine D, and D, receptor agonists (Starr and Starr, 
1995). 
In addition, there is evidence of the involvement of GLU in the control of locomotion 
(Angulio and McEwen, 1994; Witkin, 1993), probably through the dopaminergic system. 
GLU release has been reported to be stimulated by NO-donors (Guevara-Guzman ef al., 
1994) and blocked by NOS inhibitors (Montague ef al., 1994). Moreover, both NOS 
inhibitors and haemoglobin, which binds extracellular NO, reduce the release of striatal DA 
induced by GLU receptor agonist NMDA (Ban bauer ef al., 1992). 
Along with DA and GLU, other conventional neurotransmitters (GABA, 5-RT, NA and 
Ach) were implicated in the regulation of locomotor activity (Angulio and McEwen, 1994; 
Mancuso el al., 1994). It is known that NO stimulates the release of various 
neurotransmitters, including NA (Mancuso ef al., 1994), GABA, 5-RT and Ach 
(Guevara-Guzman ef al., 1994; Lonart ef al., 1992; Prast and Phillippu, 1992). Evidently, 
decrease in locomotion induced by NOS inhibitors is a complex phenomenon due to 
derangement of not only dopaminergic transmission, but also of other neurotransmitter 
systems involved in the control of locomotion. 
Additionally, it is of interest to note that there is evidence that NO attenuates anxiety 
which can further influence locomotor activity. Accordingly, the anxiolytic compound 
chlordiazepoxide exhibited increased exploration activity in mice, which was reduced by 
pretreatment with NOS inhibitor, L-NOARG (Quock and Nguyen, 1992). The authors 
suggested that an anxiogenic component present in L-NOARG might be responsible for the 
decreased locomotion of animals. However, this explanation should not be generalised, since 
there is still no evidence that the new NOS inhibitors used in this study may exert a similar 
anxiogenic effect. 
Furthermore, the question arises whether reduction of locomotion is due to the inhibition 
of central or peripheraln-NOS, or both. Recently it has been found that n-NOS is localized at 
high levels in fast-twitch fibres at the sarcolemma of skeletal muscle (sarcolenunal n-NOS) 
(Nakane ef al., 1993). Contractile nlllction of skeletal muscle has been augmented by NOS 
inhibitors, willie NO produced near the sarcolemma opposes contractile force (Kobzik ef al., 
1994). A possible contribution of the inhibited sarcolemmal n-NOS in the locomotion should 
be considered. 
In conclusion, the new and potent NOS inhibitors, 3-Br-7-NI, TRIM, S-Me-TC and 7-N!, 
reduce locomotor activity in mice. The results suggest an importance of NOS activity and 
NO for locomotion. 
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CHAPTER 6 
NITRIC OXIDE AND NEURONAL ACTIVITY 
Vigilance alld EEG Power ill Rats: 
Effects of Potent Illhibitors of the Neurollal Nitric Oxide SYllthase 
6.1 Abstract 
We examined the effects of potent n-NGS inhibitors, 3-bromo-7-nitro indazole (3-Bf-7-NI) and 
S-methyl-L-thiocitrulline (S-Me-TC) on general behaviour, vigilance stages and 
electroencephalographic (EEG) power spectra in rats, In addition, we studied the effect of 7-llitfo 
indazole (7-NI) on EEG power spectra in rats during dark and light periods. 
3-Br-7-NI induced ptosis and decrease of slow wave sleep and rapid eye movement sleep in the 
rat. 7-NI and 3-Dr-7-NI reduced the EEG power density in all frequency bands in the rat, suggesting 
a depression of central neuronal activity. This effect of 7-NI was more prominent during the day 
than during the night, indicating a circadian variation in the NOS response to NOS inhibitor. EEG 
power was the most reduced in the 7-9 Hz range of the rhythmic slow activity (theta rhythm), which 
is in accordance with decreased locomotion observed following administration of NOS inhibitors. 
Although S-Me-TC is the most potent NOS inhibitor in vitro experiments, it had less effect on 
vigilance and EEG power in the rat than other NOS inhibitors used in this study, probably due to its 
short lasting and blood pressure raising effect. The present results indicate that nitric oxide exerts an 
excitatory and circadian dependent effect in the central neuronal structures involved in the regulation 
of vigilance. 
6.2 Introduction 
NO is a highly reactive molccule produced by the enzyme NOS. Three NOS isoenzymes 
have been isolated, n-NOS, e-NOS and i-NOS. It seems that in the brain all three isoenzymes 
are present. The e-NOS is expressed in endothelial cells, but the neuronal distribution in the 
hippocampal neurons has been also suggested (Lowenstein, 1995). In addition, the NO 
produced by microvcssel endothelial cells in the brain I'nay penctrate in thc surrounding 
tissue, affecting ncuronal activity and brain functions. The i-NOS was identified in astrocytes 
(Simmons and Murphy, 1992), while the n·NOS (also known as a brain NOS) have been 
found in distinct populations of central neurons (Bredt el al., 1990). Furthermore, n-NOS 
was detected in the peripheral nervous (autonomic/enteric) system (Rand and Li, 1995) and at 
high levels in fast-twitch fibres at the sarcolemma (sarcolenunaln-NOS) of skeletal m.uscle 
(Nakane el al., 1993). 
Concerning the role of NO in vigilance we observed that the relatively weak and non 
specific inhibitor of NOS, NG-monomethyl-L-arginine (L·NMMA) had a sleep promoting 
effect in the rat (Dzoljic el al., 1994). A specific inhibitor of the n-NOS, '7-NI, without 
pressor effect (Moor et al., 1993), induced a prominent central depression, associated with 
reduced motility, loss of righting reflex and disrupted sleep architecture in rats (Dzoljic et al., 
1996). We suggested that mild sedation caused by NOS inhibitors may facilitate sleep, while 
prominent central depression can lead to the disruption of the sleep pattern. Other authors 
observed a decrease of slow wave sleep (S\VS) in rats following administration of NOS 
inhibitor NG-nitro-L-arginine methyl acetate (L-NAME) (Kapas el al., 1994). L-NAME is 
an unspecific NOS inhibitor and potent pressor agent (Rees et al., 1991). An increase in 
blood pressure may affect the vigilance. A rise in blood pressure induced mechanically or by 
hypel1ensive drugs stimulates wakefulness (Baust and Heinemann, 1967; Fevell and Johnson, 
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1984; Ebenezer, 1994). Evidently, the final effect of NOS inhibitor on vigilance and other 
central functions can be different, mainly determined by potency and selectivity of the drug. 
In order to determine further a role of NO in the eNS, we examined the effect of two 
relatively new and potent non-L-Arg derived inhibitors of n-NOS, 3-Br-7-NI and S-Me-TC 
on general behaviour, sleep/waking pattern and EEG power spectra in rats. In addition, we 
examined the effect of7-NI on EEG power spectra in rats, during the dark and light periods. 
3-Br-7-NI is more potent inhibitor of rat n-NOS than 7-NI but less specific (Bland-Ward 
and Moore, 1995), while S-Me-TC is the most potent NOS-inhibiting agent described to date 
(Narayanan and Griffith, 1994) and represents a new class of NOS inhibitors with strong 
pressor activity (Frey ef al., 1994; Narayanan ef al., 1995). In contrast to L-Arg-derived NOS 
inhibitors, the S-Me-TC is not metabolised to L-citrulline, a product that is converted to 
L-Arg in vivo and may sustain overproduction of NO (Hattori ef al., 1994). 
6.3 Methods 
6.3.1 AI/imals 
Experiments were performed on male Wistar rats (300-350 g). The animals were housed in a 
room with controlled temperature (21±1 'c), humidity (50±1 %) and light (06.00-18.00 h). 
Rats had a free access to food and water, before and during the experiment. 
6.3.2 Implal/laliol/ Procell"re 
The animals were anaesthetized with pentobarbital (60 mg/kg, intraperitoneally, Lp.) and 
implanted (stereotaxically) with epidural stainless steel screw electrode over the parietal 
cortex (2 mm posterior and 2 mm lateral to bregma) for recording the EEG. Two additional 
electrodes were inserted into the neck muscle for recording the electromyogram (EMG). A 
reference electrode (for grounding of animal) was placed over the frontal cortex epidurally. 
All electrodes were fixed in a socket and secured to the skull with dental cement. After 
surgery the rats were housed individually in perspex cages (LxWxH: 28x23x30) and allowed 
7 days for recovery in a soundRproof and electrically shielded room in which the experiments 
with EEGIEMG recording were carried out. 
6.3.3 EEG al/d EMG Recordil/g 
During the last days of the recovery period, the animals were habituated to the recording 
cables for 3-4 h daily. The subjects were connected with flexible cables equipped with a 
swivel connector, permitting a free movement of animals. The EEG and EMG signals were 
recorded and amplified by a polygraph (Grass 78, Grass Instruments Co., Quincy, 
Massachusetts, USA), located outside recording room and COlUlccted to a 386 microcomputer. 
Polygraph was calibrated to 100 m V 11 cm. The half-amplitude frequency response was 
1-100 Hz for the EEG with a selective 50 Hz filter in each channel. EEGIEMG recording 
started on the 7th day after operation and consisted of a 4 h session from 10.00-1 4.00 h. The 
vehicle of the corresponding NOS inhibitor, used as a control, was administered to the rat 011 
the 7th day after operation. The following day (8th day after operation) the corresponding 
NOS inhibitor was administered. Vehicles and NOS inhibitors were injected Lp. at the end 
of the 1st h after attachment to the cables. Tins time period of 1 h was indicated as an 
adaptation period. The adaptation time period was used to eliminate the factor of stress due 
to handling and attac1unent to the cables in order to ensure the stability of the EEG/EMG 
Chapter 6: Nitric oxide and neuronal activity 109 
recording. During the adaptation period, the animal was not treated with vehicle or drug and 
vigilance stages were not evaluated or presented in figures. After animal has been injected by 
vehicle or drug (on the end of adaptation period), the EEGIEMG registration stm1ed for the 
following 3 h in which the EEG power and stages of vigilance were evaluated. 
6.3.4 Sleep Scorillg 
At the end of the recovery period (7th day after surgelY), the animal was connected by a cable 
to a rotating connector for the recording of the EEG and EMG. Scoring of the sleep mld 
waking stage was based on the visual observation of EEG and EMG patterns. The records 
were read by an experienced investigator and each lOs epoch was classified visually being 
wakefulness, S\VS or rapid eye movement (REM) sleep. Stages of vigilance were scored 
according to previously published criteria (Ursin and Larsen, 1983): wakefulness with low 
voltage EEG activity; SWS with sleep spindles and 1-4 cis slow waves; REM sleep with low 
voltage EEG and low neck muscle tone. The SWS latency or REM sleep latency was defined 
as the length of time (min) from the dmg injection to the first lOs period of SWS or REM 
sleep, respectively. 
6.3.5 EEG POIVer Spectral Allalysis 
EEG spectral analysis was performed by using a Fast-Fourier-Transformation. Signals were 
recorded with Multi Channel Registration Program (CAID, Dijkzight, Rotterdam). The EEG 
recording lasted 3 h and was digitized with a sampling frequency of 150 Hz. The EEG data 
were collapsed into the bins 0.5 to 20.0 Hz. Artifacts epochs were excluded from the 
analysis. Due to considerable intraindividual variations in the absolute power densities, the 
power values for each rat were therefore expressed relative to control. In the begin of the 
self-control condition (7th day after operation) lasting 3 h, the rat was injected with vehicle. 
The mean-power value for each of the frequency bands during vehicle nm (self-control) 
recording was set to 100% and the corresponding percent deviation of drug run (next day, 8th 
day after operation) was calculated. 
In order to observe the effect of7-NI in rats during active period (dark period, night) and 
sleeping period (light period, day), the measurement ofEEG power in the vehicle (control, 30 
min prior to EEG recording) treated animals started during the dark period (23.00-2.00 h) and 
continued with the same procedure the next day during the light period (11.00-14.00 h). The 
same measurement of EEG power was repeated after 5 days, but the animals were treated 
with 7-NI (30 min prior to EEG recording). 
6.3.6 EtfliCflI Approval 
The experiments and protocol of this study were approved by the Faculty Conunission for 
experiments, handling and care of animals. 
6.3.7 Cltelllicals 
7-NI (Lancaster, Miihlheim am Main, Germany) was suspended in arachis oil by sonification. 
3-Br-7-NI (Alexis, Sissach, Switzerland) was dissolved in dimethyl sulfoxide (DMSO, Merck, 
Hohenbrull, Germany), while the solvent for S-Me-TC (BacJlem, Bubendorf, Switzerland) 
was saline. Dmg solutions/sllspensions were prepared before experiment. The doses of NOS 
inhibitors and duration of the observation period (3 h) were selected on the basis of several 
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criteria: duration of the effect of NOS inhibitors on the NOS in vitro (Babbedge ef 01., 1993), 
doses of S-Me-TC to increase blood pressure (Narayanan ef 01., 1995) and duration of effects 
and doses of NOS inhibitors used in our preliminary sleep experiments in rats. All drugs 
were administered intraperitoneally (i.p.). 
6.3.8 Sialislical Analysis 
Data were analyzed with statistical software by comparing mean power values ill each 
frequency band, using multiple analysis of variance (MANOV A). Significant differences 
between treatment were further evaluated with paired I-test. 
6.4 Results 
6.4.1 Bellavlonral Effecls 
Rats were observed 3 It following drug injection for any unusual behaviour. Behavioural and 
sleep effects of 7-N! in rats were described earlier (Dzoljic ef al., 1996, see introduction). 
3-Br-7-NI (30 mg/kg and 75 mgikg, II ~ IS) induced signs of peritoneal irritation in rats 
(writhing, licking the place of drug administration with occasional squalling). Administration 
of DMSO alone (vehicle, 0.4 mIl induced the same effect. Tllis behaviour lasted a less than 
30 s. !n animals treated with 3-Br-7-N! (but not with DMSO alone) peritoneal irritation was 
followed by flat body posture, decreased locomotion and occasional ptosis (2 of 8 animals) 
and loss of righting reflex (in one case, cut off 10 s). S-Me-TC (30 mg/kg, II ~ 14) did not 
affect overt behaviour. 
6.4.2 Vigilance and EEG pOlVer speclflllll 
The changes in the EEG power following solvent (at least in the first 30 min) were no 
noticeable. !f in the following time period the rat fell asleep an increase of EEG power 
occurred. 
7-N! (50 mg/kg, n ~ 5). Similarly to our earlier observations (Dzoljic ef 01., 1996), 7-N! 
disrupted the sleep architecture in rats. Normal sleep/wake pattern was replaced by decreased 
EEG amplitudes and behavioural depression, expressed in decreased locomotion, ptosis and 
loss of the righting reflex. Since this prominent behavioural depression can not be related to 
any physiological vigilance stage, the EEG power densities values following adrnil1istration 
of7-N! were expressed relative to the EEG power densities in the control conditions (100%) 
in which all three vigilance stages (wakefulness, SWS and REM sleep) were present. The 
EEG power was suppressed by 7-N! in each frequency band and this effect was dose related 
(15-50 mg/kg, /I ~ 4-5 for each dose, Fig. 6.1). 
The maximum decrease in the EEG power was seen in the high theta frequency band (7-9 
Hz). This effect of 7-N! (50 mg/kg, /I ~ 5) was more pronounced during the light period 
(11.00-14.00 h) than during the dark one (23.00-2.00 h, Fig. 6.2). 
3-Br-7-N! (30 mgikg, /I ~ 5) decreased significantly the SWS (Fig. 6.3), while the SWS 
latency was increased (75 ±, 19 min, versus 23 ± 5.4 min in the control). Since the REM 
sleep was nearly abolished (Fig. 6.3), the EEG power of REM sleep was not examined. 
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Fig. 6.1 The EEG power densities in rats (11=4-5 for each dose) during 3 h recording periodfollowing 
intraperitoneal (i.p.) adminish'atioll of7-nitro indazole (7-NI). All values are expressed relative to the 
EEG power densities ill the selfconh'ol conditions (=100%) during 3 h period Horizolltallines at the 
bottom of the graph indicate significant differences from the corresponding control (P<0.05). Note a 
dose related decrease of the EEG power spectra induced by 7-NL 
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Fig. 6.2' The EEG power densities in rats (u=5) following administration of 7-uilro indazole (7-N1) 
during 3 h ill the dark period (23.00·2.00 h, solid circle) alld ill the light period (11.00-14.00 II, open 
circle). Horizol/talline at the bottom of the graph indicates a significant difference between animals 
treated with 7-NI during light period (open circle) and corresponding conh'ol (P<0.05). Asterisks 
indicate significant difference (P<0.05) between animals treated with 7-NI during the light period in 
respect to the same animals treated with 7-N1 ill the dark period. Note a more prominent decrease of 
the EEG power during the light period compared to the dark period 
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Fig, 6.3 The sleep pattern il1 rats (11=5) during 3 II period (ill mill per I~ following i.p. ilijection of 
3-bromo 7-11;11'0 indazote (3-BI'- 7-NI, 30 mgikg. solid circle) or vehicle (dimethyl sulfoxide, open 
circle). Asterisks indicale significant difference (P<O.05) from the control {I-test after AfANOVAj. 
Note the decrease in the SWS in the first two II following drug adminish'olion. while REM sleep is 
nearly abolished. 
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Fig, 6.4 EEG power densities;l1 rats (11=5) following i.p. adminislmOon of 3-brolJ/O 7-nitro indazole 
(3-Br-7-NI, 30 mglkg) OJ' vehicle (dimethyl sulfoxide, 0,1 mI). AlIl'alues are e.'pressed relative to the 
EEG power densities in the control conditions (=100%). Horiz01Jfalline althe boltom of the left 
figure indicates significant difference from Ihe control (P<0.05) during 2nd h of EEG recording 
(solid circle). Non-sleeping period, characterized with reduced behavioural activity (see results and 
discussion), is indicated as Wakefulness. Note a significant decrease of EEG power spectra during 
wakefulness (particularly ill the frequency band 7-9 Hz) with no significant changes in EEG power 
spectra of SlVS. 
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In the non-sleeping animals dominated aroused EEGIEMG pattern (low EEG amplitudes 
and high EMG amplitudes) and depressed behaviour as described above (decreased 
locomotion and occasional ptosis and loss of righting reflex). The EEG power was decreased 
in each frequency range during the EEG wakefulness, particularly during the 2nd h following 
dmg administration, but no significant changes in EEG power spectra of the SWS were 
observed (Fig. 6.4). 
S-Me-TC (30 mglkg, II ~ 6) had no effect on SWS or REM sleep and the EEG power 
densities during wakefulness and SWS were decreased but not significantly (Fig. 6.5). 
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Fig. 6.5 EEG power densities ill rats (/1=6) ill wakefulness alld slow wQ)'e sleep (SJVS) following i,p. 
administration of S-me(hyl-L-thiocill'lIl1ille (S-Ale-TC, 30 mg/kg, solid circle 01' Iriangle) or vehicle 
(saline, 0.5 ml, i,p., open circle), Nole a lendency (nol siglllficallt) 10 decrease of EEG power. 
6.S Discussion 
The major finding of this study is that NOS inhibitors, 7-NI and 3-Br-7-NI (but not 
S-Me-TC) decreased the EEG power in rats. In addition, 3-Br-7-NI reduced sleep stages. 
Concerning sleep stages and EEG power, a non-sleep period following administration of 
indazole-derived NOS inhibitors (7-NI and 3-Br-7-NI) was characterized by arousal-like 
EEGfEMG pattern (low EEG amplitudes and high EMG amplitudes) and reduced behavioural 
activity (decreased locomotion and occasional loss of righting reflex and ptosis). Evidently, 
indazole-derived NOS inhibitors decreased the sleep but did not increase wakefulness. Thus, 
an arousal-like EEGIEMG pattern was not associated with awake behaviour, suggesting a 
dissociation between the EEGfEMG pattern and behaviour. Additionally, the EEG power 
was suppressed in each frequency range by NOS inhibitors, 7-NI and 3-Br-7-NI. However, 
this effect was more prominent in the high theta frequency band (7-9 Hz). High frequency of 
theta rhytlllll in rats is associated with locomotion and voluntary movements (Depoortere, 
1987). Decrease of high theta rhythm is consistent with reduced locomotion, observed in this 
study following administration of NOS inhibitors. Although, a decrease of the EEG power 
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was observed during the desynchronization and the behavioural excitation in animals treated 
with cocaine or d-amphetamine (Ferger el al., 1994), the generalised reduction of the EEG 
power associated with depressed behaviour (decreased locomotion, Chapter 5; loss of righting 
reflex and ptosis, Dzoljic el al., 1996) is rather reflection of the central depression than the 
excitation. Depression of the neuronal activity in various brain regions leads to the decrease 
of cortical and hippocampal inputs. The reduced input to the hippocampus results in 
decreased theta activity, whereas the diminished cortical afferent activity causes a decrease of 
EEG power in other frequency bands. The qualitative changes in the EEG power induced by 
each of these two indazole-derived NOS inhibitors are similar to the effect of high doses of 
alcohol (0,75 mg/kg, i.p., Ehlers el al., 1992) or benzodiazepines (3 mg/kg, i.p., Glatt el 01., 
1983) in rats. Accordingly, a prominent central depression lead to the reduction oflocomotor 
activity and dismption of normal sleep architecture. The central depression induced by 
indazol-derived NOS inhibitors is consistent with anticonvulsant activity of 7-NI (Van 
Leeuwen el 01., 1995) and other NOS inhibitors used in this study (Chapter 4). 
It is of interest to note that depression ofthe EEG power by 7-NI is less prominent during 
the dark period (active period of rat) than during the light period. In vehicle treated rats 
(control) we did not find a significant difference between the EEG power spectra in the light 
and the dark, probably due to comparison of relatively short time periods of the day and the 
night (3 h each). In any way, it seems unlikely that differences in the EEG power spectra in 
the light and in the dark period could be the reason for different effects of NOS inhibitors in 
the light and in the dark phase. However, it has been reported that NOS activity in the rat 
brain is higher during the dark phase compared to the light phase (Kapas el al., 1995). The 
idea of circadian dependence of the NOS activity can be further supported by recent 
observation that amount of the n-NOS in the rat pineal gland is regulated by enviromnental 
lighting condition (Spessert el 01., 1995). The elevated activity of NOS in rats during the 
dark phase with corresponding physiological increase of the NO production, is probably more 
resistant to the NOS inhibitors during the night than during the day. In addition, these results 
s~ggest a possible involvement ofthe NO in the circadian neuronal activity. 
Concerning the difference between NOS inhibitors, it seems clear that 7-NI excI1s a more 
prominent behavioural effect in rats (Dzoljic el al., 1996) than 3-Br-7-NI (this study). This is 
probably due to the difference in doses used (50 mg/kg of 7-NI, mol weight 160, versus 30 
mg/kg 3-Br-7-NI, mol weight 242), but also to the less significant NOS isoform selectivity of 
3-Br-7-NI, compared to the 7-NI (Bland-Ward and Moore, 1995). However, it is more 
interesting that the S-Me-Te, known as the most potent inhibitor of NOS ill vitro experiments 
(Narayanan e/ al., 1995) is less effective in our ill vivo experiments, compared to other two 
indazole derivatives. Quantitative differenees between 7-NI and S-Me-TC could not be 
explained by dose differences, since the doses were the same (30 mg/kg) and both drugs have 
a similar mol weight (2421266). It is more likely that differences between these NOS 
inhibitors may due to different pharmacokinetic characteristics (absorption, protein binding, 
penetration in the brain, biotransformation in vivo) or different pharmacodynamic properties 
of indazole- and thiocitrulline-derivatives. In this respect, S-Me-TC exerts a more potent 
pressor activity (Narayanan e/ ai., 1995) than indazole-derivatives. The rise in blood pressure 
induced mechanically (by occlusion of thoracic aorta) or by hypertensive agents (vasopressin) 
stimulates wakefulness (Baust and Heinemaml, 1967; Fevell and Jolmson, 1984; Ebenezer, 
1994). It has been suggested that cortical arousal can be induced by afferent impulses from 
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pressoreceptors (Bowes el al., 1981). Evidently, an increase of systemic blood pressure and 
reduction of local cerebral blood flow (Tanaka, 1991), both due to the inhibition of e-NOS, 
may significantly reduce an oxygenation and perfusion of the neuronal tissue. This may 
affect the neuronal reactivity in the CNS and development of the corresponding vigilance 
stage. Thus, an arousal effect of hypertension following inhibition of e-NOS may oppose a 
central depression induced by inhibition of n-NOS. Therefore, indazole-derived inhibitors of 
n-NOS, which do not affect significantly systemic blood pressure may have a qualitatively 
different effect on vigilance than citmlline-derived S-Me-TC (or L-Arg-derived NOS 
inhibitors) with prominent pressor activity. Duration of the S-Me-TC-induced hypel1ension 
was only 20 min (Narayanan e/ al., 1995). Tlus indicates that the most potent NOS inhibitor 
has a relatively short lasting effect, probably due to the reversibility of n-NOS inhibition by 
S-Me-TC. This idea is supported by experiments in vitro in which was demonstrated a 
reversibility of the n-NOS inhibition induced by S-Me-TC. If mixture ofinlubited n-NOS by 
S-Me-TC was allowed to stand with excess L-Arg for 5 min or longer, the substantial NOS 
activity was recovered, reaching normal value within 10-15 min (Frey et al., 1994). This may 
explain a minor changes in the cumulative 3 h EEG power following S-Me-TC. In addition, 
S-Me-TC, as the most potent NOS inllibitor, more completely blocks the negative feedback 
mechanism exerted by NO on the NMDA receptors (Izumi e/ al., 1992). Activation of 
NMDA receptors and corresponding transmission may lead to the increase of neuronal 
excitation and arousal. 
Regarding the specificity of new NOS inhibitors, an i'nvolvement of some additional non-
specific effects unrelated to the NOS synthesis, particularly when high doses are used, could 
not be excluded. Recent experiments of Connop et al. (1994) have shown a maximal 
inhibition of nigra I and cerebellar NOS (80/96 %) in rats by 7-NI (20 mg/kg, Lp.). Animals 
were, sacrificed 30 min after administration of7-NI. This rises a question whether the effects 
of higher doses of 7-NI are related to NOS inllibition. NOS inhibition is reversible and our 
post i1*ction period was 3 h. Therefore, the possibility of different levels of the NOS 
activity in various time intervals, following different doses of 7-NI could not be nded out. 
Accordingly, it could be expected that low dose of 7-NI (15 mg/kg) will induce a shorter 
duration of the maximal NOS inhibition than lugh doses of 7-NI (30-50 mg/kg). This may 
explain a dose related effect of 7-NI, observed in these experiments and many other studies 
using 7-NI in similar or even high dose range. Although, there is no evidence for 
nOll-specific effect of7-NI or other NOS inhibitors used in this study, the interpretation of the 
effects of these new drugs and the role of NO in the observed phenomena need an additional 
verification. 
Concluding, indazole-derived NOS inllibitors (7-NI, 3-Br-7-NI) induced central 
depression of neuronal activity with decreased EEG power, leading to disruption of normal 
sleep architecture and depressed behaviour (reduced locomotion and occasional loss of 
righting reflex and ptosis). The effect of 7-NI is less prominent during the dark period, 
indicating a circadian rhythmicity in NOS response to NOS inhibitors. The behavioural 
depression and reduction of EEG power by citl1llline-derived NOS inhibitor S-Me-TC is less 
prominent. This is probably due to fully reversible and short lasting NOS inhibition by 
S~Me~TC, prominent increase of systemic blood pressure and reduced negative feed back 
blockade ofNMDA by NO, leading to arousal-inducing effect. We are suggesting that brain 
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neuronal NO exerts an excitatory and circadian dependent effect in the neuronal structures 
involved in the regulation of vigilance. 
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CHAPTER 7 
NITRIC OXIDE AND CENTRALLY-ACTING DRUGS 
Brain Nitric Oxide Levels: Different Effects of Hypnotic 
and Allaleptic Drugs 
7.1 Abstract 
Nitric oxide concentrations in the frontal cortex of anaesthetized rat were measured using an 
electrochemical sensor, before and after intraperitoneal (Lp.) administration of a hypnotic drug 
(pentobarbital, 20·40 mglkg) or a convulsant agent (pentylenetetrazol, 50 mglkg). The concentration 
of NO was decreased by pentobarbital, while it was increased by pentylenetetrazol. These results 
indicate that endogenous NO may be involved in the mechanism of action of hypnotic and epileptic 
drugs. This further suggests that NO concentrations in the human brain may decrease following 
hypnotic or antiepileptic drug therapy and increase during epileptic attacks or administration of 
excitatory 8mphetamine.like drugs. It is concluded that central NO is an important endogenous 
neuroexcitatory transmitter involved in the seizure susceptibility and activity of some 
centrally·acting dmgs, such as hypnotics and analeptics. 
7.2 Introduction 
Nitric oxide (NO) exerts a significant effect on the neuronal excitability in the brain by 
releasing three main central excitatory neurotransmitters, ASP, OLD and NA 
(Guevara-Guzman el al., 1994; Montague el al., 1994). Several studies seem to indicate that 
NO affects seizure threshold, but the results are still controversial. Both proconvulsant 
(Osonoe el al., 1994; Van Leeuwen el al., 1995; Chapter 4) and anticonvulsant effects (Starr 
and Starr, 1993; Maggio el al., 1995) of NO are described. However, concerning the 
vigilance stages, the results are more consistent, indicating an excitatory effect of NO. It has 
been reported that a significant decrease in central NO levels occurs during slow wave sleep 
and that higher NO concentrations are associated with increased neuronal activity, such as in 
wakefulness or rapid eye movement (Burlet el al., 1995; Williams ef al., 1997). Furthermore, 
Kapas el al. (1995) found that NOS activity in the rat brain is higher during the dark phase 
(predominately active period in rodents) than in the light phase (predominately sleeping 
period). Such findings are consistent with our previous results demonstrating a decrease of 
central NO levels following administration of the NOS inhibitors, which is accompanied with 
depression of various fonns of central neuronal and behavioural activity, such as a decrease in 
wakefulness (Dzoljic and de Vries, 1994), loss of righting reflex (Dzoljic el al., 1996), 
inhibition of locomotion (Chapter 5) and reduced EEG power (Chapter 6). 
The above account suggests that central depression might be associated with decreased 
concentration of NO in the brain, while an increase in brain NO levels could be expected 
during central neuroexcitation. In order to provide data for this hypothesis, we Ill.easured 
brain NO concentrations during dmg-induced central depression and excitation. 
7.3 Methods 
7.3.1 AI/imals ami Surgery 
Male Wistar rats (340-360 g. n=20), divided in 4 equal groups. were anaesthetized 
(HypnormR, 0.15 ml/kg, Lp.) and artificially ventilated with a frequency of 70/min. 
Experiments were performed in the laboratory room with constant temperature (21.0± 1.0 °C), 
while the rectal temperature of the animals was maintained at 37.0±0.5 °c with a heating pad. 
The head of the animal was mounted in the stereotaxic head holder and a hole was drilled into 
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the right frontal region of the skull. After dura was sliced, a sensor for the detection of NO 
was stereotaxically implanted perpendicularly into the right c011ex at coordinates: 2.0 mm 
lateral, 2.0 mm anterior to bregma and 2.0 nun bellow the dura. A ground electrode was 
placed subcutaneously in animal's neck. In order to prevent manifest convulsions, the rats 
which were treated with pentylenetetrazol were injected with d-tubocurarine (0.1 mg/kg, i.p.), 
10 min prior to pentylenetetrazol. 
7.3.2 Delectioll of NO 
Electrochemical methods using amperometric sensors have frequently been employed to 
detect quantitative changes in brain NO levels in vivo in various species, including the rat 
(Malinski et al., 1993; Burlet et al., 1995; Williams et al., 1997). In this study, therefore, we 
also employed a similar experimental approach, using the NO meter (ISO-NO Mark II) with 
an amperomctric micro-sensor (ISO-NOP 200; both from \Vorld Precision Instmment, Inc, 
Sarasota FL, USA), where oxidation of NO is convel1ed into electric current for the 
measurement of NO. The micl'OMsensol' (tip diameter: 200 j..tm) is a combination of 
electrodes, which require no external reference electrode for use. It has a detection limit of 
10 nM NO. The microMsensor electrodes are separated from the external enviroIUnent by a 
gas permeable polymeric membrane over the end of a sleeve. The electrodes extend slightly 
out of the sleeve, stretching the membrane. The integrity of membrane covering the end of 
the sensor probe was regularly checked by immersing the probe in a strong saline solution (1 
M). If the current observed after few minutes in saline was not off scale, the membrane was 
considered as a nomlal. The electrode was calibrated daily before each experiment by 
measuring the current generated by 1 0 ~tm NO in aqueous solution, prepared by adding 
saturated NO solution to 120 ml saline. Aqueous NO solution was prepared under strict inert 
atmosphere and stored in allMglass flacon with a very small head space. The mean sensitivity 
of the sensor was 1.1 pA/nM change in NO concentration. 
In order to remove tissue particles which may accumulate on the membrane, the tip was 
cleaned after each use by immersing it in the distilled water for 30 min. After implantation of 
the sensor into the frontal cortex of the anaesthetized rat and its attaclullent to the ISO-NO 
meter, the current measured was recorded on a chart recorder cOlmected to an amplifier. The 
recording of the current continued until stabilization of current (NO levels), usually over a 
1-2 h period. Stabilization of NO levels was defined when during a 15 min period current 
oscillations were less than 10%. 
After NO baseline was reached, animals were injected Lp. with drugs or vehicle. The 
recording of the current continued for the next 60 min. The NO concentrations for each 
experiment were calculated by comparing the current measured from experimental 
amperometric curve with the current obtained after calibration with the NO solution. Due to 
appreciable iIi.terindividual variations in absolute NO concentrations, data were expressed as a 
percentage of the respective baseline values. On completion of experiments, animals were 
killed with an overdose of sodium pentobarbital. 
7.3.3 Statistical Evaillatioll 
ANOVA followed by Dunnett's multiple comparison test was performed at each time to 
determine when a significant difference was observed (P<0.05). 
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7.3.4 Drugs 
HypnormR (fentanyl citrate 0,315 mg/ml and fluanisone 10 mg/ml, Janssen), NarcovetR 
(pentobarbital sodium 60 mg/ml, Arnhem), pentylenetetrazol (dissolved in 0,9% NaC!, 
Sigma) and d-tuhocurarine (ampoules, Sigma). Fresh drug solutions we're prepared before 
each experiment. Pentobarbital was administered in doses (20-40 mg/kg), which are known 
to exert the hypnotic and anticonvulsant effects in the rat. We used only one dose of 
pentylenetetrazol (50 mglkg), which is known to induce clonic-tonic epileptic convulsions. 
In preliminary experiments the suhconvulsant low dose of pentylenetetrazol (25 mglkg) was 
without effect and, therefore, discarded in further study. 
7.3.5 Etltical Approval 
The experimental protocol of this study was approved by the Faculty COImnission for 
Experiments, Handling and Care of Animals. 
7.4 Results 
NO concentrations in the frontal cerebral cortex of anaesthetized rats during the baseline 
period at stabilisation were in the range of 0.5-4.6 IlM (mean±S.E.M. 2.2± 1.3 fIM). In 
control animals injected with vehicle (0.5 ml saline, n=5), a slow but non-significant decline 
in the brain NO levels occurred during the 1 st h. However, the decline of NO concentrations 
continued, reaching in our preliminary experiments the significance level in the foHowing 
hours, until animals died spontaneously. Therefore, the comparison between NO 
concentrations in control rats (vehicle treated) and drug-treated animals was limited to the 
first 60 min after dmg injection. As shown in Fig. 7.1, treatment with pentobarbital (20 or 40 
mg/kg, each group n=5) induced a significant and dose-dependent decrease of the brain NO 
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Figure 7.1 NO concentrations in the /rontal cor/ex of anaesthetized rats, be/ore (/=0) and after i.p. 
administration of or vehicle (control, 0.5 1111 saline) pentobarbital (PB, 20 or 40 IlIg1kg) or 
pentylenetetrazol (PTZ, 50 I1Iglkg); 11=5 in each group. NO concentrations, measured by an 
electrochemical micro-sensor, are expressed as percentage of respective baseline value. Drugs or 
vehicle were administered (at 0 mill) after stabilisation of NO current (see A1alerials alld Methods). 
Asterisks represents significant differences compared to the control (P<O.05, ANOVA followed by 
Dunnett's test). Note a dose-dependent decrease of NO concentrations following administration of 
pentobarbital aud all elevation of NO levels induced by pentylenetetrazol. 
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concentrations, compared to the control group. In contrast, pentylenetetrazol (50 mg/kg, n=5) 
increased brain NO levels, reaching significance (P<0.05) with respect to the control group 
after 30 min (Fig. 7.1). When ANOVA reached significance (30 min, F~13.1O; 45 min, 
F~23.94; 60 min, F~28.42), it was followed with DUlUlett's test. Significance for 
pentylenetetrazol was observed at 30 min (d'~16.94), while the significance for both drugs, 
pentylenetetrazol and pentobarbital, reached at 45 min (d'~17.45) and 60 min (d'~16.96). 
7.5 Discussion 
Baseline concentrations of NO registered in the rat frontal cortex in this study (_10,6 M) 
correlate with NO concentrations found in the rat frontal cortex through the sleep-waking 
cycle (Burlet el al., 1995) and in the rat parietal cortex during middle cerebral artery 
occlusion (Malinski el al., 1993; Zhang el al., 1995). However, in these last two studies, the 
baseline concentrations of NO was lower (~lO·8 M), compared to the baseline NO levels 
found in our study. This may be due to different experimental conditions, such as different 
anaesthetics used (fentanyl and fluallisone in our study versus ketamillc and xylazine), 
different levels of anaesthesia with corresponding difference in the cerebral blood flow 
(which affects NOS activity) andlor different location of the working electrode (frontal cortex 
in our study versus parietal cortex). It is of interest to note that a spontaneous decline of NO 
concentration (not significant in the 1st h of recording), which became more prominent in the 
following hours, before spontaneous death of animals. Spontaneous decrease of brain NO in 
control animals is probably due to the applied anaesthesia (Alimoffand Miller, 1993; Tobin 
el al., 1994) and the subsequent decline of vital functions and central blood flow. 
The main finding of this study is that hypnotic and excitatory drugs affect brain NO 
concentrations in an opposite way. Pentobarbital decreased, while pentylenetetrazol 
increased the c011ical brain NO levels. The mechanism of interactions between these dmgs 
and NO is not clear, but some possibilities can be considered. 
It is known that barbiturates inhibit the release of EAA, GLU and ASP (Alifimoff and 
Miller 1993) and reduce the sensitivity of brain neurons to GLU (Galindo, 1969). It indicates 
that barbiturates may inhibit NO synthesis by reducing GLU levels and its activity in the 
brain tissues. This hypothesis is supported by the finding that barbiturates reduce cGMP 
formation in many brain regions (Kant el al., 1980). It is known that a decrease in synaptic 
OLU concentration leads to a reduction of NMDA receptor excitability and Ca2+ influx in 
neuronal cells. These changes would reduce brain NOS activity, NO release and, 
consequently, cGMP formation, known to be regulated by NO (Garthwaite 1991). 
Furthermore, the corresponding decrease of excitatory effects of NO can modulate vigilance 
and neuronal excitability (see Introduction). Evidently, the NO system is an additional factor 
which may contribute (together with barbiturate-induced activation of GAB A-inhibitory 
system) to the mechanism of hypnotic action of pentobarbital and, probably, other 
sedatives/hypnotics and anticonvulsants. 
Related to pentylenetetrazol, it has been shown that its proconvulsant effect is associated 
with activation of NMDA receptors and an increase in cOMP levels in the brain (Moncada 
el al., 1991). NMDA receptor activation leads to a stimulation of NOS activity and NO 
release (Garthwaite, 1991), which may clarify elevated NO concentrations (and cGMP) 
following administration of pentylenetetrazol. This implicates that activated excitatory NO 
system may contribute to the pentylenetetrazol-induced neuronal excitability. A possible 
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involvement of NO pathway in the action of other analeptics, for example amphetamine-like 
drugs, should be considered. A less prominent effect of pentylenetetrazol on brain NO levels, 
compared to the opposite effect of pentobarbital is probably due to the use of anaesthetized 
animals in this study. Anaesthetics may block the glutaminergic transmission (Alimoff and 
Miller, 1993). Thus, they may indirectly attenuate the pentylenetetrazol-induced activation of 
NMDA receptors and cOITespondillg NOS activity and NO release. Experiments in 
unanaesthetized animals Jllay further clarify the role brain NO in the mechanism of action of 
centrally-acting drugs. 
In conclusion, the results show that NO concentrations in the frontal cot1ex of anaesthetized 
rat are decreased by pentobarbital and increased by pentylenetetrazol. This suggests that 
brain NO levels contribute to the pharmacologically-modulated excitability of central 
neurons, induced by hypnotic and analeptic drugs. It further implicates that NO exerts an 
impot1ant effect 011 the" neuronal activity and seizure susceptibility. 
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CHAPTERS 
GENERAL DISCUSSION 
8.1 NO alld Seizures 
Concerning the role of NO in epilepsy, it has been repOlied that NOS inhibitors exert both 
proconvulsant (Stan and StaIT, 1993; Penix et al., 1994) and anticonvulsant COsonoe el al., 
1994; Van Leewen ef ai" 1995)effects, This study shows that relatively selective n-NOS 
inhibitors, 3-Br-7-NI, TRIM and S-Me-TC, attepuate pilocarpine-induced seizures in mice. 
Since pilocarpine-induced convulsions involve predominantly the limbic system (Turski 
ef al., 1984), tltis provides evidence for the involvement of NO in limbic epilepsy. The 
results of tllls study are also consistent with the finding that L-NAME reduces the severity of 
seizures induced by the acetylcholinesterase inhibitor, tacrine (Bagetta ef al., 1992). The idea 
of the involvement of NO in the cholinergic model of seizures is supported by data showing 
an excessive release of EAA in pilocarpine-induced epilepsy (Walton ef al., 1990). 
Additionally, recent studies indicate that NO might increase neuroexcitability by releasing 
main central excitatory neurotransmitters GLD, NA and ASP (Guevara~Guzman el al., 1994; 
Montague ef al., 1994) as well as inhibiting the uptake of GLU (Lonart and Jolmson, 1994; 
1995) and NA (Lonart and Johnson, 1995; Miller and Hollinan, 1994). Our results are in 
accordance with these studies, since a decrease of NO synthesis by NOS inhibitors may 
reduce brain levels of excitatC?ry neurotransrnitters by decreasing their release and facilitating 
their uptake. This may explain the decrease of the neuronal excitability following 
administration of NOS inhibitors observed in our study. Therefore, data from these 
experiments suggest a neuroexcitatory effect of endogenous NO in the brain structures 
involved in seizure phenomena. 
Furthermore, our investigation shows that NOS inhibitors delay the occurrence of 
convulsions, status epilepticus and mortality. TIlls implicates a significant action of NOS 
inhibitors on the mechanism of onset and genesis of epilepsy, rather than on the mechatllsm 
of maintenance of seizures. In accordance with tills are experiments in which L-Arg has been 
shown to potentiate EAA-induccd seizures. Thus, De Sarro ef al. (1993) have suggested that 
NO may contribute mainly to the genesis of seizure activity. Concerning the role of cyclic 
nucleotide levels in the brain, it is implicated that cGMP levels increased by pentylenetetrazol 
may playa role in seizure onset and/or propagation (Ferrendelli ef al., 1980). The fact that 
NO increases cGMP levels (Garthwaite, 1991; Bagetta ef al., 1993) could explain the 
attenuating effects of NOS inhibitors on the genesis and propagation of seizures. 
OUf results are in agreement with data that support central anticonvulsant effects of NOS 
inhibitors. L-NAME antagonizes pentylenetetrazol-induced kindling (Becker ef al., 1995) 
and seizures induced by various excitatory drugs: kainic acid (De SatTO ef al., 1991), 
quinolinic acid (Nakamura ef al., 1995), NMDA (De Sarro ef al., 1991), pentylenetetrazol 
(Osonoe ef al., 1994), cocaine (Przewlocka ef al., 1994) and picrotoxin (Kirkby ef aI., 1996). 
L-NOARG protects rats against oxygen- (Zhang ef al., 1993) and pentylenetetrazol-induced 
convulsions (Osonoe ef al., 1994). 7-NI attenuates kainate-elicited convulsions in rats 
(MUlsch ef al., 1994) or pilocarpine- (Van Leeuwen ef al., 1995) and picrotoxin- (Kirkby 
et al., 1996) induced seizures in mice. 
Although the effect of NOS inhibitors on seizures is predominantly of central origin, the 
peripheral component should also be taken into account. Recent results have shown that 
n-NOS is well expressed in the sarcolemma of skeletal muscle (Nakane ef al., 1993), while 
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NOS inhibitors augment contractile force (Kobzik e/ al., 1994). Therefore, it remains a 
possibility that motor expression of seizures following administration of NOS inhibitors 
could be additionally modified by inhibition of sarcolemmal n·NOS. The participation of the 
sarcolemmal n~NOS in motor seizure phenomena has not been studied yet and it deserves 
serious consideration. 
8.2 NO alld Locomotioll 
Recent data suggest that NO plays an important role in motor activity. The L·Arg·derived 
NOS·inhibitor, L·NAME, reduces spontaneous locomotor activity (Sandi e/ al., 1995) and 
hyperlocomotion induced by cocaine (Pudiak and Bozard, 1993), morphine (Calignano e/ al., 
1993), substance P (Mancuso e/ al., 1994) and methampetamine (Ohno e/ al., 1995). 
Reduced locomotion following administration of NOS inhibitors observed in this study is 
in accordance with the decrease in the EEG rhythmic slow activity (RSA:=;theta rhythm, 
6·9·Hz; Dzoljic e/ al., 1996) as well as the prominent reduction ofEEO power in the high 
theta frequency (7·9 Hz; Chapter 6). The RSA in the rat is associated with locomotion and 
other voluntary movements (Depoortere, 1987). Therefore, the prominent decrease of power 
of RSA, foHawing administration of NOS inhibitors might reflect reduced neuroexcitability 
of brain shuctures involved in the central control oflocomotor activity. 
The mode of action of NOS inhibitors in locomotion is not known, but the effect of NO 
on central neurotransmitters, particularly on DA in basal ganglia could be of importance. 
Striatal dopaminergic transmission is involved in the control of locomotion (Angulio and 
McEwen, 1994) and NOS is widely distributed in neurons of the striatum (Snyder and Bredt, 
1991). It has been shown that NO induces DA release from striatal (Zhu and Luo, 1992) and 
hippocampal slices (Lonart e/ al., 1992). The idea that NOS inhibitors decrease locomotor 
activity by reducing dopaminergic transmission is consistent with the fact that these dmgs 
reduce hypermotility induced by dopamine D, and D, receptor agonists (Starr and Starr, 
1995). There is evidence of the involvement of OLU in the control of locomotion (Witkin, 
1993; Angulio and McEwen, 1994), probably through the dopaminergic system. Both NOS 
inhibitors (Montague e/ al., 1994) and haemoglobin, which binds extracellular NO, reduce 
the release of striatal DA induced by OLU receptor agonist NMDA (Hanbauer e/ al., 1992). 
Other conventional neurotransmitters (OABA, 5·HT, NA and Ach) are implicated in the 
regulation of locomotor activity (Angulio and McEwen, 1994; Mancuso ef al., 1994), while 
NO stimulates the release of these neurotransmitters (Prast and Phillippu, 1992; 
Guevara-Guzman et al., 1994; Mancuso et al., 1994). Evidently, a reduction in the locomotor 
activity induced by NOS inhibitors is a complex phenomenon based on the derangement of 
various neurotransmitter systems involved in the central control of locomotion. 
Additionally, NO may fmiher influence locomotor activity by modifying anxiety. 
However, these results are controversial. Microinjection of NOS inhibitors into the dorsal 
central grey has been reported to exert an anxiolytic effect (Ouimaraes e/ al., 1994). In 
contrast, L-NOARG can reduce exploratory activity increased by the anxiolytic compound 
chlordiazepoxide (Quock and Nguyen, 1992). From our experiments, there is no evidence 
that the new NOS inhibitors may affect anxiety. 
Taken together, the results of our investigations implicate that brain NOS activity and the 
corresponding NO release are important regulators of spontaneous locomotor activity. 
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However, the contribution of the blockade of sarcolenunal n-NOS (Kobzik el al., 1994) in the 
reduction of locomotor activity following NOS inhibitors should be fm1her examined. 
8.3 NO and Vigilance 
Results from previous studies showed that mild sedation caused by NOS inhibitors 
(L-NMMA and 7-NI) might facilitate sleep, while prominent central depression could lead to 
disnlption of sleep pattern (Dzoljic and De Vries, 1994; Dzoljic el al., 1996). In order to 
further evaluate the role of NO in the CNS, we examined the effects of new, potent and 
relatively selective n-NOS inhibitors on the EEG power spectrum, general behaviour and 
sleep/waking pattern during the dark and light periods. 
Data from our experiments show that EEG power was suppressed in each frequency 
range by NOS inhibitors. Although a decrease in EEG power was observed during 
desynchronization and behavioural excitation in animals treated with cocaine or 
d-amphetamine (Ferger el al., 1994), the generalised reduction in EEG power associated with 
depressed behaviour (loss of righting reflex and ptosis; Dzoljic el al., 1996 and decreased 
locomotion; Chapter 5) is rather a reflection of CNS depression. Depression of neuronal 
activity in various brain regions leads to reduced hippocampal and cortical inputs, which in 
him may result in decreased theta activity and EEG power, respectively. Additionally, the 
qualitative changes in EEG power induced by indazole-derived NOS inhibitors used this 
study are similar to the effects of high doses of alcohol (Ehlers el al., 1992) or 
benzodiazepines (Glatt el al., 1983) in rats. Accordingly, a prominent decrease of central 
neuronal activity leads to the reduction ofEEG power, disruption of normal sleep architecture 
(Chapter 6) and decreased locomotor activity (Chapter 5). The central depression induced by 
NOS inhibitors is consistent with the anticonvulsant activity of 7-NI (Van Leeuwen et al., 
1995) and other NOS inhibitors used in this study (Chapter 4). 
In addition, the reduction ofEEG power by 7-NI is less prominent during the dark phase 
(active period of rat) than during the light phase (sleeping period). Likewise, it has been 
reported that NOS activity in the rat brain is higher during the dark phase compared to the 
light phase (Kapas el al., 1995). The idea of circadian dependence of NOS activity is further 
supported by the recent observation that the expression of n-NOS in the rat pineal gland is 
regulated by envirOlllilental lighting condition (Spessert el al. 1995). The present results 
indicate that the excitatory effects of NO on central neuronal stmctures involved in the 
regulation of vigilance are circadian dependent. 
8.4 NO ami Celltrally-Actillg Drugs 
In this study (Chapters 4, 5 and 6), it is suggested that the decrease in brain neuronal activity 
may be associated with reduced NO levels, while an increase of NO concentrations could be 
expected during neuroexcitation. In order to provide data for this hypothesis, we measured 
brain NO levels during pharmacologically-induced central depression and excitation. Our 
results show that hypnotic and excitatory dmgs affected brain NO concentrations in an 
opposite way; pentobarbital decreased, wIrile pentylenetetrazol increased c0l1icai brain NO 
levels. The mechanism of interactions between these dmgs and NO is not clear, but some 
possibilities could be considered. 
It is known that barbiturates inhibit the release of EAA, GLU and ASP (Alifimof and 
Miller 1993), reduce the sensitivity of brain neurons to GLU (Galindo, 1968) and decrease 
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cOMP formation in many brain regions (Kant el al., 1980). Furthermore, the corresponding 
reduction of brain NO concentrations leads to decreased neuronal excitability (Moncada 
ef al., 1991; Montague ef al., 1994; Millsch ef al., 1994). Evidently, tins is an additional 
factor which may contribute (together with barbiturate-induced activation of the GABA-
inhibitory system) to the mechatnsm of hypnotic action of pentobarbital and probably other 
sedatives/hypnotics and anticonvulsants. 
Related to pentylenetetrazol, it has been shown that its proconvulsant effect is associated 
with activation ofNMDA receptors and increase in cGMP leveJs in the brain (Moncada el al., 
1991). Activated NMDA receptors stimulate NOS activity and NO release (Garthwaite, 
1991), which may clarify an elevated NO (and cGMP) concentration following admunstration 
of pentylenetetrazol. This implicates that the activated excitatory NO system may contribute 
to the pentylenetetrazol~induced increase of neuroexcitability. Likewise, it was reported that 
in the kainate elicited convulsions NO formation was increased 6-12 fold in the rat brain 
(Millsch ef al., 1994). A possible involvement of the NO pathway in the action of other 
analeptics, for example amphetamine-like drugs, should be considered. Further experiments 
in conscious animals may more precisely clarify changes in brain NO levels following drug 
administration. 
The fact that NO concentrations in the frontal cortex of the anaesthetized rat were 
decreased by pentobarbital and increased by pentylenetetrazol suggests that brain NO levels 
contribute to the pharmacologically-modulated excitability of central neurons. This further 
implicates a possible decrease of NO concentrations in the human brain following hypnotic or 
antiepileptic therapy and a corresponding increase in the central NO levels during epileptic 
attacks or administration of excitatory amphetamine-like drugs. 
It is concluded that central NO is an impOliant endogenous neuroexcitatory transmitter 
involved in seizure susceptibility, locomotion, vigilance stages and activity of some 
centrally-acting drugs, such as hypnotics and analeptics. Accordingly, interventions in the 
NO system may offer a new therapeutic approach for the treatment of brain disorders 
associated with disturbed neuronal excitability. 
8.5 Implications for Further Research 
The main ideas resulting from our experiments are: 
The possible role of NO in skeletal muscles as a modulator of motor seizure phenomena 
and locomotion should be examined. These experiments could be performed by using 
more selective NOS inhibitors, which will undoubtedly become available in time. Such 
compounds may reduce sarcolenunal n-NOS activity and corresponding NO synthesis in 
skeletal muscles, without affecting those within the eNS. 
• New and selective n-NOS inhibitors should be tested as potential anti epileptic dmgs and 
as modulators of vigilance stages in experiments accompanied with EEG recording . 
. 
Experiments performed in conscious animals could better clarify the qualitative aspects 
of interactions between centrally acting drugs and brain NO concentrations. Knowledge 
of interactions between NO and different drugs in various models of altered neuronal 
excitability may contribute to a better understanding of the role of tins endogenous gas in 
Chapter 8: General discussion 129 
the human brain, particularly during central depression, seizure phenomena and vigilance 
stages. 
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CHAPTER 9 
SUMMARY 
Tltis thesis deals with effects of relatively selective n-NOS inhibitors on neuronal and 
behavioural processes in animal models. NOS inhibitors were used as tools for elucidation of 
the actions of NO in the CNS. A part of this experimental work is also addressed to the 
measurement of brain NO concentrations during phannacologically-induced central 
excitation and depression. 
In order to give a more complete picture of this remarkable messenger molecule, the 
biosynthesis, mechanism of action ofND, distribution of NOS as well as involvement of NO 
in major physiological and pathophysiological processes and its importance in clinical 
medicine are discussed in Chapters 1-3 of this thesis. 
Comparison of previous results dealing with NO is hampered because the NOS inltibitors 
used in earlier studies were rather unselective. In this investigation, we examined the effects 
of new, potent and relatively selective n-NOS inhibitors: 7-nitro indazole (7-NI), 3-bromo 
7-nitro indazole (3-Br-7-NI), 1-(2-trifluoromethylphenyl)imidazole (TRIM) and 
S-methyl-L-thiocitmlline (S-Me-TC) in seizure phenomena, locomotion, vigilance stages and 
neuronal activity. 
Chapter 4. In order to clarifY the role of NO in seizure phenomena, we examined effects of 
3-Br-7-NI, TRIM and S-Me-TC on seizure threshold. The results show that 3-Br-7-NI and 
TRIM decreased the frequency of status epilepticus and mortality, wltile TRIM, in addition, 
significantly reduced the incidence of seizures. The latencies to onset of seizures, status 
epilepticus and mortality were significantly prolonged by all three NOS inhibitors, while the 
duration of seizures was reduced by 3-Br-7-NI and TRIM. Concerning differences between 
NOS inhibitors, several possibilities, such as distinct selectivity for NOS isoenzymes, 
corresponding changes in cerebral blood flow and modulation of negative feedback of NO on 
NMDA, were discussed. It is suggested that the main action of S-Me-TC and, probably, of 
the other two NOS inhibitors is on the mechanism of onset and genesis of epilepsy, rather 
than on the mechanism of maintenance of seizures. 
We concluded that pilocarpine-induced seizures in mice can be allenuated by NOS 
inltibitors, 3-Br-7-NI, TRIM and, to a lesser extent, S-Me-TC. These data implicate that NO 
acts as a central endogenously active agent with proconvulsant properties in the motor limbic 
structures in m-ice. However, possible involvement of peripheral NO in the modulation of 
motor seizure phenomena has not been excluded. 
Chapter 5 deals with our attempts to elucidate the role of NO in locomotion. In these 
experiments we also used non-L-Arg-derived and relatively selective n-NOS inhibitors: 7-NI, 
3-Br-7-NI, TRIM and S-Me-TC. Our results showed that 7-NI, 3-Br-7-NI, TRIM and 
S-Me-TC decreased spontaneous locomotor activity in mice. Animals treated with NOS 
inhibitors looked alert but less active, spending more time sitting in the cage than control 
mice treated with vehicle. The impression of quiescence and bradykinesia, following NOS 
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inhibitors, corresponded with decreased locomotor activity. Reduced locomotion following 
administration of NOS inhibitors observed in these experiments is in agreement with the 
decrease in the EEG rhytlmlic slow activity (RSA-theta rhythm, 6-9 Hz) as well as the 
decrease in EEG power in high theta frequencies (7-9 Hz; Chapter 6). Since the RSA in the 
rat is associated with locomotion, the prominent decrease in power of RSA, foHowing 
administration of NOS inhibitors, might reflect a depression of central neuronal stmctures 
involved in locomotion. 
The mode of action of NOS inhibitors on locomotor activity is still not known. 
However, we emphasized the possibility that NO can influence neurotransmitters implicated 
in the regulation of locomotion. Although a contribution of reduced sarcolennnal n-NOS 
activity in locomotion remains possible, we have concluded that the activity of central NOS 
and corresponding NO release in the brain are important for spontaneous locomotor activity. 
In Chapter 6, we described the effects of relatively selective n-NOS inhibitors, 7-NI, 
3-Br-7-NI and S-Me-TC on the neuronal activity and vigilance stages. The major finding of 
these experiments was that NOS inhibitors, 7-NI and 3-Br-7-NI (but not S-Me-TC) decreased 
EEG power in rats. In addition, 3-Br-7-NI reduced sleep stages. A non-sleep period 
following administration of indazole-derived NOS inhibitors (7-NI and 3-Br-7-NI) was 
characterized by an arousal-like EEGIEMG pattern (low EEG with high EMG amplitudes) 
and reduced behavioural activity (decreased locomotion and occasional loss of righting 
reflex). Evidently, indazole-derived NOS inhibitors decreased sleep but did not increase 
wakefulness. Thus, the arousal-like EEGIEMG pattern was not associated with awake 
behaviour, suggesting a dissociation between the EEGIEMG pattern and behaviour. 
EEG power was suppressed in each frequency range by NOS inhibitors, 7-NI and 
3-Br-7-NI. Decrease of high theta rhytinn is consistent with reduced locomotion, observed in 
experiments following administration of NOS inhibitors (Chapter 5). The generalised 
reduction of EEG power associated with depressed behaviour (loss of righting reflex and 
ptosis) and decreased locomotion (Chapter 5) are a reflection of central depression. 
Accordingly, a prominent central depression leads to the reduction of locomotor activity and 
disruption of normal sleep architecture. The central depression induced by indazol-derived 
NOS inhibitors is consistent with the anticonvulsant activity of NOS inhibitors observed in 
this study (Chapter 4). 
It is of interest to note that the reduction of EEG power by 7-NI was less prominent 
during the dark phase (active period of the rat)'than during the light phase (sleeping period). 
This is an additional argument that brain NO exerts an excitatory and circadian~dependent 
effect on neuronal structures involved in the regulation of vigilance. 
In Chapter 7 data related to brain NO levels during pharmacologically induced central 
depression and excitation, using an electrochemical measurement of NO are given. By using 
an electrochemical measurement of NO levels in the frontal cortex of the anaesthetized rat, 
we found that hypnotic and excitatory drugs affected brain NO levels in the opposite way. 
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The hypnotic dmg phenobarbital decreased, while the convulsant dmg pentylenetetrazol 
increased brain NO concentrations. Thus, our results implicate that central depression could 
he associated with decreased NO levels, while increased NO concentrations could be 
expected during central excitation. Although the mechanism of interaction between these 
dmgs and NO is not clear, some possibilities were discussed. 
The fact that NO concentrations in the frontal cortex of the anaesthetized rat are 
decreased by pentobarbital and increased by pentylenetetrazol provides further evidence that 
NO levels in the brain are related to neuronal excitability. It is concluded that NO plays an 
important role in the regulation of neuronal activity, seizure susceptibility and vigilance 
stages. 

SAMENVATTING 
[n dit proefschrift zijn de effecten van relatief selectieve neurale-stikstofoxyde synthese 
(n-NOS) relfllllers in neurale- en gedragsprocessen in diermodellen onderzocht. NOS 
remmers worden gebruikt als cen methode voor opheldering van stikstofoxyde (nitric oxide -
NO) activiteit in het centraal zenuwstelsel. Daarnaast zijn in eell gedeelte van dit 
experimentele werk de NO concentraties gemeten tijdens farmacologisch gC"induceerde 
centrale excitatie en depressie. 
Om cell compieet beeld tc geven van dit merkwaardige signaalmolecuul worden de 
biosynthese, het werkingsmechanisme van NO, de distributie van NOS en de betrokkenheid 
van NO in de VDornaamste fYsiologische en pathofysiologische processen, evenals de 
toepassillg als klinisch medicijn ell de therapeutische mogelijkheden besproken in de 
hoofdstukken 1-3 van dit proefschrift. 
Een vergelijking met eerder gedane onderzoeken met betrekking tot NO is moeilijk, daar 
vaak de gebmikte NOS remmers niet selectief blekcll tc zijn. Daarom is het onderzoek 
verrieht met nieuwe, effectieve en relatiefselectieve ll-NOS remmers: 7-nitro indazol (7-NI). 
3-bromo-7-nitro illdazol (3-Br-7NI), 1-(2-trifuormethylfenyl)imidazol (TRIM) en 
S-methyl-L-thiocitrulline (S-Me-TC), met betrekking tot toevallen en Iocomotie, 
waakzaamheid en neurale activiteit. 
Hoofdstuk 4. Om de rol van NO bij epileptische aallvallell op te helderen hebben we de 
effecten van 3-BR-7-N[, TRIM en S-Me-TC op de aallvaisdrempel onderzocht. 
De resultaten van deze studie geven aan dat 3-Br-7-N[ en TRIM de frequentie van status 
epilepticus en de mortaliteit verlagen, terwijl TRIM tevens de frequentle van de aanvallen 
verlaagt. De latentietijd voor toevallen, status epilepticus en mortaliteit werd significant 
verlengd door aile drie NOS remmers, terwiji door 3-Br-7-N[ en TRIM ook de duur van de 
aanvallen werd verminderd. Ten aanzien van de verschillen tussen NOS remmers werden een 
aantal mogelijke verklaringen besproken. zoals selectiviteit voor NOS iso-enzymen. 
corresponderende verandering in cerebrale bloeddoorstroming en modulatie van de negatieve 
'feedback' van NO op N-methyI-D-aspartaat (NMDA). Gesllggereerd wordt dat S-Me-TC, en 
mogelijk ook de andere twee NOS remmers, vooral een rol spelen bij het initieren van een 
epileptische aanval en niet zo zeer bij het onderhouden van een aanval. 
Hieruit concluderen wij dat pilocarpine-geYnduceerde toevallen in muizen kunnen 
worden verzwakt door NOS remmers, 3-Br-7-NI, TRIM en in mindere mate door S-Me-TC. 
De resultaten impliceren dat NO werlct als een centraal endogeen actieve stof met 
proconvulsieve eigenschappen in de motor-limbische structuren in de muis. MogeIijke 
betrokkenheid van perifeer NO in de modulatie van aanvallen is echter niet uitgesloten. 
[n hoofdsluk 5 wordt de rol van NO in /ocolllotie behandeid. In deze experimenten hebben 
we oak non-arginine derivaten en relatief selectieve n-NOS remmers gebmikt: 7-NI, 
3-Br-7-N[ en S-Me-TC. 
Onze resultaten geven aan dat 7-N!, 3-Br-7-N[, TRIM en S-Me-TC een verlaging geven 
van spontane locomotie in muizen. Dieren behandeld met NOS remmers zijn alert, maar 
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minder actief en brengen meer tijd zittend in hun kooi door, dan muizcn behandeld met 
vehicle. De indmk van rust en bradykinesie door NOS remmers correspondeerde met cen 
verminderde locomotie. De venninderde locomotie na toediening van NOS remmers, is in 
overeenstenuning met de verlaging van de EEG activiteit (RSA-theta rytlun, 6-9 Hz), en met 
de verlaging van de EEG activiteit in de hoge theta frequentie 7-9 Hz (Hoofdstuk 6). De 
RSA in de rat hangt samen met locomotie en andere willekeuring bewegingen. De 
prominente verlaging in sterkte van RSA, na toediening van NOS remmers, kan duiden op 
een depressie van stmcturen in het centrale zenuwstelsel, welke betrokken zijn bij 
bewegingen. 
Het werkingsmechanisme van NOS remmers in bewegingsactivitcitcn is nog niet bekend. 
We benadmkken echter de mogelijkheid dat NO neurotransmitters kan bernvloeden, die 
bctrokken zijn bij de regulatie van locomotie. Ondanks de 110g steeds aanwezige 
mogelijkheid van gereduceerde sarcolenuna n·NOS activiteit in locomotie, hebben we 
geconcludeerd dat de activiteit van centraal NOS en de bijbehorende NO afgifte in de 
hersenen een belangrijke rol spelen in spontane locomotorische activiteit. 
In hoofdstuk 6 beschrijven we de effecten van relatief selectieve n-NOS remmers, 7-NI, 
3-Br-7-NI en S-Me-TC op de neurale activiteit en slaap-waak stadia. 
Het belangrijkste resultaat van deze experimenten was dat de NOS remmers, 7-NI en 
3-Br-7-NI (maar niet SoMe-Tel de EEG activiteit in ratten verlagen. Daarnaast reduceert 
3-Br-7-NI de slaap stadia. Na toediening van een indazol-derivaat NOS remmer volgde een 
niet-slaap periode (7-NI en 3-Br-7-NI), welke gekenmerkt werd door op excitatie gelijkende 
EEGIEMG patronen (lage EEG- en hoge EMG amplituden) en verminderde gedragsactiviteit 
(verminderde locomotie en af en toe het verliezen van de oprichtingsrellex). Klaarblijkelijk 
verminderen indazol-afgeleide NOS remmers de slaap, maar verhogen de wakkere toestand 
niet. Een op excitatie lijkend EEGIEMG patroon is dus niet gekoppeld aan wakker gedrag, 
hetgeen een dissociatie tussen het EEGIEMG patroon en het gedrag suggereert. 
De EEG activiteit in elk frequentiegebied wordt onderdmkt door de NOS remmers 7-NI 
en 3-Br-7-NI. De daling van het hoge theta ritme komt overeen met de verminderde 
locomotie, zoals gezien na toediening van NOS-remmers (hoofdstuk 5). De algemene 
reductie van de EEG activiteit, geassocieerd met onderdrukt gedrag (verlies van de 
oprichtingsreflex en uitzakking van het bovenste ooglid) en verminderde locomotie 
(hoofdstuk 5) zijn kenmerken van centrale depressie. Vergelijkbaar leidt een prominente 
centrale depressie tot de reductie van bewegingsactiviteit en verstoring van normale 
slaapactiviteit. De centrale depressie ge'induceerd door indazol-afgeleide NOS remmers is in 
overeenstemming met de anticonvulsieve activiteit van de NOS remmers welke gebruikt zijn 
in deze studie (hoofdstuk 4). 
Het is van belang te vermelden dat de reductie van de EEG activiteit minder duidelijk 
was tijdens de donker fase (actieve periode van de rat) dan tijdens de Heht fase (slaap 
periode). Dit VDrmt een aanvullende bevestiging van de bevinding dat NO een neuro-
excitatoire stof is, welke betrokken is bij de regulatie van de slaap/waak stadia. 
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In hoofdstuk 7 zijn de resultaten weergegeven van de NO coneen/faties in de hersenen 
tijdens farmacologisch gernduceerde centrale depressie en excitatie, gebruik makend van 
electrochemische metingen van NO. 
Door gebruik te maken van electrochemische metingen van NO in de frontale cortex van 
een verdoofde rat werd gevonden dat hypnotische stoff en en excitatoire stoff en een 
tegenovergesteld effect op NO concentraties in de hersenen hadden. De hypnotische stof 
pentobarbital verlaagt, terwijl de convulsante stof pentyleentetrazol de NO concentraties in de 
hersenen verhoogt. Deze resuitaten impliceren dat centrale depressie kan worden 
geassocieerd met de afname van de NO concentratie, terwijl een toename van de hoeveelheid 
NO kan worden verwacht tijdens centrale prikkeling. Hoewel het mechanisme van de 
interactie tussen deze dmgs en NO niet opgehelderd is, worden er een aantal mogelijkheden 
besproken. 
Het feit dat de NO coneentratie in de frontale eortex van verdoofde ratten verJaagd wordt 
door pentobarbital en verhoogd wordt door pentyleentetrazol, maakt het aannemelijk dat de 
NO concentratie in de hersenen gerelateerd is aan de neurale prikkelbaarheid. Geconc1udeerd 
kan worden dat NO een belangrijke rol speelt in de regulatie van neurale activiteit, 
toevalsgevoeligheid en slaap/waak stadia. 
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EMG 
GABA 
GLU 
H4B 
5-HT 
L-Arg 
LPS 
LTP 
LTD 
NA 
NANC 
NADPH-d 
7-NI 
L-NMMA 
NMDA 
NO 
L-NOARG 
NOS 
c-NOS 
e-NOS 
i-NOS 
n-NOS 
REM 
RSA 
PNS 
TRIM 
S-Me-TC 
SWS 
acetylcholine 
angiotensin-converting enzyme 
asymmetric NG-dimcthylarginine 
L-arginine 
aspartate 
basal forebrain 
3-brolllO 7-nitro indazole 
cerehral blood flow 
central nervous system 
cyclic guanosine 3',5' monophosphate 
cerebro-vascular resistance 
dopamine 
dimethyl sulfoxide 
excitatory amino acid 
electroencephalogram 
electromyogram 
gama-aminobutyric acid 
glutamate 
tetrahydrobiopterin 
5-hydroxytryptamine, serotonin 
L-arginine 
Iipopolysaharide 
long term potentiation 
long term depression 
noradrenaline 
non adrenergic non cholinergic 
nicotine amide dinucleotide phosphate diaphorase 
7-nitro indazole 
L-N°-mono-methyl-L-arginine 
N-methyl-D-aspartate 
nitric oxide 
N°-nitro-L-arginine 
nitric oxide synthase 
constitutive nitric oxide synthase 
endothelial nitric oxide synthase 
inducible nitric oxide synthase 
neuronal nitric oxide synthase 
rapid eye movement 
rhythmic slow activity 
peripheral nervolls system 
1-(2-trifluoromethylphenyl)imidazole 
S-methyl-L-thiocitmlline 
slow wave sleep 

